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ABSTRACT  
Memory T cell recruitment to the non-lymphoid tissue of the intestine (the gut lamina 
propria) requires the interactions between integrin α4β7 and its ligand Mucosal 
Addressin Cell Adhesion Molecule-1 (MAdCAM-1), which is exclusively expressed 
in the gut microvasculature. T cell homing to small intestine also requires the 
expression of chemokine receptor CCR9 on T cells, whose ligand - the gut chemokine 
CCL25 - is abundantly expressed in the small intestine. The α4β7 integrin and 
chemokine receptor CCR9 are known as the „homing‟ molecules whose expression is 
„imprinted‟ on T cells by intestinal dendritic cells during antigen presentation.  
In the first part of this thesis, data from in vitro studies showed that other than retinoic 
acid, soluble tissue-derived factors such as the gut chemokine CCL25 and T cell 
growth factor IL-2 also contributed to the induction of gut-homing receptor 
acquisition. Moreover, the expression of α4β7 integrin and CCR9 appeared to be 
modulated differently. The present study suggests that under the influence of tissue-
derived factors, T cell acquisition of α4β7 integrin is the „default‟ response at steady 
state, and that only fully activated T cells are able to express high levels of CCR9. 
In the second part of this thesis, T cell gut homing was investigated in the context of 
disease, i.e. inflammatory bowel disease (IBD), including Crohn‟s disease (CD) and 
ulcerative colitis (UC). IBD is characterized by excessive lymphocyte infiltration to 
the intestine. By quantitatively analyzing peripheral blood and intestinal lymphocyte 
subsets, proportional changes in the circulating gut-homing T cells (α4β7
+
) was found 
to be associated with CD. In addition, my data suggest that downregulation of T cell 
receptor zeta chain (TcRδ) correlates to disease severity in both CD and UC. 
Measuring TcRδ expression may thus provide an additional tool for the monitoring 
and management of IBD.  
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Chapter 1 Introduction  
1.1 An overview of the mammalian immune system 
The mammalian immune system consists of two arms of defence mechanisms against 
the invasion of pathogenic microorganisms, the innate immunity and the adaptive 
immunity. In general, the innate immunity provides a non-specific fast–acting first 
line of defence while the adaptive immunity mounts a delayed but more targeted 
antigen-specific response. The innate cells generate non-specific anti-microbial 
responses using germline-encoded receptors to recognize antigens compared to the 
adaptive immune responses where somatic recombination is used (Medzhitov and 
Janeway, 1997).  
1.1.1 Innate immunity 
Upon tissue invasion by pathogens, the first line of defence is carried out by the cells 
of innate immunity including - the monocytes, macrophages, neutrophils, basophils, 
eosinophils, mast cells and natural killer cells. Neutrophils, basophils and eosinophils 
are also known as granulocytes, due to the presence of dense granules in their 
cytoplasm. Macrophages are tissue-resident phagocytes derived from circulating 
monocytes upon their arrival at the tissues. These cells exist in large numbers even 
under physiological conditions in connective tissue in association with the 
gastrointestinal tract and the lung, as well as the spleen (Janeway, 2005). In the liver 
macrophages are known as the Kupffer cells, and in the brain microglial cells. 
Neutrophils, however, are not found in healthy tissues. These cells are the most 
abundant white blood cell type constituting 60-70% of leucocytes in the blood 
circulation, and are the first cells to arrive at the scene of tissue injury.  
Innate immune cells, such as the macrophages, recognize pathogens via the 
expression of germline-encoded pattern-recognition receptors (PRRs) which bind to 
pathogen-associated molecular patterns (PAMPs) shared by a large group of 
pathogens rather than specific structures (Medzhitov and Janeway, 1997, Janeway, 
1989). An example of PRRs is the Toll-like (TLR) receptors, which are capable of 
sensing a broad range of organisms from viruses to parasites (Moser and Leo, 2010). 
Upon recognition of antigens in the tissue, macrophages also recruit large numbers of 
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neutrophils to the site of infection. These cells remove pathogens via the mechanism 
of phagocytosis, during which microorganisms are internalized and killed (Janeway, 
2005). Eosinophils are thought to be particularly important in the removal of parasitic 
antigens. As well as playing a central role in the initiation of allergic inflammatory 
responses, mast cells and basophils are also able to remove bacterial antigens 
(Abraham and Arock, 1998). There is also evidence suggesting that basophils could 
trigger adaptive immune responses during the course of intestinal nematode infection 
(Min et al., 2006).  
1.1.2 Adaptive immunity 
The main players in the adaptive immune system are T and B lymphocytes. T cells 
play a key role in the generation of efficient cell-mediated immune responses, while B 
cells differentiate into plasma cells which secrete antibodies that bind to antigens 
leading to their neutralisation, opsonization and eventual removal (Janeway, 2005). 
These cells generate potent antigen-specific responses and have the capacity to 
eliminate any foreign antigens the body may encounter.  
The  adaptive immunity must be activated via various signals transmitted by cells and 
molecules of the innate immunity, such as the tissue-resident dendritic cells (DCs) in 
order to launch antigen-specific immune responses. Dendritic cells are so-called 
professional antigen presenting cells which provide the vital link between the innate 
and the adaptive immunity. Other than DCs, macrophages and B lymphocytes can 
also present antigens to T cells, but are less powerful . These antigen-presenting cells 
process and present antigens to the T lymphocytes of the adaptive immune system and 
lead to their subsequent activation (Medzhitov and Janeway, 1997). 
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In the peripheral tissue, DCs exist in their immature state. Upon sensing pathogens 
through their PRRs, DCs migrate from the tissue to the local draining lymph nodes 
(via the afferent lymphatics), during which they undergo maturation. DCs process 
pathogens into peptides and present them on the MHC (Major Histocompatibility 
Complex) molecules to naïve T lymphocytes (mature T cells that have never 
encountered cognate antigens) leading to their activation, differentiation and 
ultimately execution of effector functions (Steinman, 1991, Banchereau et al., 2000, 
Palucka and Banchereau, 2002). 
Following activation, different subsets of effector and memory T cells with different 
phenotypes, cytokine profiles and functions are generated. Memory T cells are a 
heterogenous population consisting of long-lived central memory T cells (TCM), short-
lived effector T cells (TEFF) and long-lived effector memory T cells (Westendorf et al.) 
(Sallusto et al., 2004; Sallusto et al., 1999). This heterogeneous population consists of 
helper CD4
+
 T cells, killer CD8
+ 
T cells and regulatory T cells. (Murphy and Reiner, 
2002, Sakaguchi and Powrie, 2007). Helper T cells help activating other immune cells 
(such as macrophages and B cells); whereas killer T cells (also known as cytotoxic 
CD8
+
 T cells) directly kill infected target cells. Helper T cells are subdivided into T 
helper cell 1 (Th1), T helper cell 2 (Th2) and the recently discovered Th17 cells based 
on their phenotype and cytokine profile (Sallusto and Lanzavecchia, 2009).  
Th1 cells produce high levels of IFN-γ and activate macrophages and CD8+ killer 
cells. These cells are important for generating responses against viruses, intracellular 
bacteria and tumours. Th2 cells produce IL-4, IL-5, IL-10, and IL-13; these cells 
mainly function to remove parasites and to activate naïve B cells for antibody 
production (Zenewicz et al., 2009). Th2 also activate basophils and mast cells during 
allergic responses (Zenewicz et al., 2009). The recently discovered Th17 cells are also 
defined by their cytokine profile, they are responsible for the secretion of high levels 
of IL-17A and have a distinct effector lineage to Th1 and Th2 CD4
+
 T cells 
(Harrington et al., 2005). Th17 cells also produce other cytokines, such as IL-21, IL-
22, IL-17F, as well as TNF-α (Harrington et al., 2005), some of which overlap with 
other T cell phenotype. Th17 cells can recruit neutrophils and are important for the 
removal of extracellular bacteria (Ye et al., 2001, Kolls and Linden, 2004).  
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Following T cell activation, effector and memory T cells leave the secondary 
lymphoid organs via the efferent lymphatics vessels, enter the blood circulation via 
the thoracic duct and eventually migrate into the site of infection in the tissue to clear 
the invading pathogens (Wiedle et al., 2001). Following the clearance of initial 
antigens long-lived memory T cells (TCM + TEM) persist in the body in order to mount 
a rapid response towards future immunological challenge by the same antigen 
(Sallusto et al., 2004). Immunological memory is a unique feature of the adaptive 
immunity.  
1.1.3 Inflammatory responses  
A key event in the initial phase of an immune response is the development of 
inflammation, which is the result of soluble factors released by the damaged tissue 
and the migration of leukocytes into the tissue (Janeway, 2005). Such soluble factors 
include cytokines and chemokines, which are defined as proteins that affect the 
behaviour of other cells. Chemokines are cytokines with chemotactic properties which 
attract cells expressing the appropriate chemokine receptors to the site of 
inflammation in a process called chemotaxis (Johnston and Butcher, 2002). Many cell 
types produce chemokines in response to inflammation(Moser et al., 2004). Upon 
tissue penetration by pathogenic microorganisms, tissue-resident macrophages 
recognize constituents of the pathogen, remove them via phagocytosis while 
producing cytokines and chemokines that attract neutrophils and monocytes from the 
blood circulation. During inflammation, endothelial cells lining the blood vessels 
produce a broad range of chemokines such as IL-8 and RANTES (Regulated upon 
Activation, Normal T-cell Expressed, and Secreted) in order to attract circulatory 
leukocytes to the site of inflammation (Speyer and Ward, 2011). Additionally, 
cytokines released from macrophages, such as interferon-gamma (IFN-γ) and tumour 
necrosis factor-alpha (TNF-α), activate the endothelium to up-regulate the expression 
of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and 
vascular adhesion molecule-1 (VCAM-1). The combination of chemokines and 
adhesion molecules is essential to induce leukocytes migration from the blood 
circulation across the endothelium to the inflamed tissue in order to remove pathogens.  
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Both innate and adaptive immunity are dependent on the migration of leukocytes 
across endothelial cells; additionally, effector T cell subsets must be able to migrate to 
specific sites of the body to execute effective localized immune responses. The 
physiological process by which lymphocytes find and localize to particular tissues and 
to the microenvironment therein is known as lymphocyte extravasation (Janeway, 
2005). Details of human lymphocyte migration will be discussed in detail later in this 
thesis. 
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1.2 Human lymphocyte recirculation and homing  
Effective immune responses are dependent on the continuous trafficking of 
lymphocytes through blood, lymphoid organs and non-lymphoid tissue in a process 
known as recirculation (Wiedle et al., 2001). While other leukocytes migrate in 
response to non-specific inflammatory stimuli, the migratory patterns of naïve and 
memory T lymphocytes are well-defined and vary depending on their activation, 
differentiation and function (Marelli-Berg et al., 2010). For instance, naive T cells 
express CD62L and CCR7 and predominantly traffic to the secondary lymphoid 
organs whereas antigen-experienced T cells acquire the ability to migrate to non-
lymphoid sites of inflammation in the tissues where antigens are located (Butcher et 
al., 1999, Lewis et al., 2008). By possessing a unique set of adhesion molecules and 
chemokine receptors - the „homing‟ molecules, distinct memory T cell populations are 
able to interact with organ-specific endothelial cells and are recruited to distinct target 
tissues (Butcher and Picker, 1996, Picker and Butcher, 1992). For instance, 
lymphocyte trafficking to the intestinal lamina propria is mediated predominantly by 
the interaction between intestinal mucosal addressin cell adhesion molecule 1 
(MAdCAM-1) and lymphocyte α4β7 integrin (Berlin et al., 1993). Human T cell 
homing to the skin requires the binding of cutaneous lymphocyte antigens (CLA, an 
E–selectin ligand) and T cell chemokine receptor CCR4 to the vascular lectin 
endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) and the thymus and 
activation-regulated chemokine (TARC, CCL17) respectively (Reiss et al., 2001, 
Berg et al., 1991). The patterns of T cell migration to the intestine and the skin have 
been well characterized.  
Details of T cell homing to the gut associated lymphoid tissue (GALT) and its 
relevance in health and disease will be discussed in detail in this thesis. 
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1.2.1 T lymphocyte extravasation 
The physiological process by which lymphocytes find and localize to particular 
tissues and to the microenvironment therein is known as extravasation (Janeway, 
2005).  
A wide range of chemokines, adhesion molecules and junctional molecules expressed 
on the EC are required to mediate and regulate this tightly-controlled process; these 
molecules bind to their counter receptors on the migrating lymphocytes directing their 
entry into the tissue. Similarly, monocytes and neutrophil migration also involves a 
cascade-like process similar to lymphocytes (Ley and Kansas, 2004).  
In normal healthy living tissue, the vascular endothelium is impermeable to 
macromolecules; it forms a non-thrombotic, non-adhesive barrier (Yonekawa and 
Harlan, 2005); upon inflammation, the endothelial monolayer undergoes molecular 
and physiological changes such as the up-regulation of adhesion molecule expression. 
This in turn allows the exit of lymphocytes across the endothelium into the tissue 
without disrupting the endothelium integrity. The initial stage of lymphocyte 
trafficking is mostly mediated by selectins, which belong to a group of so-called C-
type lectins that are expressed exclusively on bone marrow derived cells and 
endothelial cells (Ley and Kansas, 2004). Selectins are responsible for the initial 
contact between the circulating lymphocytes and the endothelium monolayer, they are 
vital in the mediation of lymphocytes tethering and rolling on the EC. 
After the initial contact with the rolling lymphocytes, locally produced chemokines 
displayed on the endothelial cells (EC) bind to their receptors and subsequently 
induce integrin activation (Diamond and Springer, 1994). Chemokine signaling either 
induces integrin conformational changes leading to the upregulation of integrin 
affinity; alternatively it triggers integrin clustering on the cell surface thus increasing 
integrin avidity (Diamond and Springer, 1994; Johnston and Butcher, 2002). 
Activated integrins bind to their ligands on the EC leading to the establishment of 
firm adhesion of migrating leukocytes to the endothelial cells. This step of 
extravasation is thus referred to as activation (Fabbri et al., 1999).  
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Chemokines are small proteins of 8-14 kDa with chemotactic properties which control 
cell trafficking (Godessart, 2005). Chemokines fall into four families based on the 
number and the positions of their amino-terminal cysteine residues (Luster, 1998). 
Chemokines that have adjacent cysteines are CC chemokines, those that have 
cysteines separated by one amino acid are CXC chemokines (Janeway, 2005). Two 
other chemokine families are the XC and the CX3C chemokines (Zlotnik and Yoshie, 
2000). XC chemokines lack cysteines one and three of the typical chemokine 
structure, CX3C chemokines have three amino acids between the first two cysteines 
(Zlotnik and Yoshie, 2000, Kelner et al., 1994, Bazan et al., 1997). The structures of 
these chemokines, examples of each family and their receptors are listed in Table 1 
(Godessart, 2005). Chemokines can also be categorized based on their functions; 
those that are homeostatic and produced constitutively and those that are induced 
during inflammatory conditions (Ebert et al., 2005). Homeostatic chemokines are 
important during hematopoiesis in the bone marrow and thymus, they also control 
cellular traffic in the secondary lymphoid organs and contribute to the immune 
surveillance of the peripheral tissues. Inflammatory chemokines on the other hand 
recruit effector leukocytes as well as cells of the innate immune system to the sites of 
inflammation (Moser and Willimann, 2004, Ebert et al., 2005) 
Chemokines may be synthesized by the endothelium itself and released on the luminal 
surface (blood side) for binding to their receptors on the incoming lymphocytes; 
alternatively, they are produced by tissue parenchymal cells and transported across the 
endothelium and displayed on the EC in a process involving the glycosaminoglycans 
(GAGs) synthesized by the vascular endothelium (Roitt et al., 1998).  
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Table 1. Structures and examples of the four chemokine families.  
Adapted and modified from (Godessart, 2005). 
 
Integrins comprise a major group of adhesion molecules and consist of two non-
covalently bound polypeptide chains - α and β chains. Integrins are categorized based 
on the type of β chain. For example, β1 integrins include very late antigen 1 (VLA1, 
α1β1), and very late antigen 4 (VLA4, α4β1); β2 integrins include the leukocyte 
associated function antigen 1 (LFA-1, αLβ2), and the integrin α4β7 which is important 
in T cell homing to the gut (Garrood et al., 2006). During the activation step of 
lymphocyte extravasation, integrins bind to their ligands expressed on the 
endothelium such as the ICAMs, VCAM-1, and MAdCAM-1 and others which lead 
to the firm arrest of lymphocytes on the endothelium. Following firm adhesion on the 
EC monolayer, lymphocytes eventually transmigrate into the target tissue. 
Lymphocyte transendothelial migration occurs at the junction between endothelial 
cells without disrupting the EC monolayer in a process known as diapedesis involving 
the junctional adhesion molecules. Alternatively, leukocytes may migrate across the 
endothelial cell body into the tissue known as the transcellular route (Engelhardt and 
Wolburg, 2004). This phenomenon was first observed in the mouse model of 
experimental autoimmune encephalomyelitis (Wolburg et al., 2005). It is 
hypothesized that the contribution of each pathway depends on the type of blood 
Chemokines
CCL3,CCL4,
CCL17
CCL25
Receptors
CCR1
CCR4
CCR9
CXCL11
CXCL12
CXCR3
CXCR4
XCL1
XCL2
XCR1
XCR2
CX3CL1 CX3CR1
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vessel, target tissue, the recruitment stimuli and the type of cells (Vestweber, 2007). 
Once across the endothelial barrier, migrating lymphocytes continue to move through 
the subendothelial matrix and the extravascular tissue to the site of inflammation in 
response to chemotactic gradients (Yonekawa and Harlan, 2005). The cascade of 
leukocyte transendothelial migration is illustrated below in Figure 1.  
 
 
Figure 1. Multi-step lymphocyte trans-endothelial migration.  
The initial contact between circulating lymphocytes and the endothelium is mediated by 
selectins (Rolling/Tethering). This is followed by the exposure of lymphocytes to the 
chemokines presented on the surface of endothelium, upon binding to the chemokine receptor 
expressed by the lymphocytes, conformational changes of integrins are triggered (Activation). 
Binding of integrins to their receptors on the endothelium leads to the firm arrest of 
lymphocytes, which eventually transmigrate across the endothelial cells (EC) in a step known 
as diapedesis or through a trans-cellular route without interrupting the EC integrity.  
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1.2.1.1  Naïve T cell homing to the peripheral lymph nodes (PLN) and gut- 
associated lymphoid tissue   
Naïve and memory T cells have different surface phenotypes and migratory patterns 
(Sprent, 1994).  Memory cells express a range of markers that are not found on naïve 
T cells (Shimizu et al., 1990, Mackay, 1993). For instance, human naïve T cells 
express surface marker CD45RA, while memory T cells express the lower molecular 
weight isoform CD45RO following activation (Vitetta et al., 1991).  
Naive T cells predominantly traffic to the secondary lymphoid organs (SLOs) 
including peripheral lymph nodes, mesenteric lymph nodes (MLNs), Peyer‟s patches 
(PP) and the spleen (Mackay et al., 1990). Naïve T cells have little or no ability to 
produce cytokines (Garcia de Tena et al., 2006). In the SLOs, naïve T cells encounter 
antigens presented by tissue-resident dendritic cells, undergo clonal expansion, 
differentiation and become effector and memory T cell populations. Previous studies 
have shown that naive T cells enter the lymph nodes via high endothelial venules 
(HEVs), which are specialized sites in the post capillary venules characterized by 
plump, cuboidal high endothelial cells exclusively found in the SLOs (Vestweber, 
2003, Weninger et al., 2003).  
Homing of naïve T cells to the peripheral lymph nodes (PLN) requires homing 
receptor L-selectin (CD62L) and chemokine receptor CCR7. L-selectin binds to 
peripheral lymph node addressin (PNad) highly expressed on the HEVs of PLNs and 
MLNs in the gut (Streeter et al., 1988), while CCR7 binds to chemokine CCL19, 
CCL21 expressed by the high endothelial venules (HEV) of the PLNs (Williams et al., 
1998, Baekkevold et al., 2001). CCL21 is also expressed on the PPs in the gut 
(Bargatze et al., 1995). Naïve T cells have also been shown to utilize CXCR4 which is 
the receptor for stromal cell-derived factor1(SDF-1, CXCL12) to circulate through 
secondary lymphoid tissue (Campbell et al., 2003).  
In humans, the majority of T cells entering the PP are found to be naïve T cells. This 
process requires the interaction of integrin α4β7 on T cells and MAdCAM-1 on the 
mucosal vasculature (Berlin et al., 1993, Bargatze et al., 1995). Consistent with this 
observation, human naïve T cells are found to express low levels of α4β7 (Erle et al., 
1994, Rott et al., 1996). Murine studies subsequently showed that both L-selectin and 
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integrin α4β7 are required in a sequential and synergistic manner for mediating naïve T 
cell migration to the mesenteric lymph nodes (Wagner et al., 1998). L-selectin binds 
to the PNad expressed on the MLNs inducing the initial rolling and tethering of T 
cells during transendothelial migration; α4β7 integrin subsequently binds to 
MAdCAM-1 and mediates firm adhesion and transmigration of naïve T cells to the 
mesenteric lymph nodes (Wagner et al., 1998). In addition, mice with a β7 mutation 
have been found to display a 90% reduction in lymphocyte migration to the Peyer‟s 
patches; and T cell migration is reduced by 55% in mice that are deficient for L-
selectin (Wagner et al., 1998). Collectively, this evidence highlights the importance of 
both L-selectin and integrin α4β7 in naïve T cell homing to the gut secondary 
lymphoid tissue.  
1.2.1.2 Homing of memory T cells to the peripheral non-lymphoid tissue 
Upon encountering antigens in secondary lymphoid organs, naïve T cells are 
sequestered and interact with antigens for 2-3 days (Sprent, 1980). Naive T cells 
subsequently differentiate into short-lived effector T cells and a small fraction of 
long-lived memory T cell population. Memory T cells leave the secondary lymphoid 
organs via the efferent lymphatics, enter the blood circulation through the thoracic 
duct and travel to the inflamed tissue. As mentioned previously, memory T cells are a 
heterogenous population consisting of long-lived central memory T cells (TCM), short-
lived effector T cells (TEFF) and long-lived effector memory T cells (Westendorf et 
al.); these cells are defined by their different phenotypes, functions and migratory 
patterns (Sallusto et al., 2004; Sallusto et al., 1999). This is illustrated in Figure 2.  
Similar to naïve T cells, TCM express L-selection, CCR7, and have similar migratory 
patterns to naive T cells; however, unlike naïve T cells they also express 
inflammatory chemokine receptors which enable them to enter sites of chronic 
inflammation (Ley and Kansas, 2004). TCM do not have immediate effector functions 
but are able to proliferate rapidly during secondary immune responses (Manjunath et 
al., 2001). In contrast, both short-lived TEFF and long-lived TEM lack the expression of 
CD62L and CCR7, instead they use tissue-specific integrins and chemokine receptors 
to preferentially migrate to the non-lymphoid tissues (von Andrian and Mackay, 2000, 
Sallusto et al., 1999). Once activated, T cells express ligands for P- and E- selectins 
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that are induced at the site of inflammation, such interactions enable them to home to 
extralymphoid tissues. Short-lived TEFF represent mostly recently activated T cells, 
and are eliminated at the end of primary immune responses (Sprent, 1994, Sprent and 
Webb, 1995). TEM have immediate effector function, and are present in the blood, 
peripheral tissues, spleen but not in the resting lymph nodes (Masopust et al., 2001). 
A recent murine study revealed that TEM and TFF can also be recruited to the reactive 
lymph nodes in a CCR7 independent pathway using cheomokine receptor CXCR3 in 
order to kill antigen-presenting dendritic cells thus preventing excessive T cell 
stimulation (Guarda et al., 2007). In both humans and mice, the pathways by which 
naïve T cells differentiate into different subsets of memory cells remain to be clarified 
and not yet fully understood (Champagne et al., 2001, Appay et al., 2002, Wherry et 
al., 2003, Sallusto et al., 2004).  
1.2.1.3 Memory T cell homing to the skin  
Human memory T cells require the expression of cutaneous lymphocyte antigen 
(CLA) to traffic to the skin by binding to E-selectin (ELAM-1, endothelial cell-
leukocyte adhesion molecule) constitutively expressed at a low level by the skin 
endothelial cells and is upregulated upon cutenous inflammation (Berg et al., 1991, 
Groves et al., 1991). Human skin-infiltrating lymphocytes also express CCR4, the 
chemokine receptor for CCL17 (also known as the thymus and activation-regulated 
chemokine TARC) displayed on the skin venules (Reiss et al., 2001). Further studies 
revealed that CCL27 (the cutaneous T cell-attracting chemokine, CTACK) is also 
crucial for attracting CLA
+
 memory T cells to the skin by binding to its receptor 
CCR10 (Morales et al., 1999). Other key molecules participating in memory T cell 
homing to skin include intergrin α4β1 (VLA-1), which binds to vascular cell adhesion 
molecule 1 (VCAM-1) predominately expressed on the endothelium in non-mucosal 
site of inflammation (Rott et al., 1996). T cells expressing high levels of α4β1 
preferentially home to the systemic non-mucosal sites including the skin, nervous 
system and bone marrow (Batra et al., 2007).  
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The expression of homing receptors on T cells for the skin and the gut are mutually 
exclusive (Rott et al., 1996). For instance, CCR4 is exclusively expressed by CLA
+
 
skin-homing T cells but not by intestinal memory T cells (Reiss et al., 2001), and that 
integrin α4β1 targets T cells to the non-mucosal sites whereas integrin α4β7 targets 
memory T cells to the intestine (Rott et al., 1996). The molecules essential in 
mediating the trafficking of different subsets of T cells are summarized in Figure 2. 
 
(Ward and Marelli-Berg, 2009) 
Figure 2. Molecular interactions required for homing of different subsets of T 
cells to their respective sites.  
Naïve T cells predominately traffic to the secondary lymphoid tissues such as the peripheral 
lymph nodes (PLNs), PP and MLNs in the gut. Memory T cells predominately travel to the 
non-lymphoid tissue such as the skin, the lamina propria of the gut, and the central nervous 
system. This figure is adapted from (Ward and Marelli-Berg, 2009). 
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1.2.1.4 Memory T cell homing to the small and large intestine under steady 
conditions  
Effector and memory T cells and B cells require the interaction of integrin α4β7 and 
MAdCAM-1 to migrate to the effector site of the gut mucosa - lamina propria (Berlin 
et al., 1993, Lefrancois et al., 1999b).  
Previous studies have also shown that human peripheral blood CD4
+
, CD8
+ 
T cells 
and B cells have heterogenous expression of α4β7 (Erle et al., 1994, Schweighoffer et 
al., 1993). The level of α4β7 expression is much higher on memory cells than that on 
naïve cells (Erle et al., 1994, Rott et al., 1996). The ability of α4β7 expressing cells to 
bind to MAdCAM-1 is found to be influenced by the level of α4β7 expression and its 
functional state (Erle et al., 1994). MAdCAM-1 is constitutively expressed on the 
postcapillary venules of intestinal lamina propria, the MLNs, the HEVs of the Peyer‟s 
patches (Butcher et al., 1999) and the endothelial venules of both small intestine and 
the colon (Briskin et al., 1997). Other than its crucial function in mediating 
lymphocyte homing to the gut, studies in mice have also revealed that α4β7 plays a 
critical role in the formation of gut-associate lymphoid tissue (Wagner et al., 1996). 
Mice lacking MAdCAM-1 have a disordered architecture in their PP and MLNs 
(Pabst et al., 2000).  
Upon arrival in the small intestinal lamina propria, some T cells further migrate to the 
gut epithelium to become intraepithelial T cells in a process dependent on the 
interaction of chemokine receptor CCR9 and its ligand CCL25 (also known as the 
thymus expressed chemokine TECK in humans and mice) (Stenstad et al., 2007, 
Kunkel et al., 2000, Zabel et al., 1999). CCL25 is expressed in the thymus and on the 
small intestinal glands and crypts (Nishimura et al., 2009). CCL25 has also been 
found on blood vessel endothelial cells and gut epithelial cells in mice (Koenecke and 
Forster, 2009). Within the murine small intestine, CCL25 is found at a higher 
concentration at the proximal segments compared to the distal segments (Koenecke 
and Forster, 2009). Its receptor CCR9 is found on thymic T cells, α4β7
+
 lamina propria 
T cells and intraepithelial lymphocytes in the small intestine as well as IgA- secreting 
plasma cells in the secondary lymphoid organs in humans and mice (Kunkel et al., 
2000, Kunkel et al., 2003, Zabel et al., 1999). 
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In mice, the CCR9-CCL25 axis has been shown to play a key role in the homing of 
antigen-specific CD8
+
 T lymphocytes to the small intestine lamina propria 
(Johansson-Lindbom et al., 2003) but less so for CD4
+
 effector T cells (Stenstad et al., 
2006). Murine studies have also found that CCL25 plays a key role in the generation 
of murine small intestinal CD8αα+CD3+ intraepithelial lymphocytes (Marsal et al., 
2002). In humans, CCL25 is abundantly expressed in various regions of the small 
intestine (jejunum and the ileum), but not in the colon or the caecum (Papadakis et al., 
2000, Kunkel et al., 2000). Consistently, CCR9 is found on all of the small intestinal 
lamina propria intraepithelial CD4
+
 and CD8
+ 
T cells (Papadakis et al., 2000, Kunkel 
et al., 2000). In summary, these observations highlight the importance of CCR9-
CCL25 interactions in memory T cell homing to the small intestine, however it is not 
required for T cell migration to the colon in humans or mice (Wurbel et al., 2000, 
Kunkel et al., 2000).  
Blockade of CCL25 was also found to have no effect in murine T cell adhesion in the 
colon in both uninflamed and inflamed conditions while significantly inhibiting T cell 
adhesion to the small intestine (Hosoe et al., 2004). In humans, there is also no 
evidence suggesting CCL25-CCR9 interaction is required for lymphocyte homing to 
the healthy or inflamed colon (Nishimura et al., 2009). Over 90% of both CD4
+
 and 
CD8
+ 
T cells isolated from the human small intestine (including intraepithelial CD8
+
 
T cells) express CCR9, in contrast only 25% of colonic CD4
+
 and CD8
+
T cells are 
CCR9 positive (Kunkel et al., 2000, Papadakis et al., 2000). In human peripheral 
blood, only a small percentage of total circulating CD4
+
 and CD8
+
 T cells co-express 
α4β7
+ 
and CCR9, this further proves that T cell homing to the small and large intestine 
may not be achieved via the same pathways (Zabel et al., 1999). Instead, CCL25 may 
be responsible for compartmentalizing the mucosal immune responses (Kunkel et al., 
2000, Kunkel et al., 2003). Interestingly, studies have also shown that T cell homing 
to the colon appears to follow a distinct mechanism involving both integrin α4β1 and 
α4β7 (Soriano et al., 2000). Compared to the small bowel, relatively little is known 
regarding the mechanisms governing memory T cell homing to the colon (Koboziev 
et al., 2010).  
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Studies on human peripheral T cells support the notion that the CCL25-CCR9 axis is 
key in memory T cells homing to the small intestine.  
CCR9 is found to be expressed on around 2-4% of peripheral blood CD4
+
 and less 
than 1% of CD8
+
 T cells, additionally, its expression is shown to be particularly 
associated with memory CD4 and CD8
+
 T cells (CD45RO
+
) that co-express integrin 
α4β7 (Zabel et al., 1999). In contrast, human naïve T cells express a lower level of 
CCR9 (Zabel et al., 1999). Further studies on the CCR9 expressing T cells in the 
human periphery revealed that these cells also expressed activation markers such as 
CD25, CD69 which were not found on the CCR9
-
 subset (Papadakis et al., 2003). In 
addition, a higher percentage of CD4
+
CCR9
+
 cells were found to produce IFN-γ when 
compared to CD4
+
CCR9
-
 subset; IL-10 production was also found to be exclusively 
associated with CD4
+
CCR9
+
 T cells (Papadakis et al., 2003). Memory CD4
+
CCR9
+
 
cells were also shown to be capable of providing help to B cells for the production of 
IgA, IgG and IgM when tested in vitro (Papadakis et al., 2003). This observation was 
supported by studies in CCR9 deficient mice where a reduced number of IgA 
secreting plama cells within the lamina propria were found; such mice were also 
unable to mount a T cell-dependent antigen-specific IgA response following oral 
antigen challenge (Nishimura et al., 2009). Collectively, these data suggest that 
circulating memory CD4
+
CCR9
+
 T cells represent mucosal T cells recently activated 
in vivo and that the combined expression of α4β7 and CCR9 may be the „address codes‟ 
for memory T cells homing to the small intestine in humans and mice. However 
additional mechanisms must also be present as experimental evidence demonstrated 
that small intestine homing by memory T cells could also be achieved in an α4β7 and 
CCR9-independent manner (Kuklin et al., 2000, Stenstad et al., 2006).  
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1.3 Mucosal immunity 
1.3.1 Anatomy of the human gastrointestinal tract 
The human gastrointestinal tract (GI) runs from the mouth to the anus. The upper GI 
includes the oesophagus, stomach and duodenum; while the lower GI includes the 
small intestine, large intestine and the anus. The inside of the entire GI tract is lined 
with a mucus layer situated above an epithelial layer and the interspersed gut-
associated lymphoid tissue (GALT) (Barnes and Powrie, 2009).  
The mucus layer above the epithelium consists of two strata, the outer layer colonized 
with bacteria and the inner layer resistant to bacterial penetration (Johansson et al., 
2008). Being in direct contact with the microbes, the mucus layer together with 
epithelial cells thus provides a first line of defence against the penetration of 
commensal and pathogenic microbes into host tissue (Barnes and Powrie, 2009). In 
the inflamed colon, the mucus layer was found to be thinner thereby allowing bacteria 
adherence and subsequent infiltration (Swidsinski et al., 2007). 
The mammalian gut mucosa hosts around 10
13
 to 10
14
 bacteria of 400 species and 
subspecies (Hao and Lee, 2004). The colon has a much higher bacterial content (10
7
 - 
10
8
 bacteria/ml of intestinal content ) than the small intestine (10
3
 – 104 bacteria/ml of 
intestinal content) (Hao and Lee, 2004). This is attributable to several factors such as 
the pH, peristalsis, bacteria adhesion and the amount of mucin being produced. The 
colon is a major site of colonization of microbiota largely composed of members of 
the Firmicutes and Bacteroidetes phyla (Eckburg et al., 2005). In contrast, the low pH, 
and swift peristalsis through the stomach and the small bowel makes the stomach and 
the upper small intestine (duodenum and jejunum) inhospitable for microorganisms 
(Hao and Lee, 2004). However, the distal small intestine – the ileum, with decreased 
peristalsis and acidity, hosts higher numbers of micorbiota similar to the colon (Hao 
and Lee, 2004). 
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1.3.1.1 Mechanisms of protection of the gut mucosa  
The vast amount of gut bacteria make key contributions to human health, for instance, 
they facilitate the maximization of dietary energy extraction in the host (Duerkop et 
al., 2009, Wostmann et al., 1983). Intestinal symbiotic bacteria also protect the host 
from the invasion of pathogenic bacteria, which are poorly adapted to compete for 
nutrients from the host compared to the symbionts (Duerkop et al., 2009, Stecher et al., 
2007, Stecher et al., 2005).  
 
The interaction between bacteria and the host also promotes the development of 
healthy gut immunity by governing the development of inflammatory Th17 cells 
(Ivanov et al., 2008), the production of regulatory T cells (Hall et al., 2008) and the 
antibody class switching of B cells (He et al., 2007). Despite making multiple 
beneficial contributions towards the human health, the presence of the abundant 
intestinal bacteria poses a potential threat to the host. In order to create a healthy 
mutual relationship between commensal bacteria and their host, both the innate and 
adaptive immune system have evolved sophisticated mechanisms to monitor the 
bacteria-host interaction and to prevent the development of harmful immune 
responses which could lead to pathology (Duerkop et al., 2009).  
 
The co-existence of bacteria and the host without triggering inflammatory responses 
is achieved by sequestering bacteria in the gut lumen therefore limiting bacterial 
contact with the gut epithelium (Duerkop et al., 2009). Several types of cells 
contribute to this process as part of the innate immunity operating at the gut mucosal 
surface. These include the largest epithelial surface of the body composed of abundant 
intestinal epithelial cells (enterocytes) connected by tight junctions (Barnes and 
Powrie, 2009), mucin-secreting goblet cells and antibacterial-peptide producing 
Paneth cells (Artis, 2008). These cells prevent the entry and colonization of bacteria 
beyond the epithelial layer into the tissue.  
 
  
Chapter 1 Introduction 
 
39 
Enterocytes do so via the production of a variety of antimicrobial proteins and by 
promoting bacterial killing by targeting bacterial cell walls (Mukherjee et al., 2008) 
whilst allowing nutrient entry into the tissue (Duerkop et al., 2009). Mucin 
glycoproteins produced by goblet cells form a protective mucus layer that extends up 
to 150 µm from the epithelial surface  thereby isolating bacteria in the gut lumen from 
the gut epithelium (Gum et al., 1994). Paneth cells found at the base of small 
intestinal crypts harbor secretory granules containing antimicrobial proteins such as α-
defensins (Duerkop et al., 2009). Defensins interact with bacteria and destroy them by 
permeabilizing their membranes (White et al., 1995).  
 
Cells of the adaptive immune system also make contributions in order to keep the 
commensals away from the epithelium and to defend the mucosal surfaces. For 
example, B cells found in abundance in the intestinal lamina propria sequester enteric 
bacteria in the gut lumen by secreting bacteria-specific IgA, which is trans-cytosed 
across the epithelium and deposited on the apical surface of the epithelium preventing 
bacterial invasion of the mucosal surfaces (Macpherson et al., 2005). In addition, 
intraepithelial lymphocytes interspersed among epithelial cells secrete epithelial 
growth factors to repair the gut epithelium following epithelial injury (Chen et al., 
2002).  
 
As well as preventing bacterial entry beyond the mucus, efficient clearance of the 
symbiotic bacteria breaching the mucosa is also vital to avoid mucosal inflammation. 
This is achieved by phagocytosis carried out by the lamina propria macrophages 
(Sansonetti, 2004). Penetrating commensals are susceptible to elimination by 
phagocytosis, which may have evolved to avoid generating overwhelming 
inflammation that will damage their luminal habitat (Macpherson and Uhr, 2004). In 
contrast, many pathogenic bacteria have developed mechanisms to escape or subvert 
such biocidal activity by killing the phagocytes or surviving inside them (Sansonetti, 
2001). In the presence of bacterial invasion of the epithelium, neutrophils are also 
recruited to the basal side of the epithelium. 
The „defence‟ mechanisms mentioned above are summarized in Figure 3. 
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Other than these „physical‟ defence mechanisms, the gut has also developed 
sophisticated cellular mechanisms in order to maintain a minimum level of activation 
and create an overall „tolerogenic‟ environment. We next focus on the gut associated 
lymphoid tissue (GALT) and its importance in the generation of „tolerance‟ towards 
the abundant commensal bacteria present in the gut.  
 
(Duerkop et al., 2009) 
Figure 3. Cells and molecules that play an active role in defending the mucosal 
surface.  
Bacteria found in the lumen are sequestered in the mucus layer which separates the epithelial 
lining from the gut lumen. The outer mucus layer is filled with bacteria, but the inner layer is 
resistant to bacterial penetration. Antimicrobial proteins secreted by the gut epithelial cells 
eliminate potential harmful bacteria by directly killing them. Plasma cells in the lamina 
propria secrete IgA which is trans-cytosed across the epithelium. IgA binds to the bacteria 
limiting their number. The integrity of the gut epithelium is maintained by the tightly packed 
cells, in case of injury, γδ intraepithelial lymphocytes secrete growth factors promoting the 
repair of the epithelium. Macrophages in the lamina propria clear those bacteria that have 
breached the epithelium by phagocytosis. This scheme is adapted from (Duerkop et al., 2009). 
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1.3.2 Architecture and geography of the human gut associated 
lymphoid tissue – GALT 
The gut-associated lymphoid tissue (GALT) is where the gut immune responses are 
generated and executed, as shown in Figure 4. 
The GALT includes the epithelial lining, solitary lymphoid follicles, Peyer‟s patches 
(PP), mesenteric lymph nodes (MLNs), lamina propria (LP) and cells localized within 
(Agace, 2008). The gut epithelium plays a vital role in the immune surveillance of the 
mucosa by participating in the immune responses generated at the mucosal surface 
(Sansonetti, 2004). Epithelium collaborates with antigen presentation cells such as 
dendritic cells (DCs) and other lymphoid cells in the mucosal lymphoid follicles 
distributed throughout the entire GI tract (Sansonetti, 2004). These follicles and their 
associated epithelium known as the follicular associated epithelium (FAE) either exist 
singularly in the colon and the rectum (Fujimura et al., 1992) or as aggregates known 
as Peyer‟s patches (PP) in the distal portion of the human small intestine - the ileum 
(Owen, 1999). The FAE is characterized by the presence of a specialized epithelial 
cell called the Microfold cell (M cell) (Sansonetti, 2004). The layer of tissue directly 
below the mucosal epithelial surface is known as the gut lamina propria (LP), in 
which the effector immune cells reside (Cho, 2008). Single lymphoid follicles, 
Peyer‟s patches and the MLNs are known as the inductive sites of the GALT, where 
DCs present antigens to naïve T cells and activate them in order to initiate the 
adaptive immune responses (Kunkel et al., 2003, Macpherson et al., 2005). The 
MLNs also serve a vital function by forming a barrier between the local and systemic 
immune responses (Macpherson et al., 2005). In experiments where MLNs were 
removed, bacteria were found in the spleen following a single intestinal challenge 
with commensal bacteria; repeated challenge subsequently led to dramatic 
splenomegaly (Macpherson and Uhr, 2004).  
 
Following T cell activation in the local secondary lymphoid tissue, memory T cells 
return to the circulation and eventually home to the effector sites of the gut – the 
lamina propria and the intestinal epithelium in order to clear the penetrating 
commensals (Kunkel et al., 2003, Macpherson et al., 2005). This process will be 
discussed later (Section 1.3.5). 
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(Mowat, 2003) 
Figure 4. Gut-associated lymphoid tissue of the small intestine.  
The GALT is coated by a thick mucus layer situated above an epithelial layer filled with 
densely-packed epithelial cells. The inductive sites of the GALT are the Peyer’s patches (PP) 
and the mesenteric lymph nodes (MLNs) where naïve T cells are primed. PPs are aggregates 
of immune follicles and their associated epithelium known as the follicular associated 
epithelium (FAE) situated at the subepithelial dome (SED). The FAE is characterized by the 
presence of M cells. Antigen-experienced T cells home to the effector sites of the GALT which 
include the epithelium and the lamina propria where they reside as either intraepithelial 
lymphocytes (IELs) or lamina propria lymphocytes (LPLs). This scheme is modified and 
adapted from (Mowat, 2003).  
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1.3.3 Maintenance of gut tolerance by intestinal dendritic cells in the 
GALT...... 
A key feature of the intestinal immune system is its ability to avoid the development 
of destructive inflammatory responses against normal non-harmful microbiota and to 
be able to initiate efficient immune responses again infections (Coombest& Powrie, 
2008). In this section, we discuss how intestinal dendritic cells contribute to the 
maintenance of gut tolerance. 
1.3.3.1 Dendritic cells 
In both humans and mice, dendritic cells (DCs) are a heterogeneous population 
categorized into subsets based on their origins, phenotype, locations, migratory 
pathways and functions (Shortman and Liu, 2002, Shortman and Naik, 2007).  
Both human and murine DCs fall into two main categories, the conventional myeloid 
DCs and the pre-dendritic precursor cells (Shortman and Liu, 2002, Shortman and 
Naik, 2007). Conventional DCs include migratory DCs found in the peripheral tissues 
and lymphoid-tissue-resident DCs; the former subset migrate to the lymph nodes 
through the lymphatics and present antigens to naïve T cells, examples are dermal 
DCs in the skin and lamina propria DCs in the intestine, and the latter include thymic 
and splenic DCs that do not migrate through the lymph (Shortman and Naik, 2007). 
Conventional DCs found at steady-state have typical DC morphology and exhibit full 
DC functions, in contrast, DC precursors do not (Shortman and Naik, 2007). Dendritic 
precursors include monocytes and plasmacytoid DCs which are round non-dendritic 
circulating cells; these cells require inflammatory signals to develop into fully-
functional DCs, and therefore are also known as inflammatory DCs (O'Keeffe et al., 
2002, Shortman and Naik, 2007, Hochrein et al., 2002). Murine studies have 
demonstrated the requirement of granulocyte / macrophage colony-stimulating factor 
(GM-CSF) for the development of monocyte-derived DCs in vivo and in vitro (Inaba 
et al., 1992a, Inaba et al., 1992b). In humans, both GM-CSF and IL-4 are required for 
the generation of monocyte-derived DC in vitro (Sallusto and Lanzavecchia, 1994).  
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1.3.3.2 Intestinal dendritic cell subsets 
Within the GALT, DCs found in the inductive sites (PP, MLNs) and the effector sites 
(small intestinal and colonic LP) have different functions and phenotypes (Mowat, 
2003, Ruedl et al., 1996, Ruedl and Hubele, 1997, Anjuere et al., 1999, Iwasaki and 
Kelsall, 2001, Iwasaki and Kelsall, 1999, Coombes and Powrie, 2008). The 
heterogeneous mucosal DCs can be classified based on their phenotypes and 
migratory properties, which also correlate to their functional differences. Much 
known about these DCs comes from the freshly isolated DCs from murine tissues, in 
contrast, blood is the only readily available source to study human DCs (Shortman 
and Liu, 2002).  
DCs in the Peyer’s patches  
DCs found in the small intestinal PP, MLNs and LP express CD11c, and may or may 
not express CD11b and CD8α (Iwasaki and Kelsall, 2001). Three major CD11c+ 
subsets have been identified in mice based on their expression of CD8α and CD11b; 
CD8α- CD11b-, CD8α- CD11b+ and CD8α+ CD11b- (Iwasaki and Kelsall, 2000, 
Iwasaki and Kelsall, 2001). Despite being situated in close proximity to the gut lumen, 
PP DCs do not directly sample antigens, instead, this is achieved via M cells and gut 
epithelial cells as described in Section 1.3.5. 
DCs in the lamina propria  
LP DCs are responsible for monitoring and surveying the gut lumen for commensal 
bacteria and food antigens (Bjorck, 2001). Small intestinal lamina propria have 
similar subsets of DCs compared to the PP (Johansson and Kelsall, 2005). Majority of 
the murine DCs found here are conventional myeloid DCs with a CD4
-CD8α- 
phenotype (Niess, 2008). Based on the expression of the fractalkine receptor CX3CR1 
and integrin αE chain CD103, small intestinal LP DCs are further divided into 
migratory DCs (CD103
+
) and non-migratory CX3CR1
+ 
DCs (Bogunovic et al., 2009, 
Johansson and Kelsall, 2005, Ng et al., 2010, Niess et al., 2005). Migratory DCs do 
not directly uptake antigens but constitutively migrate to the draining MLNs at steady 
state and under inflammatory conditions (Ng et al., 2010), whereas non-migratory 
DCs directly sample luminal antigens by extending their dendrites into the gut lumen 
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but these DCs are unable to migrate to the MLNs and efficiently stimulate naïve T 
cells (Schulz et al., 2009, Ng et al., 2010). 
DCs in the mesenteric lymph nodes 
The MLN DCs consist of those migrating DCs from the LP and the PP arriving in the 
steady state and resident DCs developed from blood-borne precursors (Coombes and 
Powrie, 2008, Naik et al., 2006, Ng et al., 2010). In both humans and mice, subsets of 
DCs found in the MLNs can also be differentiated by the expression of CD103 
(Coombes et al., 2007, Jaensson et al., 2008). CD103
 
is particularly found on MLN 
DCs expressing a high level of CD11c, and is likely to mark those arriving from the 
lamina propria (Coombes and Powrie, 2008, Kilshaw, 1993, Annacker et al., 2005). 
These DCs make a vital contribution to the generation of gut tolerance and immunity, 
which will be discussed further.  
1.3.3.3 Tolerogenic properties of intestinal dendritic cells 
Peripheral tolerance 
Based on their developmental stage, DCs exist either in the immature state or the 
mature state. Immature DCs are usually found in all peripheral tissues and express 
low levels of MHC class II and co-stimulatory molecules (Palucka and Banchereau, 
2002, Mommaas et al., 1995). In the absence of inflammatory stimuli, immature DCs 
maintain peripheral tolerance (against self antigens) by clonal deletion of auto-
reactive T cells, inducing T cell anergy or regulatory T cells (Hawiger et al., 2001, 
Lutz and Schuler, 2002, Schwartz et al., 1989, Steinman and Nussenzweig, 2002). In 
the intestine, the majority of the lymphoid-resident DCs are also found to be 
phenotypically and functionally immature and play a role in maintaining peripheral 
tolerance in the steady state (Wilson et al., 2003). Following the detection of 
pathogenic microbes, immature DCs undergo maturation during migration to the 
tissue-draining lymph nodes, upregulate co-stimulatory molecules and become highly 
immunogenic (Palucka and Banchereau, 2002, Steinman and Nussenzweig, 2002). 
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Induction of tolerance towards commensal bacteria 
Compared to DCs present in other locations, intestinal DCs are understood to 
preferentially induce a tolerogenic non-inflammatory gut environment in response to 
the abundant commensal bacteria (Westendorf et al., 2010). Mucosal DCs also 
express lower levels of bacteria-sensing Toll-like receptors (TLRs) compared to 
splenic DCs and myeloid DCs in the blood, and are thereby less responsive towards 
bacterial stimulation (Hart et al., 2005, Takenaka et al., 2007). Studies using murine 
DCs have also shown that CD11b
+
 myeloid DCs in the Peyer‟s patches are of 
particular importance in the induction of gut tolerance, these DCs simulate T cells to 
produce the anti-inflammatory cytokines IL-4, IL-10, in contrast, both CD11b
-
 and 
splenic DCs favour Th1 responses and the production of pro-inflammatory cytokines 
such as IFN-γ and IL-12 (Iwasaki and Kelsall, 2001, Iwasaki and Kelsall, 1999). Sato 
and colleagues have also shown that during naïve T cell stimulation in vitro, murine 
PP DCs but not splenic DCs produce a high level of IL-6; when PP DCs were co-
cultured with naïve B cells, higher levels of IgA were produced as compared to 
splenic DC stimulation (Sato et al., 2003).  
As mentioned before, another mechanism by which intestinal DCs maintain gut 
tolerance is via the induction of regulatory T cells during antigen-presentation (Barnes 
and Powrie, 2009), we next discuss the importance of regulatory T cells in mucosal 
tolerance. 
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1.3.4 Role of regulatory T cells in the maintenance of mucosal 
tolerance  
One of the main avenues to achieve gut homeostasis is via regulatory T cells (Tregs), 
these cells promote host tolerance to the abundant commensal bacterial and food 
antigens found in the gut. Tregs are characterized by their constitutive expression of 
transcription factor FoxP3, which confers their potent suppressive activity (Sakaguchi, 
2004, Bennett et al., 2001). Humans with mutations affecting the FoxP3 gene suffer 
from fatal autoimmune diseases (IPEX: immune polyendocrine enteropathy X-linked 
syndrome) with the gut being the most frequently affected organ (Bennett et al., 2001). 
Similarly, mice with a spontaneous mutation in the FoxP3 gene – known as scurfy 
mice also develop fatal autoimmune diseases affecting multiple organs, however 
intestinal inflammation is not observed due to the short life spans of these mice 
(Sakaguchi, 2004). In IPEX patients and scurfy mice, chronically activated and self-
reactive CD4
+
 T cells are found to be responsible for the symptoms developed 
(Ramsdell and Ziegler, 2003). These studies thus demonstrated the importance of 
Tregs in gut homeostasis in both animals and humans.  
1.3.4.1 Naturally occurring regulatory T cells 
Regulatory T cells were first described in mice by Sakaguchi and coworkers in 1995 
as a subset of CD4
+
 T cells with a constitutive expression of IL-2 receptor alpha-chain 
CD25 (Sakaguchi et al., 1995). These naturally occurring cells are developed in the 
thymus and constitute approximately 5-10% of all peripheral helper CD4
+
 T cells in 
mice (Roncarolo and Levings, 2000). They are anergic in nature and exhibit potent 
suppressive function both in vivo and in vitro (Itoh et al., 1999, Papiernik et al., 1998, 
Roncarolo and Levings, 2000). These suppressor cells were also found to require 
activation signals via the T cell receptor, however once activated the suppressor 
function is antigen non-specific (Thornton and Shevach, 2000).  
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Human CD4
+
CD25
+ 
regulatory T cells were discovered in the peripheral blood in 
2001 (Baecher-Allan et al., 2001, Jonuleit et al., 2001). Unlike mice, in which both 
CD25
high
 and CD25
low
 of the CD4
+
CD25
+
 population exhibit suppressor functions, in 
humans, only those CD4
+
CD25
high
 subsets have suppressor functions (Baecher-Allan 
et al., 2001). Human CD4
+
CD25
high
 regulatory T cells account for 1-2% of the total 
peripheral CD4
+
 T cell population (Baecher-Allan et al., 2001). Following the 
discovery of these cells, transcription factor FoxP3 was subsequently identified as the 
true signature of murine CD4
+
CD25
+
 regulatory T cells crucial for their development 
and functions (Fontenot et al., 2003), this was later on confirmed in humans 
(Roncador et al., 2005).  
It must also be considered that high levels of CD25 and FoxP3 are also transiently 
expressed by human recently activated conventional T cells which do not have 
suppressor functions (Gavin et al., 2006, Wang et al., 2007). Thus, a Treg-specific 
marker is yet to be identified. Despite this, markers important for the survival and the 
suppressive functions of Tregs have been identified such as the cytotoxic T 
lymphocytes antigen 4 (CTLA-4) and glucocorticoid-induced TNF-receptor-related 
protein (GITR) (Sakaguchi et al., 2010). 
1.3.4.2 Induced regulatory T cells 
Aside from the thymically generated naturally occurring regulatory T cells, Tregs can 
be induced from naïve CD4
+
 CD25
- 
T cells in vitro and in vivo (Chen et al., 2003, 
Curotto de Lafaille et al., 2004, Thorstenson and Khoruts, 2001). So far, the 
differentiation of naïve T cells into induced Tregs (iTregs) in vivo has been 
documented in the murine intestine (Coombes et al., 2007), inflamed lung (Curotto de 
Lafaille et al., 2008), tumors (Liu et al., 2007) and transplanted tissues (Cobbold et al., 
2004).  
The possible underlying mechanisms of iTreg generation have also been explored for 
both human and mice. In vitro generation of iTregs is shown to be dependent on TGF-
β and IL-2 (Chen et al., 2003; Zheng et al., 2007). Vitamin A metabolite retinoic acid 
also facilitates the generation of regulatory T cells mediated by TGF-β following 
priming by DCs in the secondary lymphoid tissue (Sun et al., 2007, Coombes et al., 
2007). In addition, studies have shown that only CD103
+
 DCs in the small intestinal 
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LP and the MLNs are capable of generating FoxP3
+
 Tregs in the presence of TGF-β 
and retinoic acid (Coombes et al., 2007, Sun et al., 2007). Interestingly, regulatory T 
cells generated in the presence of retinoic acid also express fully functional gut-
homing receptors α4β7 and CCR9 (Kang et al., 2007a). Natural Tregs and induced 
Tregs have also been shown to have similar functions, both are anergic and able to 
suppress effector T cell responses in vitro and in vivo (Sallusto and Lanzavecchia, 
2009). 
1.3.4.3 Regulatory T cell function 
Several mechanisms by which regulatory T cells suppress immune responses have 
been identified so far, most of which come from murine studies (Vignali et al., 2008, 
Shevach, 2000). Murine naturally occurring regulatory T cells were originally found 
to suppress other cells in a contact-dependent manner involving granzyme B but 
independent of perforin, resulting in the death of target cells (Gondek et al., 2005). 
Further studies then demonstrated that the inhibition activity of Tregs is mediated or 
at least partially mediated by the release of soluble cytokines TGF-β and IL-10 
independent of cell contact (Jonuleit et al., 2002, Beissert et al., 2006). In this context, 
TGF-β induces the conversion of peripheral CD4+CD25- naïve T cells into 
CD4
+
CD25
+
FoxP3
+
 regulatory T cells, while IL-10 attenuates the function of antigen-
presenting dendritic cells (Chen et al., 2003). As mentioned before, CTLA-4 is 
constitutively expressed by regulatory T cells at steady state (Read et al., 2000), 
blocking of this molecule inhibits their ability to prevent colitis in animal studies 
(Read et al., 2006). In addition, Tregs have been shown to use CTLA-4 to inhibit the 
metabolism of DCs in a process involving tryptophan (Fallarino et al., 2003).  
Unlike mice, the functional studies of human regulatory T cells are restricted to in 
vitro co-culture assays (Sakaguchi et al., 2010). It has been found that human Tregs 
are able to kill target cells using granzyme A or B in a perforin-dependent manner 
(Grossman et al., 2004a, Grossman et al., 2004b). Similar to mice, human Tregs are 
also able to suppress immune responses by inhibiting DC function (Ito et al., 2008). 
Nonetheless, there is no direct evidence suggesting findings in vitro genuinely reflect 
the suppressor functions of human regulatory T cells in vivo. To date, the precise 
molecular mechanisms of how human Tregs execute their suppressor functions 
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remains unclear. Interestingly, it has been suggested by Powrie that Tregs residing in 
different organs exert suppressor functions via different mechanisms (Fiona Powrie, 
presentation in seminar on regulatory T cells).  
1.3.4.4 Regulatory T cell trafficking   
Regulatory T cells play a key role in the maintenance of gut homeostasis, whether this 
is achieved via migration to the effector site of the gut tissue like conventional 
effector T cells or the associated secondary lymphoid tissue is still not fully 
understood (Izcue et al., 2009). In a previously established mouse model of colitis, it 
was shown that Tregs transferred into the recipients migrated to the mesenteric lymph 
nodes and the colon lamina propria leading to the amelioration of colitis (Mottet et al., 
2003). However, Tregs have also been shown to prevent intestinal inflammation in 
mice lacking MLNs, PP and the spleen indicating that these sites are dispensable in 
order for regulatory T cells to function (Makita et al., 2007).  
Both human and murine resting Tregs express CD62L and CCR7 which allow them to 
predominately recirculate to the secondary lymphoid organs and suppress the 
initiation of immune responses locally (Valmori et al., 2005). Further studies have 
shown that effector/memory T regs in both humans and mice express E-cadherin 
receptor CD103 (Huehn et al., 2004, Lehmann et al., 2002). Tregs are thus sub-
divided into three categories, the CD25
+
 CD103
-
 resting Tregs, and the CD103
+
 
effector memory Tregs that may or may not express CD25 but possess the most potent 
suppressive functions (Siegmund et al., 2005, Lehmann et al., 2002, Allakhverdi et al., 
2006). While CD103 is specifically associated with intraepeithelial and lamina 
propria T cells as well as a subset of intestinal DCs, its expression is not exclusively 
associated with gut-homing intestinal Tregs. Instead, CD103 is important for the 
homing and the retention of Tregs in the skin, and simply labels those Tregs that seek 
inflammatory sites (Suffia et al., 2005, Lehmann et al., 2002).  
A range of adhesion molecules and chemokine receptors are found to be expressed by 
murine CD103
+
 Tregs, such as the P-selectin ligands, the integrin α4β1 and α4β7, which 
allow their access to the extralymphoid tissue (Huehn et al., 2004). Murine effector 
regulatory T cells isolated from the skin and the gut express their respective organ-
specific homing receptors; those from the gut MLNs express a high level of α4β7 but 
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not P-selectin ligand (which targets cells to the skin) while the opposite holds true for 
those Tregs isolated from the skin (Siewert et al., 2007). Following antigen challenge 
in vivo, effector Tregs generated in the gut MLNs expressed α4β7 similar to 
conventional T cells; while the effector Tregs in the peripheral lymph nodes expressed 
P-selectin ligand but not α4β7 (Menning et al., 2010, Siewert et al., 2007). α4β7
+
 
regulatory T cells generated in vitro are also able to effectively clear acute colonic 
inflammation when transferred into the diseased animals (Menning et al., 2010).  
In humans, expression of trafficking markers on circulating regulatory T cells is less 
well characterized compared to mice. Current studies have shown that a high 
frequency of the peripheral blood Tregs express skin-homing receptors (CCR4, CLA), 
in contrast, CD103 and the gut-homing receptors α4β7 and CCR9 are found on a small 
number of circulating Tregs (Iellem et al., 2003, Hirahara et al., 2006). This 
observation raises the question of how regulatory T cells execute their suppressor 
functions in the gut (Sakaguchi et al., 2010). A possible explanation is that the ligand 
of α4β7 – MAdCAM-1 is also capable of binding to CD62L found on regulatory T 
cells in humans and mice (Picker and Butcher, 1992, Siegmund et al., 2005, Valmori 
et al., 2005). CD62L therefore target Tregs to the MLNs and the PP where they carry 
out suppressor functions (Iellem et al., 2003).  
The molecular mechanisms underlying the acquisition and regulation of homing 
molecules by Tregs in relation to their suppressor function in humans are not yet fully 
understood. This holds important implications in harnessing their therapeutic potential 
in diseases in which immune suppression is lacking. 
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1.3.5 Role of GALT DCs in the generation of protective immunity: 
from Peyer’s patches, mesenteric lymph nodes to the lamina propria  
In the presence of pathogenic bacteria, mucosal DCs are able to trigger rapid local 
adaptive immune responses in order to protect the host from potential tissue damage.  
 
There are multiple ways in which luminal antigens gain entry into the GALT beyond 
the epithelium. This can be achieved either by M cells, via the epithelium or directly 
by lamina propria resident DCs. M cells transport antigens from the gut lumen to the 
basolateral side of the epithelium, antigens are subsequently endocytosed and 
processed by DCs situated in the subepithelial dome of the PP (Coombes and Powrie, 
2008). Gut epithelial cells can also take up antigen, though much less efficiently than 
M cells (Kyd and Cripps, 2008). Antigens can also directly cross the epithelium and 
subsequently captured by the LP DCs (Ng et al., 2010). DCs are also able to directly 
take up antigens that have „leaked‟ into the lamina propria due to the break-down of 
epithelium integrity during intestinal inflammation (Ng et al., 2010). DCs residing in 
the lamina propria can directly sample the gut lumen by forming tight-junction-like 
structures with epithelial cells (Rescigno et al., 2001). Additionally, antigens could be 
transported to the lamina propria DCs by IgG in the gut lumen via neonatal Fc 
receptors expressed on the intestinal epithelium (Yoshida et al., 2004). These 
mechanisms are illustrated in Figure 5 , which is adapted and modified from (Mowat, 
2003).  
 
Following antigen-presentation by DCs, naïve T cells undergo differentiation and 
proliferation, T cells in the Peyer‟s patches (PP) eventually drain into the mesenteric 
lymph nodes (MLNs) through afferent lymphatics of the gut (Salmi and Jalkanen, 
2005). Antigen-loaded DCs in the PP can also migrate to the MLNs, where they prime 
naïve T cells (Mowat, 2003). Naïve T cells reside in the MLNs for an undefined 
period of time during which they undergo further differentiation before emerging as 
effector / memory cells in the circulation and finally accumulate in the gut mucosa 
(Mowat, 2003). It is during antigen presentation in the MLNs that T cells acquire the 
gut-homing receptors (gHRs) which allow them to enter the effector site of the GALT 
via endothelium lining the blood vessel; some memory T cells further migrate to the 
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gut epithelium in the small intestine (Berlin et al., 1993, Lefrancois et al., 1999b, 
Mora et al., 2003, von Andrian and Mempel, 2003).  
 
T cell acquisition of the gHRs – integrin α4β7 and CCR9 is induced by intestinal DCs 
in a mechanism involving vitamin A metabolism which will be discussed in detail 
next (Iwata et al., 2004).  
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(Mowat, 2003) 
Figure 5. Antigen uptake and presentation by mucosal dendritic cells. 
There are several routes by which antigens are acquired by intestinal DCs. 
1. M cells transfer intact antigens to DCs in the PP. 2. LP DCs directly sample the gut lumen 
by extending dendrites across the gut epithelium. 3. Antigens can cross the epithelium and 
subsequently captured by the LP DCs. 4. Luminal antigens can also be transported to the LP 
DCs by IgG via neonatal Fc receptors expressed on the epithelium. 5. In case of a break-
down in epithelium integrity, antigens breach the epithelium and are found in the lamina 
propria. 6. Luminal antigens can directly gain entry into the blood stream and are carried 
into the spleen where they are processed by splenic DCs. 7. Lastly, epithelial cells may act as 
antigen presenting cells (APCs) and directly present antigens to naïve T cells.  
Following priming in the PP, T cells eventually drain into the MLNs. Alternatively, antigen-
loaded APCs leave the PP and enter the MLNs, where they prime naïve T cells. During 
antigen-presentation in the MLNs, gHR expression is imprinted on T cells by DCs in a 
process involving vitamin A metabolism. α4β7
+
CCR9
+ 
effector T cells
 
leave the MLNs via the 
efferent lymphatics and enter the blood stream from where they exit into the effector sites of 
the gut: the lamina propria or further to the small intestinal epithelium. This figure is adapted 
from (Mowat, 2003). 
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1.3.5.1  Mechanisms of gut-homing receptor acquisition in T cells by DCs during 
antigen presentation 
It was first demonstrated in mice that only DCs isolated from the MLNs and the PP 
preferentially up-regulated integrin α4β7 and chemokine receptor CCR9 when 
activating naïve T cells (Mora et al., 2003, Stagg et al., 2002, Johansson-Lindbom et 
al., 2003). In contrast, T cells activated in the cutaneous secondary lymphoid tissue 
expressed skin-homing receptors (Campbell and Butcher, 2002, Stagg et al., 2002). 
The mutually exclusive sets of skin and gut-homing receptors expressed by T cells 
commit them to either destination (Zabel et al., 1999, Rott et al., 1996). These results 
highlighted the importance of local microenvironment in T cell acquisition of homing 
receptors; however, the underlying molecular mechanisms were not immediately clear. 
Following these observations, Iwata and colleagues subsequently discovered the 
significance of vitamin A metabolite retinoic acid (RA) in the imprinting of gut 
homing specificity on T cells (Iwata et al., 2004).  
The small intestine has long been established as the primary site for the absorption 
and the processing of vitamin A and beta-carotenoids (Moore, 1930). Vitamin A 
enters the body exclusively through diet, and is mainly obtained as retinol from the 
liver, dairy products or as carotenoids from plants (Sigmundsdottir and Butcher, 
2008). Vitamin A is inactive and requires enzymatic processing to become activated 
(Sigmundsdottir et al., 2007). It is first converted to retinal catalyzed by alcohol 
dehydrogenases (ADH) commonly found in most cells, and then to retinoic acid (RA) 
catalyzed by retinal dehydrogenases (RALDH) which are only expressed by certain 
cell types including DCs found in the PP, LP and the MLNs in the small intestine 
(Napoli, 1999, Duester, 2000, Iwata et al., 2004). In the gut, vitamin A is metabolized 
locally by small intestinal DCs resulting in the production of retinoic acid, which 
along with antigens are presented to naïve T cells during antigen-presentation 
(Sigmundsdottir and Butcher, 2008, Iwata et al., 2004). As a result, RA binds to its 
receptors – the retinoic acid receptor RAR and RXR expressed on naïve T cells, this 
RA-dependent signaling thus imprints T cells with gut homing properties by up-
regulating the expression of α4β7 and CCR9 during T cell activation (Sigmundsdottir 
and Butcher, 2008, Iwata et al., 2004, Coombes et al., 2007, Jaensson et al., 2008, 
Johansson-Lindbom et al., 2005, Sun et al., 2007).  
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Aside from producing RA, DCs can also internalize exogenous RA produced by other 
cells in the gut such as LP macrophages (Denning et al., 2007), mesenteric lymph 
node stromal cells (Hammerschmidt et al., 2008) and gut epithelial cells (Lampen et 
al., 2000). However, the contribution of RA from sources other than DCs towards the 
imprinting process is not fully understood (Ng et al., 2010).  
Murine studies have also demonstrated that GALT DCs are more effective at 
converting retinal to RA than splenic DCs and other peripheral lymph node DCs, 
GALT DCs are thus more effective at inducing integrin α4β7 and CCR9 expression on 
T cells (Iwata et al., 2004). In line with this observation, only CD103
+
 DCs are able to 
induce the expression of α4β7 and CCR9, these DCs were also found to express higher 
levels of enzymes required for vitamin A metabolism compared to CD103
-
 DCs 
(Johansson-Lindbom et al., 2005, Jaensson et al., 2008). Moreover, among these 
CD103
+
 DCs, lamina propria DCs are the most effective at generating α4β7
+
 CCR9
+
 
CD8
+
 T cells compared to the MLN DCs or PP DCs (Johansson-Lindbom et al., 2005). 
However, the MLNs are believed to serve as the primary site where imprinting of gut 
homing specificity occurs as antigen-loaded DCs are carried into the MLNs via 
draining lymphatics (Forster et al., 2008, Coombes and Powrie, 2008, Macpherson 
and Uhr, 2004, Mowat, 2003, Malmstrom et al., 2001). Further studies have shown 
that similar mechanisms involving vitamin A metabolism were also used to instruct 
regulatory T cells and B cells to become gut-tropic cells (Siewert et al., 2007, Mora et 
al., 2006, Kang et al., 2007b, Sun et al., 2007).  
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1.3.5.2 Cellularity of the gut lamina propria 
Upon arrival at the target tissue (such as LP of the gut), effector T cells re-encounter 
their cognate antigens presented by macrophages, DCs and B cells and generate a 
more rapid and vigorous response accompanied by the release of cytokines, which in 
turn promote T cell clonal expansion (such as IL-2), and upregulation of adhesion 
molecules expressed on the endothelium vasculature which leads to further 
recruitment of lymphocytes to the site of infection (Koboziev et al., 2010). Lamina 
propria lymphocytes (LPLs) and intraepithelial lymphocytes (IELs) have important 
functions in maintaining gut homeostasis, the dysregulation of which has been 
associated in intestinal diseases such as inflammatory bowel disease and celiac 
disease (Agace, 2008).  
 
Lamina propria is the effector site of the gut-associated lymphoid tissue and consists 
of activated or memory B cells, CD4
+TCRαβ+, and CD8+TCRαβ+ T cells generated 
following activation in the PP or the gut MLNs as previously described (Agace, 2008). 
B cells mature into IgA-producing plasma cells and remain in the lamina propria 
(Mowat, 2003). CD4
+
 T cells isolated from the LP of healthy individuals are found to 
produce pro-inflammatory cytokines IFN-γ, IL-4 spontaneously but not anti-
inflammatory IL-10 (Carol et al., 1998, Braunstein et al., 1997). Although CD8
+
 T 
cells preferentially migrate to the epithelium once arriving in the lamina propria, they 
still constitute 40% of total T cells in the lamina propria (Mowat, 2003). Studies in 
mice have confirmed that CD8
+
 T cells in the lamina propria display potent 
cytotoxicity (Lefrancois et al., 1999a).  
In the small intestine and the colon of both humans and mice, IELs consist of T 
lymphocytes with unique features (Kunisawa et al., 2007, Jabri and Ebert, 2007). In 
the small intestine, IELs are primarily CD8
+
 cells subdivided into several groups 
based on the expression of T cell receptors (Agace, 2008, Hayday and Gibbons, 2008, 
Jabri and Ebert, 2007). For instance, those dominating the human small intestine are 
found to be the conventional CD8αβ+TCRαβ+ T cells (Jabri and Ebert, 2007). Small 
intestinal IELs are thought to have entered the epithelium following priming in the gut 
secondary lymphoid organs (PP, MLN) as they are found to express memory T cell 
marker CD45RO (Agace, 2008, Lundqvist et al., 1995). This is also confirmed by 
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murine studies which have shown that IELs in the small intestine are mainly of 
memory phenotype (Camerini et al., 1993, Ibraghimov and Lynch, 1994). In contrast, 
in the human large intestine, majority of the IELs are TCR αβ+CD4-CD8- double 
negative cells of naïve phenotype (Jabri and Ebert, 2007, Kunisawa et al., 2007). IELs 
reside as single cells among the epithelial cells, and monitor stressed or damaged 
epithelial cells and play a key role in the maintenance of gut homeostasis by 
regulating both innate and acquired immunity (Kunisawa et al., 2007).  
Following their recruitment to the gut, memory T cells must be retained in the gut in 
order to exert their effector functions. This role is fulfilled by the interaction of 
integrin αEβ7 on T cells and its ligand E-cadherin expressed on the gut epithelial cells 
in humans and mice (Cepek et al., 1994). By binding to E-cadherin, αEβ7 may also 
function by regulating T-cell interaction with epithelial cells (Agace, 2008). 
Interestingly, in αEβ7 knockout animals, a reduced number of both intraepithelial 
lymphocytes and lamina propria lymphocytes are found, suggesting E-cadherin may 
bind to other receptor besides αEβ7 (Schon et al., 1999). While α4β7 is mainly found on 
circulating memory CD4
+
 and CD8
+
 T cells, B cells that are „committed‟ to the gut, 
integrin αEβ7 is expressed predominantly on the intraepithelial and lamina propria 
CD8
+
 T lymphocytes that have already homed to the gut in both humans and mice 
(Kilshaw and Murant, 1991, Shaw and Brenner, 1995).  
In humans, αEβ7 is expressed on over 95% of the IELs, 50% of lamina propria 
lymphocytes but only 2% of the peripheral T lymphocytes (Shaw and Brenner, 1995). 
Studies in human peripheral blood lymphocytes also showed that αEβ7 is 
predominantly found on memory CD8
+
 T cells (CD45RO
+
) co-expressing high level 
of α4β7 (Rott et al., 1996). Collectively, these findings support the concept that αEβ7 
functions to mediate the retention of lymphocytes in the gut mucosa (Shaw and 
Brenner., 1995). Further studies in mice have demonstrated that CD8
+
 T cells down-
regulate α4β7 once homed to the lamina propria, but upregulated integrin αEβ7 
(Ericsson et al., 2004). Interestingly, in the same study, CCR9 was also found to be 
responsible for the initial induction of αEβ7 on CD8
+
 T cells, however, in the absence 
of CCR9, maximum level of αEβ7 was still generated following a prolonged residency 
of CD8
+
 T cells in the small intestine epithelium (Ericsson et al., 2004).  
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1.4 IBD: A breakdown of gut tolerance and homeostasis  
1.4.1  Disease phenotype  
The inflammatory bowel diseases (IBD) are chronic and relapsing immunologically 
mediated disorders affecting approximately 1 in 250 of the UK population(Carter et 
al., 2004). The disease has two subtypes, ulcerative colitis (UC) and Crohn‟s disease 
(CD). Ulcerative colitis is characterized by continuous diffuse mucosal inflammation 
limited to the colon. There are chronic inflammatory changes characterized by the 
presence of crypt architectural distortion and disruption, with a significant chronic 
inflammatory (lymphocytic) infiltration. When the disease is active, there is also a 
significant superficial neutrophil infiltration. UC may affect any length of colon, but 
is generally continous moving proximately from the rectum. The Montreal 
classification divides disease into proctitis (rectum only), left-sided disease to the 
splenic flexure and extensive disease where inflammation extending proximal to the 
splenic flexture (Silverberg et al., 2005). In contrast, Crohn‟s disease is characterized 
by patchy transmural inflammation which extends into the entire depth of the 
intestinal wall with the presence of granuloma and lymphocytic infiltration (Baumgart 
and Sandborn, 2007). Unlike UC, Crohn‟s disease can affect any part of the 
gastrointestinal tract from mouth to the anus; however it is usually limited to the small 
intestine, terminal ileum and the colon (Podolsky, 2002). Granulomas formed by 
macrophages are also often associated with inflammation seen in Crohn‟s disease 
(Podolsky, 2002). CD and UC share similar clinical features such as bloody diarrhea, 
severe weight loss, fever, abdominal pain and anemia. IBD severely affects patients‟ 
quality of life, Crohn‟s disease in particular is also a predisposing factor for small 
bowel and colorectal cancer (Canavan et al., 2006). 
1.4.2 Clinical indices 
There are a variety of tools for assessing clinical activity within the context of clinical 
trials. They all have weakness, and do not generally take account of endoscopic and 
histological findings. One of the commonest and simplest tools for determining UC 
activity is the Simple Clinic Colitis Activity Index (SCCAI), and disease remission is 
defined as having a score of below 3 (Walmsley et al., 1998a). For Crohn‟s disease, 
the CDAI (Cohn‟s Disease Activity Index) is comprehensive but requires a week-long 
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diary, for routine purposes the Harvey-Bradshaw index (HBI) is simple and effective. 
A score of above 8 is severely active and below 5 is considered remission (Harvey 
and Bradshaw, 1980). 
1.4.3 Treatments 
Treatment options for UC and CD are similar, and a variety of treatments may be used 
for active disease and maintenance of remission. The major classes of drugs used are 
steroids, anti-inflammatories, immunosuppressants and biologics.  
Steroids are used for active UC and CD and is normally a short-term treatment 
(Schwartz and Cohen, 2008). Anti-inflammatories such as 5-ASA (5-aminosalicylic 
acid) are used for treating active UC and maintenance of remission. They have little 
role in CD (Gearry et al., 2007). Immunosuppressants such as azathioprine and 
methotrexate affect the immune responses and may be used for active disease and 
maintenance of remission (Lichtenstein et al., 2006). Biologics such as anti-TNF 
binds to TNF-α and are used for active disease and maintenance (Rutgeerts et al., 
2004, Travassos and Cheifetz, 2005, Neuman, 2007).  
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1.4.4 Disease pathogenesis  
1.4.4.1  Genetic factors 
Although the etiology of IBD remains unknown, a widely accepted hypothesis is that 
IBD is the result of overly aggressively T cell response to common gut commensal 
bacteria in genetically susceptible hosts (Sartor, 2006). Many IBD susceptibility genes 
have been discovered so far, among which  polymorphism in the NOD2 (nucleotide 
binding oligomerization domain 2) gene in particular carries the highest risk of 
development of Crohn‟s disease than any other disease susceptibility genes (Podolsky, 
2002). NOD2 encodes an intracellular protein that recognizes muramyl dipeptide 
(MDP) derived from peptidoglycans found in the bacterial cell wall (Inohara et al., 
2003). Many cells have been found to express NOD2 such as macrophages, 
endothelial cells, dendritic cells and intestinal Paneth cells and epithelial cells 
(Abraham and Cho, 2006). Studies have found North American and European patients 
with Crohn‟s disease including those with a family history are more likely to have 
variants of NOD2 expression than those without Crohn‟s disease (Podolsky, 2002). 
This association involves three NOD2 polymorphisms which change the amino acid 
sequence in the protein it encodes therefore affecting the responses generated towards 
bacteria-derived peptidoglycan (Ogura et al., 2001, Hugot et al., 2001). Wild-type 
NOD2 protein activates the nuclear factor NFκB (NF-κB) and mitogen-activated 
protein (MAP) kinase signaling pathways leading to the production of anti-bacterial 
peptides and pro-inflammation cytokines such as TNF-α and IL-1β (Kobayashi et al., 
2005, Abraham and Cho, 2006). In patients with NOD2 variants, reduced levels of 
NF-kB activation in macrophages and decreased secretion of pro-inflammatory 
cytokines upon stimulation with bacterial peptidoglycan have been reported 
(Abraham and Cho, 2006). Mutations in the NOD2 genes are found to be particularly 
associated with Crohn‟s disease affecting the ileum, owing to its ability in causing 
defective bacteria-sensing pathway in Paneth Cells (Ogura et al., 2003). In healthy 
individuals, chronic NOD2 stimulation leads to a down-regulation of pro-
inflammatory cytokines production by macrophages rendering tolerance to bacterial 
stimulants, which was not observed in carriers of NOD2 variants (Hedl et al., 2007).  
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1.4.4.2 Environmental factors 
The presence of commensal gut flora has been shown to be vital in the initiation and 
perpetuation of IBD. Genetically-modified mice deficient in IL-2 or IL-10 raised in 
germ-free environments do not develop chronic intestinal inflammation, which only 
occurs when transferred to specific pathogen free environment (Sadlack et al., 1993, 
Kuhn et al., 1993). There is dysbiosis in IBD, which describes an imbalance in 
putative „harmful‟ versus „protective‟ intestinal bacterial species (Tamboli et al., 
2004). For example, an increased concentration of Gram negative anaerobes including 
those belonging to the Bacteroidetes phylum has been reported in both UC and CD, 
while a reduction in Firmicutes species was observed in IBD patients compared to 
healthy controls (Manichanh et al., 2006, Ott et al., 2004, Van de Merwe et al., 1988). 
Increasing numbers of studies have also reported that smoking plays a role in the 
cause of IBD. Interestingly, smoking protects against UC but is associated with an 
increased risk of developing CD (Cosnes et al., 2001). In addition, the use of non-
steroidal anti-inflammatory drugs could also lead to flares of colitis caused by IBD 
(Evans et al., 1997).  
1.4.4.3 T cell-mediated immune responses in IBD 
The immunopathologies of both UC and CD are strongly associated with the influx of 
leukocytes into the site of inflammation such as T cells, B cells and granulocytes 
(Koenecke and Forster, 2009). In animal models, the development of chronic 
enterocolitis depends on intestinal T cells (Strober et al., 2002). Dysregulation of 
CD4
+
 helper T cells in particular has been shown to contribute to the pathogenesis of 
IBD in both humans and mice (Elson et al., 2005, Izcue et al., 2008, Fujino et al., 
2003, Nguyen et al., 2007). While other non-specific mediators of inflammation 
including growth factors, prostaglandins and reactive oxygen metabolites such as 
nitric oxide enhance inflammation and contribute to the tissue destruction seen in IBD 
(Fiocchi, 1998, Demetter et al., 2005), here I focus the discussion on the importance 
of T cell mediated responses in the pathogenesis of IBD. 
 
Chapter 1 Introduction 
 
63 
1.4.4.3.1 Th1, Th2, Th17 responses  
Typically, T cell receptors (TcR) on naïve T cells recognize antigens presented on 
MHC molecules by professional antigen presenting cells such as DCs in the 
secondary lymphoid tissue such as local draining lymph nodes. As naïve T cells are 
exposed to a local milieu filled with cytokines, they respond by activating various 
signaling pathways and transcription factors leading to the generation of different 
effector cell types defined by their cytokine profile (Mosmann and Coffman, 1989, 
Zenewicz et al., 2009, Zhou et al., 2009). 
Th1 CD4
+
 T cells are generated under the influence of IL-12 and transcription factor 
T-bet (Kaplan et al., 1996) and characterized by the production of IL-2 and a high 
level of IFN-γ and TNF-α (Zenewicz et al., 2009, Danese and Fiocchi, 2006), and is 
found to be predominantly associated with CD (Strober and Fuss, 2002, (Parronchi et 
al., 1997). In contrast, the situation in UC is more complex. A Th2 response 
characterized by the secretion of IL-4, IL-5, IL-10, and IL-13 has been described  
(Inoue et al., 1999, Heller et al., 2005), but an increase in Th1 cytokines such as TNF-
α has also been reported in UC (Akazawa et al., 2002, Casellas et al., 1994). The 
transcription factor GATA-3 is essential to commit T cells to a Th2 phenotype (Zheng 
and Flavell, 1997, Fort et al., 2001).  
The recently discovered Th17 cells further complicate the scene and have since been 
shown to be important in the pathogenesis of both subtypes of IBD (Bettelli et al., 
2007, Zenewicz et al., 2009, Kobayashi et al., 2008). The development of human 
Th17 cells relies on IL-1β, IL-6, IL-21 and IL-23, but is inhibited by IL-12 and TGF-
β (Yang et al., 2008, Acosta-Rodriguez et al., 2007). Human Th17 cells produce IL-
17A, IL-17F, IL-21 and IL-22, the over-expression of which has been found in the gut 
biopsies of the inflamed colon as well as the sera of these patients (Fujino et al., 2003, 
Nielsen et al., 2003, Zenewicz et al., 2009). These Th17-associated cytokines can play 
a pro-inflammatory role or have a protective effect in IBD (Liu et al., 2009, Zenewicz 
et al., 2009). For example, while studies in mice have demonstrated the pro-
inflammatory nature of IL-23 (Hue et al., 2006, Uhlig et al., 2006b), IL-22 appeared 
to play a protective role by protecting mucin-producing goblet cells (Sugimoto et al., 
2008, Zheng et al., 2008, Zenewicz et al., 2008).  
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Indeed another reason why Th17 cells have attracted so much attention owes to their 
link to the generation of induced regulatory T cells during T cell activation. (Zhou et 
al., 2008, Mucida et al., 2007). For example, in mice, TGF-β alone can induce Foxp3+ 
Tregs, but inhibit Th17 development (Fantini et al., 2004, Acosta-Rodriguez et al., 
2007), however when combined with IL-6 differentiation of Th17 cells is promoted 
suggesting the complexity between cytokine milieu and the cellular responses 
generated (Bettelli et al., 2007). Further, it was shown that the pathogenic potential of 
Th17 can be restrained by IL-10, the production of which is ceased by IL-23 
(McGeachy et al., 2007). Clearly, the balance between the generation of pro-
inflammatory and regulatory responses is crucial in the maintenance of gut 
homeostasis, and dysregulated cellular responses may lead to the initiation, 
persistence and the relapses of IBD (Xavier and Podolsky, 2007).  
1.4.4.3.2 T cell gut homing as a pathogenic mechanism in IBD 
As previously discussed, the interaction between integrin α4β7 and MAdCAM-1 is 
crucial for lymphocyte homing to the gut. In the presence of inflammation, the 
mechanisms, cells and molecules governing this process become much more complex 
partially due to the presence of pro-inflammation cytokines.  
MAdCAM-1 is constitutively expressed in the postcapillary venules of intestinal LP, 
MLNs, the HEV of PP (Berlin et al., 1995, Butcher et al., 1999) and venules of both 
the small intestine and the colon (Briskin et al., 1997). Under inflammatory conditions, 
MAdCAM-1 expression can also be induced by pro-inflammatory cytokines such as 
TNF–α and IL-1 (Sikorski et al., 1993). MAdCAM-1 can thus be up-regulated on the 
endothelium of the inflamed colonic and small intestinal postcapillary venules 
enhancing lymphocyte entry to the gut (Briskin et al., 1997). In addition, α4β7-
dependent lymphocyte adhesion to MAdCAM-1 can be up-regulated by chemokine 
stromal cell-derived factor-1α (SDF1α, CXCL12) (Wright et al., 2002).  
The importance of adhesion molecules in mediating lymphocyte trafficking to the gut 
highlights their functions as potential therapeutic targets in treating chronic 
inflammation such as IBD. Recent clinical trials have shown that treatment with 
adhesion-molecule inhibitor – anti-α4 monoclonal antibody increases the rate of 
clinical remission, and improves the quality of life in patients with active Crohn‟s 
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disease (Ghosh et al., 2003). Anti-α4β7 (Hamann et al., 1994) and anti-MAdCAM-1 
(Palecanda et al., 1999) monoclonal antibodies have also been shown to effectively 
inhibit lymphocyte homing to the gut. Previous clinical trials have shown that 
humanized anti-α4β7 monoclonal antibodies are effective in the induction of clinical 
and endoscopic remission in patients with active ulcerative colitis (Feagan et al., 
2005). Interestingly, α4β7 was found to play a redundant role in other gastrointestinal 
diseases such as human small-intestinal nematodes infection, whereby blockade of 
α4β7 or MAdCAM-1 by antibody did not prevent CD4
+
 T cell infiltration into the site 
of infection leading to the eventual expulsion of parasites (Bell and Else, 2008).  
In mice, blocking MadCAM-1/α4β7 pathway alone was effective in reducing colonic 
inflammation (Picarella et al., 1997). In line with the finding that MAdCAM-1 can 
also bind to L-selectin other than α4β7 (Berg et al., 1993), blockade of both MadCAM-
1 and L-selectin is required for the attenuation of chronic ileitis in mice, suggesting 
the MAdCAM-1/L-selectin axis might be important in T cell homing to the small 
bowel (Rivera-Nieves et al., 2005).  
In addition to MAdCAM-1, other adhesion molecules such as VCAM-1 and ICAM-1 
have also been shown to contribute to lymphocyte trafficking in a variety of acute and 
chronic inflammatory conditions including IBD (Henninger et al.,1997).  
VCAM-1 is induced on the vascular endothelium in the non-mucosal site of 
inflammation, and binds to integrin α4β1 (Bevilacqua, 1993, Rott et al., 1996). In 
contrast, ICAM-1 is constitutively expressed on the endothelium of many organs in 
humans and mice and upregulated following inflammation and binds to LFA-
1(Osborn, 1990, Bevilacqua, 1993, Henninger et al., 1997, Stanley et al., 1994). 
Interestingly, in an experimental mouse colitis model, only blockade of VCAM-1 but 
not MAdCAM-1 or ICAM-1 using monoclonal antibody was able to attenuate colitis 
suggesting its potential in anti-inflammatory therapy in IBD (Soriano et al., 2000). 
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While the MAdCAM-1/ α4β7 interaction enables T cell homing to the entire intestine, 
the interaction between CCR9 and CCL25 is required for antigen-experienced T cell 
homing to the small intestine and small intestinal epithelium (Stenstad et al., 2007, 
Kunkel et al., 2000, Zabel et al., 1999, Berlin et al., 1993, Lefrancois et al., 1999b). 
In mice, blockade of CCL25 was found to have no effect in T cell migration to the 
colon while significantly inhibiting T cell access to the small intestine (Hosoe et al., 
2003), suggesting that blocking the CCL25-CCR9 axis may have therapeutic potential 
in treating human CD involving the small bowel.  
Besides CCL25-CCR9 interaction, other chemokine and receptor interactions have 
also been reported in IBD, such as the CXCL10-CXCR3 axis and the CCL20-CCR6 
axis. Human chemokine CXCL10 (also known as interferon-inducible protein 10, IP-
10) is expressed on the colonic epithelial cells and the small intestine lamina propria 
in both physiological and inflammatory conditions (Uguccioni et al., 1999). CXCL10 
binds to receptor CXCR3 on T cells and has been shown to attract activated T cell 
adhesion to the endothelium (Angiolillo et al., 1995, Loetscher et al., 1996). While, an 
increased level of CXCL10 has been reported in patients with UC (Uguccioni et al., 
1999), murine studies suggest that CXCL10 is associated with the survival of colonic 
parenchymal cells rather than the infiltration of T cells to the site of inflammation 
(Sasaki et al., 2002).  
CCL20, also known as MIP-3α (macrophage inflammatory protein) is constitutively 
produced by the follicle-associated epithelial cells in the dome region of Peyer‟s 
patches in the murine small intestine (Nishimura et al., 2009). In human studies, an 
elevated level of CCL20 has been found in the crypts and on the epithelial cells of 
patients with both UC and CD (Kwon et al., 2002). CCL20 binds to CCR6, whose 
expression has been found on the α4β7
+
 gut-homing memory T cells (Liao et al., 1999). 
However, the contribution of CCL20-CCR6 interaction in the pathogenesis of IBD is 
yet to be established. 
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1.4.4.3.3 Regulatory T cells in IBD 
The ability of thymus-generated naturally occuring Tregs to suppress colonic 
inflammation was first demonstrated in mice (Powrie et al., 1993). In mice, once 
Tregs were depleted, the major target of inflammation was the gastrointestinal tract 
(GI), underlying the importance of regulatory T cells in maintaining a healthy GI tract 
(Powrie et al., 1993). In antigen-specific animal models of intestial inflammation, 
induction and expansion of antigen-specific regulatory T cells also prevent 
uncontrolled intestinal inflammation (Westendorf et al., 2005).  
In IBD patients with active disease, a reduction in the proportion of circulating 
suppressive Tregs (CD4
+
CD25
+
CD45RO
+
Foxp3
+
) has been reported by many groups 
(Takahashi et al., 2006, Maul et al., 2005, Saruta et al., 2007b), suggesting a 
quantitative defect in Treg in IBD. In line with this finding, an increase in the number 
of Tregs were found in the MLNs and the LP of the inflamed mucosa of IBD patients 
compared to healthy controls(Makita et al., 2007, Maul et al., 2005, Saruta et al., 
2007b, Yu et al., 2007). However, when compared to the patients with non-IBD 
related colonic inflammation, the number of mucosal Tregs in IBD patients was lower 
(Uhlig et al., 2006a, Maul et al., 2005). Hence, based on these results, correlation 
between quantitative defects in Treg and IBD is inconclusive and still debatable. In 
addition, as the expression of FoxP3 is found on Tregs as well as those recently 
activated T cells this also makes quantification of Tregs in human studies less 
accurate (Allan et al., 2007, Wang et al., 2007).  
Functional studies have also shown that Tregs isolated from the intestine of IBD 
patients display similar immunosuppressive function compared to those isolated from 
healthy controls (Maul et al., 2005, Saruta et al., 2007b, Makita et al., 2004). As these 
studies have been carried out outside the inflamed environment and its associated 
cytokine milieu, these results may not be faithful reflections of Treg activity in vivo 
(Himmel et al., 2008). Nonetheless, Krus and colleagues have shown that IBD 
patients have a defective generation of Tregs in vivo, and as a result these patients do 
not develop tolerance to oral antigens compared to healthy popualtions, but instead 
generate proliferative responses. (Kraus et al., 2004a, Kraus et al., 2004b).  
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In summary, whether and how lack of Treg suppressor function contributes to the 
development of IBD remains unclear and awaits further in-depth analysis. 
1.4.4.4 B cells in IBD 
As mentioned before, at steady sate, mature B cells are found in the lamina propria of 
the GALT, here they produce immunoglobulin IgA which is translocated across the 
epithelium and deposited on the apical surface of the epithelium thus preventing 
bacterial invasion of the intestinal mucosal surfaces (Macpherson et al., 2005, Agace, 
2008, Mowat, 2003). However, the role of B cells in the pathogenesis of IBD is still 
not clear. The presence of antimicrobial antibodies in the serum of patients with IBD 
compared to healthy controls implies that B cells are indeed active under such 
inflammatory conditions (Lodes et al., 2004). Studies in a murine model of 
spontaneous ileitis similar to human Crohn‟s disease found that B cells play a pro-
inflammatory role in driving the inflammation (Olson et al., 2004, Matsumoto et al., 
1998). In these mice, a significant increase in the number of B cells were found in the 
MLNs compared to the wild-type mice; when transferred together with CD4
+
 T cells 
into SCID mice, it resulted in increased severity of ileitis (Olson et al., 2004). 
However, the anti-inflammatory properties of B cells have also been reported in 
murine models of colitis (Mizoguchi et al., 2000). Taken together, the role of B cells 
in the pathogenesis of IBD is yet to be determined (Velazquez et al., 2005). 
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1.4.5 Disease biomarkers  
1.4.5.1  IBD biomarkers  
Current therapies for IBD have limitations such as significant side effects and 
elevated costs, therefore significant improvement is required (Scaldaferri et al., 2010). 
Although current biological therapy targets key molecules involved in the induction 
and maintenance of chronic intestinal inflammation, due to the variation of disease 
phenotypes among patients, there is a need to differentiate between the aggressive 
form and the benign course from a therapeutic point of view in order to tailor therapy 
to patients (Scaldaferri et al., 2010, Dotan, 2009). Therefore, any biological markers 
that will accurately predict disease activity and subsequent responses to therapy in 
patients will be very helpful towards personalizing pathogenesis-orientated therapy in 
IBD (Scaldaferri et al., 2010). An examples of such marker is the pro-inflammatory 
cytokine TNF-α, the level of which is found to be elevated in the colorectal mucosa 
and stools of both UC and CD patients (Akazawa et al., 2002, Casellas et al., 1994). 
Measuring the level of TNF-α in the mucosa of IBD patients has also been shown to 
be able to predict long-term remission following treatment with monoclonal antibody 
anti-TNF-a - infliximab (Schmidt et al., 2007). Despite this evidence, currently no 
biomarkers are in clinical use for IBD. 
Other than IBD, potential biomarkers have been identified for a range of chronic 
inflammatory conditions, which may have implications in IBD. Here I discuss the 
relevance of T cell receptor zeta chain (TcRδ), which has been shown to be strongly 
associated with chronic inflammatory disorders such as rheumatoid arthritis and 
systemic lupus erythematosus (SLE). 
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1.4.5.2 TcRζ expression as a biomarker for chronic inflammation  
Downregulation of the T cell receptor δ chain leading to impaired T cell functions has 
been described in a number of chronic inflammatory conditions such as rheumatoid 
arthritis, SLE, bacterial and viral infections and cancer (Baniyash, 2004). While the 
underlying molecular mechanism is unclear, it was proposed that this may serve to 
limit T cell activation and effector responses at the site of tissue damage (Cope, 2002). 
The T cell receptor (TcR) is a multiunit molecule composed of variant α and β chains, 
and invariant subunits of CD3 ε-CD3 γ heterodimer, CD3 ε -CD3δ heterodimer and δ-
δ homodimer. The α and β chains recognize antigens embedded in the MHC class 
molecules presented by antigen presenting cells such as dendritic cells. CD3 ε, δ, γ 
and δ chain are signaling molecules that couple antigen recognition to a series of 
subsequent intracellular signal transduction pathways leading to T cell activation 
(Germain and Stefanova, 1999, Samelson, 2002). The signaling processes are 
controlled by the immunoreceptor tyrosine-based activation motifs (ITAMs) present 
in these invariant chains (Pitcher and van Oers, 2003). δ-δ dimers associate with the 
newly synthesized hexameric complexes αβγεδε resulting in the transport and the 
expression of the entire TcR-CD3 receptor complex on the T cell surface (Sussman et 
al., 1988, Manolios et al., 1991). Following T cell activation and successful removal 
of pathogens, T cell responses are terminated through various mechanisms, one of 
which is the internalization of the TcR complex and degradation of all the subunits 
(Valitutti et al., 1997, Bronstein-Sitton et al., 1999). As a result, 24 hours following 
the initial T cell mediated responses, newly synthesized TCRs are expressed at a low 
level on cell surface and T cells remain non-responsive to antigen challenge for at 
least 72 hours (Bronstein-Sitton et al., 1999, Viola and Lanzavecchia, 1996). In 
mature T cells, the TcR δ chain is a limiting factor in the assembly, transport and 
quantity of TcRs displayed on the cell surface (Baniyash, 2004).  
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Down-regulation of TcRδ normally involves the loss of the δ protein but the 
underlying mechanisms remain unclear (Whiteside, 2004). Prolonged exposure of T 
cells to non-specific inflammatory mediators such as the cytokine TNF-α has been 
shown to cause TcRδ downregulation and suppress T cell proliferative responses 
(Isomaki et al., 2001, Cope et al., 1994). In RA patients, T cells with a downregualted 
δ chain (TcRδdim) were found to accumate in the synovial fluid of RA patients, and 
following anti-TNF treatment these cells were released from the inflamed joints and 
re-join the peripheral blood (Zhang et al., 2007).  
These studies suggest that expression of TcRδ may be an indicator for disease activity 
and response to treatment in chronic inflammatory disorders. So far, downregulation 
of the TcRδ chain has been tested in cancer as a potential prognosis marker(Whiteside, 
2004). The correlation between downregulation of TcRδ and disease activity in IBD 
has not yet been investigated. 
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1.5 Hypothesis and aims  
Expression of tissue-specific homing molecules is essential to enable T cells of 
different functionality to migrate to their respective sites, where they are required to 
perform specific immunological tasks. Current understanding regarding the 
acquisition of tissue-specific homing molecules, such as the integrin α4β7 and 
chemokine receptor CCR9 for the gut indicates that this process is dependent on 
„signals‟ present in the tissue microenvironment (Johansson-Lindbom et al., 2003, 
Mora et al., 2003, Mora et al., 2005, Dudda et al., 2005, Dudda et al., 2004). In 2004, 
Iwata and colleagues identified retinoic acid, a product of vitamin A metabolism by 
intestinal DCs as the soluble factor responsible for instructing T cells to express α4β7 
integrin and CCR9. 
The mammalian gut is a unique organ, with its mucosal surface constantly in contact 
with a vast number of microorganisms such as commensal bacteria as well as food 
antigens. For this reason, cells and molecules present in the gut-associated lymphoid 
tissue have developed multiple mechanisms in order to maintain gut homeostasis, and 
to launch effective immune responses when pathogenic microorganisms are detected. 
As the gut lumen is continuously being monitored by intestinal DCs, our initial 
hypothesis was that bacteria-DC interaction not only results in antigen presentation 
and T cell activation but also contributes to the generation of effector T cells with gut 
homing properties.  
As many soluble factors, such as chemokines, growth factors and cytokines are also 
present in the gut lymphoid tissue, we next hypothesized that tissue-derived factors 
other than retinoic acid may also have a role in the imprinting of T cell gut-tropism.  
It is well established that excessive T cell infiltration to the human intestine is partly 
responsible for tissue pathology associated with IBD (Fuss et al., 1996, MacDonald 
and Monteleone, 2001, Zenewicz et al., 2009), we hypothesized that the „extent‟ of T 
cell migration to the intestine may indicate disease activity. Secondly, as IBD shares 
immunological features with other chronic autoimmune diseases such as rheumatoid 
arthritis, we hypothesized that defects in T cell function observed in RA may also be 
associated with IBD. 
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In summary, studies conducted in this thesis were designed to address the following 
issues:  
1. The impact of signaling via pattern-recognition receptors (PRRs) in the 
generation of T cells with a gut-homing phenotype 
2. The physiological role of soluble factors in T cell gut-homing receptor 
acquisition 
3. The association between patterns of T cell homing and T cell-mediated 
intestinal disease - IBD 
4. The identification of immunological markers indicative of IBD disease 
activity  
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Chapter 2 Materials and methods 
Ethical Approval 
Ethical approval for research carried out in IBD patients in this project was granted by the 
Brent Medical Ethics Committee (REC reference 09/H0717/40) for Hammersmith Hospital 
and St Mary‟s Hospital. Patients‟ consent to participate in this study were obtained and 
documented before commencement of any procedures.  
2.1 Human samples 
2.1.1 Blood samples from IBD patients and healthy volunteers 
Patients with Crohn‟s disease (CD) and ulcerative colitis (UC) were individually 
assessed by attending physicians at outpatient clinics (St Mary‟s Hospital and 
Hammersmith Hospital) prior to recruitment into the study (exclusion criteria are 
listed below). Disease extent and severity were determined by calculating the Harvey-
Bradshaw index (HBI) for Crohn‟s disease and Simple Clinic Colitis Activity index 
(SCCAI) for ulcerative colitis. The final disease activity score for Crohn‟s disease or 
ulcerative colitis is the sum of the patient‟s score for each factor listed (Table 2 and 
Table 3). Patients with a HBI of 5 or greater are categorized as having active disease, 
below 5 are considered to have entered clinical remission (not inclusive)(Harvey and 
Bradshaw, 1980). For ulcerative colitis, patients scored below 3 are considered to be 
in remission, 3 or above are categorized as having active disease (Walmsley et al., 
1998b). Harvey-Bradshaw index and Simple Clinic Colitis Activity Index are listed in 
Table 2 and Table 4 respectively. UC and CD patients were also characterized based 
on the Montreal classification (Table 3 and Table 5). Healthy donors used as controls 
in the experiments were recruited from the Department of Immunobiology, 
Hammersmith Campus Imperial College.  
Blood samples were collected using blood vacutainers (Becton and Dickinson, Oxford, 
UK) containing lithium heparin (15 USP/ml of blood) to prevent it from clotting. 30 
ml of blood were taken from patients and healthy volunteers for the studies described 
in Chapter 7. In total, 34 IBD patients (17 CD patients, 17 UC patients) and 10 
healthy controls were recruited. The clinical details of the patients recruited are listed 
in Table 6.  
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For the procedures described in Section 2.4.2 and 2.4.3 (results presented in Chapter 
3 to Chapter 5) single donor Blood Buffy Coats were purchased from the National 
blood service (Colindale, UK). 
List of Exclusion criteria  
1. Unwilling to participate 
2. Cancer sufferers 
3. Suffer from autoimmune diseases or chronic inflammatory diseases other than 
IBD (rheumatoid arthritis, psoriasis) 
4. Pregnancy 
5. Unsuitable in the opinion of the attending physician 
 
Table 2. Harvey-Bradshaw Index  
Score  Well-
Being  
Abdominal 
Pain  
No. of 
Liquid 
Stool 
Abdominal 
Mass 
Complications 
(1 per item)  
0 Very well None  None Arthralgia 
1 Below Par Mild  Dubious Uveitis  
2 Poor Moderate  Definite Erythema 
nodosum 
3 Very poor Severe  Definite and 
tender 
Aphthous 
ulcers 
4 Terrible    Pyoderma 
gangrenosum 
     Anal Fissure 
     New Fistula 
     Abscess 
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Table 3. Montreal classification for Crohn’s disease  
Age of diagnosis Location Behaviour 
A1: below 16y L1: ileal 
B1: non-stricturing, non-
penetrating 
A2: between 17 and 40y L2: colonic B2 stricturing 
A3: above 40y L3: ileocolonic B3 penetrating 
 L4: isolated upper disease p perianal disease modifier 
 
 
Table 4. Simple Clinic Colitis Activity Index 
Score  Well-
Being  
No. of 
bowel 
movement 
(Day) 
No. of 
bowel 
movement 
(Night) 
Urgency of 
Defecation  
Blood in 
stool  
Extracolonic 
Features  
(1 per 
manifestation) 
0 Very 
well 
1-3     
1 Below 
Par 
4-6 1-3 Hurry  Trace  
2 Poor 7-9 4-6 Immediate Occasionally 
frank 
 
3 Very 
poor 
>9  Incontinence Usually 
frank  
 
4 Terrible      
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Table 5. Disease extent: Montreal Classification for ulcerative colitis  
Ulcerative Colitis Anatomy 
Ulcerative proctitis Involvement limited to the rectum                                                            
(proximal extent of inflammation is distal to the 
rectosigmoid junction) 
Left sided UC (distal UC) 
Involvement limited to a proportion of the colorectum                               
distal to the splenic flexure 
Extensive UC (pancolitis) Involvement extends proximal to the splenic flexure 
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Table 6. Information on patients recruited  
  Crohn’s 
Disease 
(CD) 
Ulcerative 
Colitis (UC) 
Healthy 
volunteers  
Total Studied (n) 17 17 10 
Gender  
     Male  
     Female 
 
7 
10 
 
7 
10 
 
2 
8 
Age      
15-25 
26-35 
36-45 
46-55 
56-65 
 
2 
4 
5 
4 
2 
 
1 
5 
5 
2 
4 
 
1 
7 
1 
1 
 
Disease Activity 
   Active (HBI>5, SSCAI>3) 
   Remission (HIB<5, SSCAI<3) 
 
8 
9 
 
8 
9 
N/A 
Age of diagnosis   N/A 
   <16 
  17-40 
    >40 
1 
16 
0 
 
 
 
Disease Extent (CD)  
  Ileal 
  Colonic 
  Ileocolonic 
 
6 
7 
4 
N/A 
Disease Extent (UC)  
  Proctitis 
  Distal UC 
  Pancolitis   
N/A  
5 
8 
4 
Behaviour 
 Non-strituring, non-penetrating 
Stricturing 
Penetrating  
Perianal disease  
 
6 
8 
1 
2 
N/A 
Therapy 
 None  
 Monotherapy 
Non-Immunosuppressant 
Immunosuppressant  
(Steroid, anti-TNF, Azathioprine)  
Combinational therapy 
 
 
5 
 
5 
2 
 
5 
 
5 
 
5 
2 
 
5 
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2.1.2 Gut biopsies collected from IBD patients 
Intestinal biopsies were collected from consenting patients in the Endoscopy unit at St 
Mary‟s hospital. Prior to undergoing endoscopic procedures, patients were clinically 
assessed individually by physicians. Disease scores were calculated as mentioned in 
Section 2.1.1. Disease extent for each patient was visualized during the endoscopy 
procedure; biopsies were taken from the inflamed region and the non-inflamed region 
of the small intestine or colon depending on disease phenotype. Endoscopy results for 
the patients recruited were reviewed at the end of the endoscopy procedure. In total, 
we collected biopsy samples from two patients with IBD; some of their clinical details 
are described below in Table 7 (further details are presented in Section 7.4.6 of 
Chapter 7). 
Table 7. Information of patients whose intestinal biopsies were collected 
Patients  Gender  Age  Diagnosis Disease Score 
1 Famale  39 CD HBI=5 
2 Female  69 UC SSCAI<3 
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2.1.3 Processing of human samples  
Blood samples collected from patients were processed immediately; peripheral blood 
mononuclear cells were extracted and stored in liquid nitrogen and used for the 
experiments described in Chapter 7. Lymphocytes freshly extracted from the human 
intestinal biopsies were phenotypically analyzed immediately.  
2.2 Reagents 
2.2.1 Monoclonal antibodies 
Fluorescence conjugated mouse or rat anti-human monoclonal antibodies (mAbs) 
used in the experiments where relevant cells were phenotyped using flow cytometry 
are listed in Table 8 and Table 9. In Table 10, purified mouse anti-human 
monoclonal antibodies used in human naïve T cell isolation and activation are listed. 
2.2.2 Cytokines and chemokines 
Human recombinant GM-CSF (Granulocyte/macrophage colony-stimulating factor) 
and IL-4 used for the culture of monocyte-derived dendritic cells (DCs) were 
purchased from First Link, UK or Peprotech, UK. Interferon-gamma (IFN-γ), Tumour 
Necrosis Factor-alpha (TNF-α) and IL-1 beta (IL-1β) used for the maturation of 
immature DCs were purchased from Peprotech, UK. The human gut chemokine 
CCL25 was purchased from Peprotech, UK.  
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Table 8. Fluorescence conjugated mAbs 
Antibody Clone Conjugate Isotype Supplier 
Anti-CD3 UCHT1 FITC mIgG1 eBioscience 
Anti-CD3 SK7 PERCP mIgG1 BD 
Anti-CD4 SK3 PERCP mIgG1 BD 
Anti-CD4 B-A1 PE mIgG2a Diaclone 
Anti-CD4 RPA-T4 FITC mIgG1 BD Pharmingen 
Anti-CD8 HIT8a PE mIgG1 BD Pharmingen 
Anti-CD8 OKT8 APC mIgG2a eBioscience 
Anti-CD8 SK1 PERCP mIgG1 BD 
Anti-CD19 HIB19 PE mIgG1 eBioscience 
Anti-CD25 2A3 PE mIgG1 BD 
Anti-CD25 M-A251 APC mIgG1 BD  
Anti-CD69 FN50 PE mIgG1 eBioscience 
Anti-TcR zeta 2H2D9 PE mIgG1 Beckman 
Coulter 
Anti-CD45RO UCHL1 PE mIgG2a BD Pharmingen 
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Antibody Clone Conjugate Isotype Supplier 
Anti-CD45RA HI100 FITC mIgG2b eBioscience 
Anti-CD45RA HI100 PE mIgG2b BD Pharmingen 
Anti-CCR7 3D12 PE Rat IgG2a eBioscience 
Anti-CD62L DREG-56 FITC, APC mIgG1 eBioscience 
Anti-CXCR3 49801 PE mIgG1 R&D Systems 
Anti-integrin α4 9F10 PE mIgG1 eBiosceinces 
Anti-integrin β1 MAR4 APC mIgG1 BD Pharmingen 
Anti-integrin β1 TS2/16 FITC mIgG1 eBioscience 
Anti-integrin β7 FIB504 APC Rat IgG2a BD Pharmingen 
Anti-integrin αE 
(CD103) 
B-ly7 FITC/APC mIgG1 eBiosciences  
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Antibody Clone Conjugate Isotype Supplier 
Anti-integrin αE 
(CD103) 
LF61 FITC mIgG1 Biolegend 
Anti-HLA,A,B,C G46-2.6 APC mIgG1 BD Pharmingen 
Anti-HLA-DR L243 PerCP mIgG2a BD 
Anti-CD14 M5E2 FITC mIgG2b BD Pharmingen 
Anti-CD16 3G8 PE mIgG1 BD Pharmingen 
Anti-CD11c B-ly6 PE mIgG1 BD Pharmingen 
Anti-CD11b CBRM1/
5 
FITC mIgG1 eBioscience 
Anti-CD1a HI149 PE mIgG1 BD Pharmingen 
Anti-CD40 5C3 APC mIgG1 BD Pharmingen 
Anti-CD80 L307.4 FITC mIgG1 BD Pharmingen 
Anti-CD83 HB15e APC mIgG1 BD Pharmingen 
Anti-CD86 2331(FU
N-1) 
PE mIgG1 BD Pharmingen 
Anti-DC-SIGN DCN46 FITC mIgG2b BD Pharmingen 
Anti-FoxP3 PCH101 FITC, PE, 
 APC 
Rat IgG2a eBioscience 
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Table 9. Control antibodies 
Antibody Clone Conjugate Isotype Supplier 
Isotype control  OX40 PERCP,PE, 
APC 
mIgG1 BD 
Isotype control OX40 PERCP mIgG2a BD 
Isotype control 20102 PE mIgG2a R&D 
Systems 
Isotype control 27-35 PE mIgG2b BD 
Pharmingen 
Isotype control eBR2a PE Rat 
IgG2a, 
mIgG2a 
eBiosciences 
Isotype control P3 FITC mIgG1 eBiosciences 
Isotype control eBMG2b FITC mIgG2b eBiosciences 
Isotype control R4-22 FITC Rat IgM BD 
Pharmingen 
Isotype control R35-95 APC Rat 
IgG2a 
BD 
Pharmingen 
Isotype control 20102 APC mIgG2a R&D 
Systems 
Isotype control eBM2a APC mIgG2a eBiosciences 
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Table 10. Purified non-conjugated mAbs 
Antibody Clone Concentration Supplier 
CD16 3G8 0.5 mg/ml BD Pharmingen 
CD19 HIB19 0.5 mg/ml BD Pharmingen 
CD33 HIM3-4 0.5 mg/ml BD Pharmingen 
CD56 B159 0.5 mg/ml BD Pharmingen 
CD45RO UCHL1 0.5 mg/ml BD Pharmingen 
CD14 MØP9 0.025 mg/ml BD Pharmingen 
CD3 UCHT1 0.5 mg/ml BD Pharmingen 
CD28 CD28.2 0.5 mg/ml BD Pharmingen 
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2.3 Cell preparation 
2.3.1 Cell culture conditions 
Cells were cultured under sterile conditions in laminar flow hoods (Mars, Middlesex, 
UK) and maintained in a sterile incubator (Wolf laborotories, UK) which provided a 
humid atmosphere consisting of 5% of CO2. 
2.3.2 Cell counting using Trypan Blue 
Live cells were counted by diluting a small amount of cell suspension using Trypan 
Blue at a ratio of 1:1. Trypan blue (Sigma-Aldrich,Poole, UK) is a dye absorbed by 
dead cells, which appeared blue under the phase-contrast microscope (Olympus, 
Essex,UK). 10 μl of cell suspension was diluted with 10 μl of trypan blue; 10 μl of the 
mixture was then transferred to a haemocytometer (Sigma-Aldrich). The number of 
live cells distributed in the four corners of the grid (highlighted grey as shown in 
Figure 6 below) was counted; the mean value was taken as the final cell count. The 
number of live cells in the cell suspension was then calculated using the formulae 
below. 
 
Figure 6. Schematic illustration of the counting grids in the haemocytometer.  
Number of cells per ml = 
Total number of cells in the 4 corners  ∕ 4  dilution factor  104 . 
Total number of cells in solution = 
Number of cells per ml  volume of cell suspension (in ml)             
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2.3.3 Cryo-preservation and thawing of cells 
Cells were stored in frozen aliquots in freezing medium, which  was composed of 
heat-inactivated filtered foetal calf serum (FCS) and 10% Dimethyl Sulfoxide (DMSO, 
Sigma-Aldrich). Every 10
6
 cells were resuspended in 1 ml of freezing medium and 
stored in 2 ml Cryovials (Greiner Bio One, UK). Cryovials were stored in Nalgene 
Cryo freezing containers (VWR International, UK) at -80°C allowing it to freeze at a 
rate of 1°C per minute before transferring to Liquid Nitrogen the following day.  
Cells were thawed immediately after being taken out of liquid nitrogen. Frozen vials 
were placed in the 37°C water bath, and then added to complete RPMI medium with 
10% FCS and spun down at 1200 rpm for 10 minutes. Live cells were then counted 
using trypan blue. 
2.4 Cell isolation and purification 
2.4.1 Isolation of human peripheral blood mononuclear cells  
 Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood 
(patients or healthy volunteers) by density gradient centrifugation using Ficoll-
Hypaque (Axis-Shield PoC AS,UK). Whole blood was first diluted using phosphate 
buffered saline (PBS, Sigma-Aldrich) at a ratio of 1:1, mixed well in a 50 ml Falcon 
tube. Diluted blood was slowly layered on top of Ficoll-Hypaque in a 50 ml Falcon 
tube at a ratio of 1:1. The mixture was then centrifuged at 2000 rpm for 20 minutes 
without brake; a ring at the interface composed of live mononuclear cells was formed 
(illustrated in Figure 7), these cells were extracted and washed with serum free RPMI 
(Sigma-Aldrich). Extracted mononuclear cells were centrifuged at 1500 rpm for 10 
minutes with brake on. Supernatant was then aspirated, the cell pellet resuspended and 
washed again at 800 rpm for 10 minutes to remove platelets. To avoid contamination 
of lymphocytes by red blood cells, the red blood cells were lysed using red cell lysing 
buffer (Sigma-Aldrich). 3-5 ml of red cell lysis buffer was added to the cell pellet; the 
mixture was left to react on ice for 10 minutes. The procedure was repeated if 
necessary. The PBMCs extracted were then washed in serum-free RPMI at 1500 rpm 
for 5 minutes. The cell pellet was then resuspended in 5-10 ml of RPMI medium with 
10% of FCS (Globepharm, Surry, UK), stained and counted using trypan blue using a 
haemocytometer as described previously in Figure 6.  
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Figure 7. PBMC isolation from peripheral blood.  
Whole blood was diluted 1:1 with PBS before being layered on top of the Ficoll-Hypaque 
solution at a ratio of 1:1. Following centrifugation at 2000 rpm for 20 minutes without brake, 
components of the blood were separated including a ring of PBMC, which was subsequently 
removed. 
2.4.2  Isolation and enrichment of CD14+ monocytes from PBMC 
using MACS® column technology 
For the purpose of obtaining human monocyte-derived DCs, enrichment of CD14
+
 
monocytes from buffy coat PBMCs was carried out by using anti-human CD14 
microbeads and the MACS® column technology (Miltenyi Biotec, Surrey, UK).  
Blood buffy coats were diluted with PBS at a ratio of 1:2 as compared to 1:1 when 
using fresh blood obtained from healthy volunteers (due to the enrichment of 
leukocytes in the buffy coat), mixed well in a 50 ml Falcon tube. PBMCs were then 
extracted using the same method described above. Monocytes and lymphocytes 
population were then separated using a 50% Percoll® (GE Healthcare, Sweden) 
density gradient. 50%Percoll® was prepared in the following way: 100% Percoll® 
was firstly diluted with 10× concentrated phosphate buffered saline (PBS) to 70% 
Percoll, this solution was further diluted to 50% using Hanks buffered salt solution 
(HBSS, Sigma-Aldrich). 50% Percoll® was used at a 1:2 ratio with cell suspension. 
Typically, freshly isolated PMBCs were re-suspended in 8 ml of RPMI with 2% FCS 
and slowly overlaid on top of 4 ml of 50% Percoll® without mixing. The cell solution 
was then spun down at 300 g for 30 minutes without brake. The resulting mixture 
Diluted 
blood
Ficoll
PBMC
Platelets and Red 
blood cells 
Ficoll
Serum
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consisted of a ring of monocytes and a pellet containing small lymphocytes and red 
cells.  
Monocyte pellets were resuspended in RPMI and 2% FCS medium. Mouse anti-
human CD14 beads were added to the cell suspension according to the manufacturer‟s 
instruction (20 μl of CD14 microbeads per 107 cells). The cell-bead mixture was 
mixed and incubated on a roller for 20 minutes at 4°C. MS columns were used for the 
extraction of CD14
+
 monocytes. MACS buffer for magnetic cell sorting was prepared 
with 2% FCS, phosphate buffered saline (PBS) and 2 mM ethylenediamine tetra-
acetic acid (EDTA, Sigma). Separation columns were firstly washed with MACS 
buffer; the cell-bead suspension was then passed through the column. The effluent cell 
suspension collected contained CD14
-
 population, while CD14
+
 contained inside the 
column were retrieved by washing the column using MACS buffer and a plunger 
(Pickl et al., 1996).The purity of CD14
+
 obtained was then determined by staining the 
cells using mouse anti-human CD14 and analyzed using Flow Cytometry.  
2.4.3 Isolation of human naïve T cells 
Human naïve T cells were isolated from the PBMCs by negative immunomagnetic 
selection using Dynal® magnets (Dynal Biotech, Norway). Following extraction from 
blood (Section 2.4.1) PBMCs were resuspended in culture media to which the 
following antibodies were added: anti-human CD19 (Knapp et al., Oxford University 
Press, 1989), CD16 (Barclay et al., Academic Press, 1997), CD14 (Pickl et al., 1996), 
CD56 (Schlossman et al., Oxford University, 1995), CD33 (Knapp et al., Oxford 
University Press, 1989), CD45RO (Schlossman et al., Oxford University, 1995) for 
the depletion of B cells, natural killer T cells, monocytes and memory T cells. The 
cell suspension was mixed well and incubated at 4°C on a roller for 30 minutes. The 
mixture was then washed in PBS and spun down at 1800 rpm for 5 minutes. 
Secondary antibody goat anti-mouse IgG Fc (Qiagen,UK) conjugated to magnetic 
beads (5 mg/ml, 1 ml of beads/ per 1×10
7
 cells) were then added to the cells already 
labeled with antibodies mentioned above.  
Prior to use, secondary antibody goat anti-mouse IgG Fc conjugated to magnetic 
beads (BioMag Goat anti-mouse IgG, Qiagen) were washed three times with RPMI to 
eliminate sodium azide, and then resuspended in the same amount of RPMI 1640. The 
beads were added to the cells and the mixture was incubated for 30 minutes at 4°C on 
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a rolling mixer. This mixture containing cells labeled with antibodies and magnetic 
beads were subsequently placed in a Dynal magnet for 3-5 minutes for the removal of 
the unwanted cell population. Naïve T cells (CD45RO
-
) remaining in the 
supernatanant were recovered and counted using Trypan Blue described in Section 
2.3.2. 
2.4.4 Extraction of intestinal intraepithelial lymphocytes (IEL) and 
lamina propria lymphocytes (LPL) 
Based on the disease location (colonic inflammation or small intestinal inflammation), 
biopsies were taken from the relevant sections of the bowel in patients with 
inflammatory bowel diseases during endoscopy procedures (courtesy of Endoscopy 
Unit Nurses and attending physician, Endoscopy Unit, St Mary‟s Hospital). Samples 
were directly placed in media before processing. 
2.4.4.1 Medium 
Medium in which biopsies were stored between collection and processing was 
composed of RPMI 1640 supplemented with 2 mM glutamine (Gibco), 50 IU/ml 
penicillin (Gibco), 1% gentamycin (Sigma), and 50 μg/ml streptomycin (Gibco), 1% 
of HEPES (Gibco) and 1% sodium pyruvate (Sigma).  
2.4.4.2 Washing buffer 
Washing buffer used during sample processing was composed of Dulbecco‟s Ca2+ 
Mg
2+
 free PBS, 50 IU/ml penicillin (Gibco), 1% gentamycin (Sigma), and 50 μg/ml 
streptomycin (Gibco). This allowed the optimal digestion of the tissue and therefore a 
better yield of the cells (this protocol was kindly provided by Dr Pedro Vieira, 
Imperial College London).  
2.4.4.3 Sample processing 
Biopsy specimens were placed in 10 ml of cold medium immediately after taken from 
the patients. Tissue surface was then washed thoroughly using the washing buffer. 
The tissue was subsequently treated in warm PBS containing 1 mM DL-Dithiothreitol 
(DTT, Sigma) and 1 mM EDTA (Sigma-Aldrich) at 37°C from 30 minutes under 
vigorous agitation. Supernatant was then passed through a 70 μm cell strainer (VWR), 
remaining tissue lumps were meshed. The strainer was rinsed thoroughly with wash 
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buffer to recover remaining cells. The cell suspension containing intraepithelial 
lymphocytes and lamina propria lymphocytes were spun down at 1800 rpm for 5 
minutes and stained for phenotypic analysis using flow cytometry. 
2.5  Cell culturing  
2.5.1 T cells  
T cells were cultured in complete media composed of 10% foetal calf serum (FCS, 
Globepharm, Surry, UK), and RPMI 1640 (Sigma Aldrich) supplemented with 2 mM 
glutamine (Gibco), 50 IU/ml penicillin (Gibco), and 50 μg/ml streptomycin (Gibco). 
FCS was heat-inactivated by immersion in a 56°C water-bath for 45 minutes, and 
filtered prior to use.  
2.5.2 Generation and maturation of human monocyte-derived 
dendritic cells................ 
Dendritic cells (DCs) were derived from CD14
+
 monocytes isolated from single donor 
Blood Buffy Coat purchased from National blood service (Colindale, UK). Monocyte-
derived DCs were generated by culturing freshly isolated CD14
+
 monocytes in 100 
ng/ml of Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF, First link, 
UK) and 1000 IU/ml of Interleukin-4 (First link, UK) for 6 days as previously 
described (Sallusto & Lanzavecchia 1994). Cells were grown in 24-well tissue culture 
plates (Corning, UK) at a concentration of 2×10
6
 per well. Cells were fed every other 
day by adding 100 μl of RPMI medium and 100 ng/ml GM-CSF and 1000 IU/ml IL-4. 
Cultured cells were maintained in a sterile incubator. 
DC maturation was induced by either bacteria-derived products such as 
lipopolysacchrides (Ultra Pure E.coli LPS, Invivogen, USA), muramyl dipeptide 
(MDP, synthetic, Invivogen, USA); or cytokines such as TNF-α (Peprotech, UK), 
IFN-γ (Peprotech, UK), and IL-1β (Peprotech, UK) (Kawai, 2007, Mailliard et al., 
2004, Han et al., 2009). LPS is a Gram-negative bacteria outer membrane glycolipid 
(Raetz, 2002). MDP is the minimal bioactive peptidoglycan motif common to all 
bacteria cell wall (Girardin et al., 2003). Immature DCs were treated with LPS at a 
concentration of 1 μg/ml (Strengell et al., 2006), MDP at a concentration of 10 μg/ml 
(Tada et al., 2005, van der Meer et al., 2009), or both at a ratio 1:1 on day 6 of culture 
for 24 hours. Alternatively, dendritic cell maturation was achieved by adding TNF-α 
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(10 ng/ml), IFN-γ (10 ng/ml) and IL-1β (10 ng/ml) in combination to the immature 
DCs on day 6 of culture. On day 7, DCs were harvested, and used for the mixed 
lymphocyte reactions and immuno-phenotyping.  
2.6 Characterization of cell population 
2.6.1  Buffers 
FACS buffers were used in immunostaining, which was consisted of PBS, 2% of 
bovine serum albumin (BSA, Sigma-Aldrich) and 1% sodium azide (VWR). 
Permeablization buffer for standard intracellular staining was prepared with FACS 
buffer and 0.05% saponin (Sigma-Aldrich). 2% mouse serum (Sigma-Aldrich) diluted 
in FoxP3 permeablization buffer (eBioscience, US) was used to block unspecific 
antibody binding in the intracellular staining procedure. FoxP3 permeabilization 
buffer, fixation/permeablization buffer were prepared following manufacturer‟s 
instruction (eBioscience, US). 
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2.6.2 Cell phenotyping - surface and intracellular staining 
For surface molecule staining, cells were kept in 5 ml round bottom polystyrene tubes 
(Falcon) and washed with 1 ml FACS buffer at approximately 10
6 
cells per tube. Cells 
were then resupended in a cocktail of mouse anti-human monoclonal antibodies (in 
different combinations depending on the conjugated flurochrome) after centrifugation 
at 1800 rpm for 5 minutes. The cell suspension was then incubated in dark at 4C for 
30 minutes, washed with 1 ml of FACS buffer and fixed with 300 μl of Cell Fix (BD 
Bioscience) before flow cytometric analysis.  
The expression of T-cell receptor zeta chain (TcR-δ) was studied by intracellular 
staining. The cell suspension was washed with cold PBS following extracellular 
staining, resuspended using pulse vortex, and incubated in 500 μl of Cell Fix in dark 
at 4C for 20 minutes and then washed in 2 ml of PBS. 500 μl of permeablization 
buffer was added to all samples and left to incubate for 10 minutes in dark at 4C. 
Cells were then washed in this buffer and stained with 10 μl mouse anti-human TcR-δ 
antibody in the dark at 4C for 40 minutes. Following incubation, cells were washed 
once with permeablization buffer and resuspended in 250 μl of FACS buffer before 
flow cytometric analysis.  
To study human regulatory T cells, an intracellular staining technique was employed 
using a different procedure. Following cell surface staining, 300 μl of freshly prepared 
fixation/permeabilization buffer (eBioscience, US) was added to each sample instead 
of washing using PBS. Cells were pulse vortexed again and incubated in dark for 45 
minutes. Cells were then washed with 1 ml of permeablization buffer (eBioscience, 
US) at 1500 rpm for 5 minutes. 100 μl of 2% mouse serum was added to each sample 
to block unspecific binding, the mixture was incubated for 15 minutes at 4C. Without 
washing, cells were then stained with 5 μl of anti-human FoxP3 antibody in the dark 
at 4C for 40 minutes, washed once with 1 × concentrated permeabilization buffer 
before flow cytometric analysis.  
Isotype controls were also included to determine the level of non-specific Fc receptor 
binding and background autofluoresence.  
The markers analyzed on different cell populations using flow cytometry are 
summarized in Table 11.  
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Table 11. Markers studied on different cell populations 
Cells  Surface Markers Analyzed  Intracellular Markers Analyzed  
PBMCs CD3,CD4,CD8,CD19,CD25 
CD45RA,CD45RO, CCR9, 
CD62L, Integrin β7, Integrin α4, 
Integrin β1, CXCR3, LFA-1 
FoxP3,TcR-δ 
Intestinal 
Lymphocytes 
CD3,CD4,CD25 
 
FoxP3, TcR-δ 
 
Monocytes 
and DCs 
CD14, CD11c, HLA-DR, CD80, 
CD86, CD103 
N/A 
Naïve T and 
Activated T 
cells 
CD4,CD8,CD45RO,CD25, 
CCR9,Integrin α4, Integrin β7 
FoxP3 
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2.6.3 Flow cytometric analysis  
After staining, cells were acquired using a FACS Calibur flow cytometer (Becton 
Dickinson, UK) connected to a Macintosh computer. Acquisition was achieved using 
Cell Quest software (Becton Dickinson, UK).  
The expression of cell-surface and intracellular markers on antibody-labeled cells 
were quantified using four-colour flow cytometry and analyzed using FlowJo 
software (Treestar, US). Forward scatter (FSC) was used to determine the size of the 
cells, side scatter was used to determine the granularity of the cells; this information 
collected allowed the identification of different cell types within the total cell 
population. As an example, Figure 8A shows the profile of different cell types found 
in the PBMC isolated from whole blood.  
Depending on the sample size, 10,000-50,000 events from the live cell gate were 
acquired. Dot plots were used to demonstrate the percentage of cells stained positive 
for different markers analyzed. Histograms overlaid with isotype controls were 
employed to illustrate the intensity of surface marker expression on the cell 
population of interest.  
2.6.3.1 Gating strategy 
In order to analyze the expression of molecules on the cell population of interest, 
different gating strategies were used during data acquisition and analysis using flow 
cytometry. Initially, live gates were drawn based on the size and the granularity of the 
population of interest detected by forward scatter and side scatter on a flow cytometer. 
This was followed by specific gating based on the positive expression of the markers 
used to identify population of interest, for example CD4
+
 and CD8
+
 T cells were gated 
on cells that are positive for CD4 or CD8.  
For the phenotypic analysis of T cells before and after activation (results shown in 
Chapter 3 - Chapter 6), based on their difference sizes, activated T cells and non-
activated T cells were gated and analyzed separately. This is illustrated in Figure 8B 
and Figure 8C. As shown in Figure 8C, freshly isolated resting T cells are smaller, 
lying in the resting lymphocyte gate. Following activation, activated cells increased in 
size and granularity compared to non-activated subpopulation (Figure 8C). 
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Figure 8. The identification of different cell types and sub-populations using 
forward and side scatter. 
Panel A shows the different cell components found in the PBMCs isolated from whole blood. 
Dead cells are labeled in blue, lymphocytes in black, monocytes are labeled in green, and 
granulocytes are labeled in orange.  
Panel B shows the size of freshly isolated resting naïve T cells from PBMCs. Following T cell 
activation (panel C), two T cell populations were detected, the larger and more granular 
activated T cells (red) and the smaller non-activated T cells (black).  
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2.7 Functional analysis 
2.7.1 T cell activation by allogeneic dendritic cells - Mixed 
Lymphocyte Reaction (MLR) 
Allogeneic mixed lymphocyte reactions (MLRs) were set up by mixing naïve T cells 
(2×10
5
) and dendritic cells (2×10
4
) from two different individuals with different MHC 
haplotypes. Two co-cultures were set up in parallel, one for phenotypic analysis and 
one for the measurement of T cell proliferation. For T cell proliferation assays, 
monocyte-derived DCs were irradiated (60 Gray) and prevented from proliferating 
prior to co-culture experiment. Following co-culture, the phenotype of activated T 
cells were assessed by flow cytometry. 
Both immature and mature DCs were used as stimulator cells in the MLRs performed 
in this thesis (Chapter 3 to Chapter 5). After 7 days of culture, immature and mature 
DCs were harvested, counted and resuspended in 100 μl of RPMI medium with 10% 
FCS. Naïve T cells isolated were also resuspended in 100 μl of RPMI medium with 
10% FCS. Allogeneic DCs and responder naïve T cells were mixed at a ratio of 1: 10 
(2×10
4
 of DCs and 2×10
5
 of T cells) in 96-well flat bottom plates. T cells were 
activated under multiple culture conditions in the presence of immature or mature 
DCs alone or with additional regents, including IL-2 (20 U/ml, Roche, UK), gut 
homing chemokine CCL25 (300 ng/ml), and active vitamin A metabolite all-trans-
retinoic acid (all-trans-RA, 2 μM, Sigma-Aldrich) in the co-culture. Following 
activation, T cells were harvested and prepared for phenotypic analysis using flow 
cytomery described in Section 2.6.2. Molecules studied on T cells are listed in Table 
11. T cell proliferation under each culture conditions mentioned above was also 
assessed by measuring 
3
HTdR incorporation (Section 2.7.3). 
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2.7.2 T cell activation using plate bound anti-CD3 and anti-CD28 
monoclonal antibodies 
Following isolation, naïve T cells were activated using plate-bound anti-CD3 and 
anti-CD28 monoclonal antibodies. These monoclonal antibodies were prepared in Tris 
base – Ph 9.5 buffer solution to achieve optimal antibody binding to the tissue culture 
plates (Inverardi et al., 1992). Tris buffer with a concentration of 50 mM was prepared 
by dissolving Tris in water with the drop-by-drop addition of hydrogen choloride 
(HCL) until the pH of the final Tris solution reached 9.5. Tissue culture plates were 
firstly coated with anti-CD3 (UCHT1, 1 µg/ml) and anti-CD28 (CD28.2, 5 µg/ml) 
monoclonal antibodies for 2 hours in the incubator (37°C, 5% of CO2), following 
which excess antibodies were washed off and naïve T cells were added. 24-well plates 
or 96-well flat-bottom tissue culture plates were used according to the number of 
naïve T cells available (minimum 1×10
5
, maximum 2×10
6
). 
T cells were activated by incubating with plate-bound anti-CD3 and anti-CD28 mAbs 
alone or in the presence of other reagents for 7 days. These reagents include IL-2 (20 
U/ml), human gut chemokine CCL25 (300 ng/ml) and all trans-RA (2 μM). These 
regents were used either alone with anti-CD3 anti-CD28 or in combination in 
respective wells. The plate was then incubated at 37°C with 5% CO2 for 7 days.  
At the end of the cultures, T cells were harvested and prepared for phenotypic analysis 
by flow cytometry as described in Section 2.6.2. Molecules studied on T cells 
following activation are listed in Table 11. T cell proliferation under each culture 
conditions mentioned above was also assessed by tritiated thymidine incorporation 
(more detail see Section 2.7.3).  
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2.7.3 Proliferation assay  
T cells activated by plate-bound anti-CD3 anti-CD28 or DCs were cultured in 
triplicate wells in 96-well plates (flat bottom for antibody stimulation, and U-bottom 
for DC stimulation) for proliferation assay. Cells were incubated at 37°C for 48 hours 
(not 7 days) before pulsing with 1µCi/well of tritiated thymidine (
3
HTdR, Amersham, 
Amersham, UK) per well for a further 18 hours. The reaction was halted by freezing 
the plate at -20°C; plates were later thawed and harvested using Tomtec harvester 96 
(Receptor Technologies, Adderbury UK) and onto filter paper (Perkin Elmer, 
Buckinghamshire, UK). Cell proliferation was measured by radioactivity 
incorporation and read by using Wallac Microbeta counter for Windows (Perkin 
Elmer). 
2.8 Statistical analysis  
Statistical analysis was carried out using GraphPad Prism5 software.  
For the results presented in Chapter 3 to Chapter 6, non-parametric two-tailed 
statistical test otherwise known as the Mann-Whitney test was performed on the 
unpaired data. For the paired data, Wilcoxon matched pairs test was performed. For 
experiments repeated three times, two tailed unpaired Student t–test was performed. 
Statistical analysis was not performed on experiments carried out fewer than three 
times.  
For the results presented in Chapter 7, as small number of samples were analyzed 
(n<10) in each experimental group, which invalidated the use of parametric method of 
statistical analysis, two-tailed Mann-Whitney test using Bonferroni correction or 
Kruskal-Wallis with Dunn‟s post test was performed having taken into account of 
multiple comparisons, the corrected p value is indicated as pc, the uncorrected p value 
is indicated as p.  
Results with p < 0.05 were considered statistically significant. 
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Chapter 3 Acquisition of gut-homing receptors by T cells 
activated by dendritic cells in the presence of the gut-derived 
factors 
3.1 Introduction 
Unlike other leukocytes that migrate in response to non-specific inflammatory stimuli, 
the trafficking of T lymphocytes is relatively organ-specific and mediated by complex 
molecular interactions between T cells and resident endothelial cells. Depending on 
their function and site of priming, different T cell subsets express unique sets of 
„homing‟ molecules consisting of adhesion molecules and chemokine receptors which 
bind to their counter-receptors differentially expressed by endothelial cells of different 
organs (Mora et al., 2006). These interactions allow the infiltration of T cells into 
target tissues (homing) and the subsequent execution of T cell effector functions. For 
example, naïve T cells predominantly traffic to the secondary lymphoid organs by 
expressing CD62L and CCR7. In contrast, memory T cells (TEFF, TEM) can traffic to 
non-lymphoid tissues drained by the lymph nodes (LNs) where priming originally 
occurred (Butcher et al., 1999, Lewis et al., 2008). The key molecules responsible for 
mediating memory T cells homing to the gut lamina propria and associated lymphoid 
tissue are the integrin α4β7 and the chemokine receptor CCR9, with the latter being 
particularly involved in the localisation of memory T cells to the small intestine 
(Berlin et al., 1993, Lefrancois et al., 1999b, Stenstad et al., 2007, Kunkel et al., 2000, 
Zabel et al., 1999). The integrin α4β7 binds to mucosal vascular addressin cell 
adhesion molecule 1 (MAdCAM-1), which is constitutively expressed by the 
postcapillary venules of intestinal lamina propria, whereas CCR9 binds to the gut 
chemokine CCL25 in the small intestinal glands and crypts (Butcher et al., 1999, 
Nishimura et al., 2009). It has been proposed that the acquisition of such tissue-
specific homing receptors by T cells is under the „instruction‟ of the local lymphoid 
tissue microenvironment likely relayed to T cells by the tissue-resident dendritic cells 
(DCs) (Horgan et al., 1992, Butcher et al., 1999, Kantele et al., 1999, Mora et al., 
2003). Following antigen uptake, these DCs migrate to the draining LNs where they 
mediate T cell priming and the subsequent homing. 
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In the context of T cell homing to the gut, studies in mice have demonstrated that only 
DCs isolated from the mesenteric lymph nodes (MLN) and the Peyers‟ patches (PP) 
can upregulate α4β7 and CCR9 in activated T cells (Mora et al., 2003, Stagg et al., 
2002, Johansson-Lindbom et al., 2003, Elgueta et al., 2008). Subsequently, it was also 
revealed that gut-resident DCs induce the upregulation of gut-homing receptors (HRs) 
on T cells by converting vitamin A into retinoic acid (RA) during antigen-presentation 
(Iwata et al., 2004). RA binds to the receptor (RAR) expressed on naïve T cells and 
endows T cells with gut homing properties by inducing the expression of α4β7 and 
CCR9 (Napoli, 1999, Sigmundsdottir and Butcher, 2008, Iwata et al., 2004).  
In the gut, DCs continuously sample the luminal environment, where both commensal 
and pathogenic bacteria can be found; bacteria-stimulation could trigger the induction 
of mucosal tolerance or the activation of a protective immune response. While the role 
of DCs in determining the immunological output following the recognition of 
bacteria-derived molecules have been extensively studied, the role of bacteria-derived 
products in the programming of T cell gut homing via DCs has yet to be investigated. 
It has also been shown that low molecular weight soluble molecules such as 
chemokines found in the non-lymphoid tissue can be „delivered‟ to the tissue draining 
lymph nodes where T cell priming occurs (Gretz et al., 2000, Roozendaal et al., 2009). 
As chemokines are expressed in a tissue-specific manner (Kunkel and Butcher, 2002), 
and that the lymphoid tissue microenvironment is crucial in driving T cells to acquire 
the relevant homing molecules, we thus wanted to test if the presence of the gut-
chemokine CCL25 could influence the subsequent acquisition of gut HRs during T 
cell activation.  
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3.2 Aims  
It has been established that gut-derived DCs induce the expression of integrin α4β7 
and the chemokine receptor CCR9 via RA (Mora et al., 2003, Stagg et al., 2002, 
Johansson-Lindbom et al., 2003, Elgueta et al., 2008). In this part of this study, the 
overall aim was to investigate signals other than RA that could also programme T 
cells to express α4β7 and CCR9 following activation. First, we sought to investigate 
the role of bacteria-derived products, such as the TLR4 agonist lipopolysaccharide 
(LPS), which is produced in a large amount by commensal Gram negative bacteria in 
the gut such as Escherichia coli and Salmonella spp (Marshall, 2005, Akira et al., 
2006, Mansfield et al., 1996). In addition, we assessed the role of bacteria-derived 
muramyl dipeptide (MDP) in driving DCs to induce gut HRs in T cells. MDP is a 
NOD2 agonist (Girardin et al., 2003), and the minimal bioactive peptidoglycan motif 
common to all bacterial cell walls; it is also found at a high concentration in the colon 
(Vavricka et al., 2004). 
Second, we tested whether the presence of the gut chemokine CCL25 during T cell 
activation by DC could drive the acquisition of the gut HRs by activated T cells. To 
address these issues, we carried out the following experiments.  
1. Characterization of integrin α4β7 and CCR9 expression in naïve T cells 
2. Analysis of α4β7 and CCR9 expression by T cells following activation by DCs 
stimulated with bacterial-derived products including TLR4 agonist LPS and 
NOD2 agonist MDP 
3. Investigation of the effect of soluble factors present in the gut environment 
such as the gut-chemokine CCL25 on the induction of α4β7 and CCR9 on T 
cells activated by DCs matured with pro-inflammatory cytokines 
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3.3 Results  
3.3.1 Human naïve T cells express low levels of gut-homing receptors 
integrin α4β7 and CCR9 
Naïve T cells require the expression of L-selectin (CD62L) and CCR7 in order to 
recirculate through the secondary lymphoid organs such as the peripheral lymph 
nodes (PLNs), MLNs, PP and the spleen (Mackay et al., 1990). CD62L binds to the 
peripheral lymph node addressin (PNad) highly expressed on the high endothelial 
venules (HEVs) of PLNs and the MLNs in the gut (Streeter et al., 1988). CCR7 binds 
to the chemokines CCL19, CCL21 expressed on the HEVs of the PLNs (Williams et 
al., 1998, Baekkevold et al., 2001). CCL21 is also expressed by the PPs in the gut 
(Bargatze et al., 1995). Previous studies have shown that naïve T cells express a low 
level of gut-homing molecule integrin α4β7 and the chemokine receptor CCR9 (Erle et 
al., 1994, Zabel et al., 1999, Rott et al., 1996).  
Based on these findings, we first isolated naïve T cells from the peripheral blood of 
healthy volunteers using negative selection (Chapter 2, Section 2.4.3, pg 90). These 
purified T cells were subsequently analyzed by flow cytometry for the expression of 
surface molecules which are characteristics of naïve cells such as CD45RA, CD62L 
and CCR7. Naïve T cells were also stained for the integrin subunit α4 and β7 as well as 
CCR9. Figure 9 shows that CD45RA
+
 naïve T cells isolated were of high purity 
(panel A, 99.9%), and that both CD4
+
 and CD8
+
 naïve T cell subsets were positive for 
the expression of both CD62L and CCR7 (panel B). Consistent with previous reports 
(Erle et al., 1994, Zabel et al., 1999, Rott et al., 1996), naïve T cells isolated in our 
study were also found to express low levels of integrin α4β7 and CCR9 as shown in 
Figure 9B. 
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Figure 9. Expression of homing receptors on freshly isolated human naïve T cells. 
Naïve T cells were negatively selected from PBMC as previously described (Chapter 2, 
Section 2.4.3, pg 90) and stained with monoclonal antibodies (mAb) recognizing the following 
molecules: CD4, CD8, CD45RA, CD62L, CCR7, integrin α4, β7, and CCR9 (indicated as the 
black dots) and analyzed by flow cytometry. Cells were also stained with isotype controls 
(represented by the pink dots) for all the marker analyzed. The markers analyzed are 
indicated on the X and Y- axis of each dot plot, quadrant gates are set based on the isotype 
controls. The percentage of cells falling within each quadrant is shown in the corner of the 
quadrant. 
A. The dot plot in the top left shows the forward (FSC) and the side scatter (Rutgeerts et al.) 
of the purified naïve lymphocytes. The CD4
+
 and CD8
+
 T cell subset was subsequently gated 
on the total lymphocytes as indicated in the middle panel. The dot plots on the right 
respectively show the expression of CD45RA in the naïve CD4
+
 or CD8
+
 T cell subset.  
B. The dot plots display the homing molecules (CD62L, CCR7, integrin α4β7, CCR9) 
expressed by the naïve CD4
+
 and CD8
+
 T cell subset. 
The results shown are representative of one of ten naïve T cell isolations.  
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3.3.2 Phenotype of monocyte-derived DCs cultured in vitro 
DCs used in this project were generated from human peripheral blood CD14
+
 
monocytes as previously described (Sallusto and Lanzavecchia, 1994). CD14
+
 
monocytes were purified from total peripheral blood mononuclear cells (PBMC) 
using micro-beads and MACS
®
 column technology (as described in Chapter 2, 
Section 2.4.2, pg 89). The isolated monocytes were then assessed for purity by flow 
cytometry. As shown in Figure 10A the entire freshly isolated monocyte population 
expressed CD14 as compared to the isotype control. This high level of purity was 
observed consistently throughout the study.  
To generate immature DCs, CD14
+ 
monocytes were subsequently cultured for 6 days 
in GM-CSF and interleukin-4 (IL-4) (as described in Chapter 2, Section 2.5.2, pg 
92). On day 6, DC maturation was induced by bacteria-derived products or by 
cytokines. 
DCs matured by bacteria-derived products  
Bacteria-derived products commonly found in the gut, such as the TLR4 ligand 
lipopolysacchrides (LPS) or the NOD2 (nucleotide-binding oligomerization domain 2) 
ligand muramyl dipeptide (MDP), either alone or in combination were used to 
stimulate DCs for 24 hours. LPS is a Gram-negative bacteria outer membrane 
glycolipid (Raetz, 2002). Like TLRs, NOD2 is also a bacterial sensor, which belongs 
to the intracellular Nods protein family (Girardin et al., 2003). NOD2 senses bacterial 
peptidoglycan through the recognition of MDP, the minimal bioactive peptidoglycan 
motif common to all bacterial cell walls (Girardin et al., 2003).  
DCs matured by cytokines  
In the experiments where we assessed the role of CCL25 in the induction of gut HR in 
activated T cells, cytokines known to induce DC maturation were used in order to 
avoid any undesirable effect of the bacteria-derived molecules. DC maturation was 
therefore achieved by adding a combination of cytokines (TNF-α, IFN-γ, IL-1β) to the 
cell culture (Kawai, 2007, Mailliard et al., 2004, Han et al., 2009).  
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On day 7, immature DCs and differentially matured DCs were harvested and 
examined for the expression of the DC marker CD11c, and markers of maturation - 
CD80, CD86 and MHC-class II. As previous studies in mice found that only CD103-
expressing DCs in the small intestine were able to induce the expression of α4β7 and 
CCR9 (Annacker et al., 2005, Johansson-Lindbom et al., 2005, Jaensson et al., 2008) 
we also examined the level of CD103 found on these DCs cultured in vitro. As shown 
in Figure 10B, both immature and mature DCs expressed CD11c, matured DCs also 
expressed higher levels of co-stimulatory molecules compared to immature DCs. This 
was consistently observed throughout our study.  
Differentiated DCs matured by different stimuli expressed an array of different 
surface markers. These differences could be explained by the individual variability 
among donors, from which DCs were derived. Monocyte-derived DCs cultured in 
vitro were also found to express CD103. Though differences in their level of CD103 
expression were observed when comparing DCs matured by different stimuli, these 
differences were not consistent, thus, CD103 expression was likely to be independent 
of the different maturation stimuli used. Overall, we obtained fully functional matured 
DCs from each of the maturation stimuli mentioned above. 
.  
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Figure 10. Phenotypic analysis of monocyte-derived DCs.  
A. CD14
+
 monocytes were isolated from blood buffy coats PBMC using CD14 microbeads. 
The purity of the freshly isolated cells was determined by flow cytometry. The histrogram 
shows the expression of CD14 on the monocytes (black line) overlaid with the isotype control 
staining (blue line).                                                              
B. CD14
+
 monocytes were differentiated into immature DCs by 6 days of culturing in the 
presence of 100 ng/ml GM-CSF and 1000 IU/ml of IL-4. On day 6, the maturation of DCs 
was stimulated by using LPS (1 μg/ml) alone, MDP alone (10 μg/ml), or in combination at a 
ratio of 1:1. Alternatively, DCs were matured using a cocktail of cytokines: TNF-α (10 
ng/ml), IL-1β (10 ng/ml), and IFN-γ (10 ng/ml) for 24 hours. Immature and mature DCs were 
stained for the expression of DC markers CD11c, CD103, MHC-class II and the co-
stimulatory molecules CD80 and CD86. Histograms show the expression of these markers 
indicated as the black line compared to their isotype controls (represented by the blue line).  
Results shown are representative examples of DC phenotype observed throughout the project. 
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3.3.3 T cells acquire the expression of gut-homing receptors 
following stimulation by DCs matured by bacteria-derived products  
3.3.3.1 Naïve T cells undergo proliferation in response to allogeneic DCs 
matured in the presence of different bacteria-derived products 
As previously established, LPS derived from Gram-negative bacteria is able to trigger 
DC maturation via Toll-like receptor TLR4 (Ardeshna et al., 2000, Poltorak et al., 
1998). Other bacteria-derived product such as MDP induces DC maturation via 
NOD2 (Tada et al., 2005, Girardin et al., 2003). In vivo, following antigen uptake, 
while migrating to the local draining lymph nodes, DCs undergo maturation and 
subsequently process and present antigens to naïve T lymphocytes leading to their 
activation (Steinman, 1991, Banchereau et al., 2000, Manickasingham and Reis e 
Sousa, 2001). In order to study the gut-homing receptor expression by T cells during 
activation by DCs matured by bacteria-derived products, we cultured and matured 
DCs in vitro and set up allogeneic mixed lymphocyte reactions (MLR) with naïve T 
cells and DCs obtained from HLA-mismatched donors.  
Following the generation of immature DCs on day 6, these DCs were treated with 
LPS at a concentration of 1 μg/ml (Strengell et al., 2006), or MDP at a concentration 
of 10 μg/ml (Tada et al., 2005), or both at a ratio 1:1 for 24 hours. DCs were then 
harvested and co-cultured with freshly isolated allogeneic naïve T cells at a ratio of 
1:10 in a MLR. Two cultures were prepared in parallel; one for the assessment of 
DC‟s ability to induce T cell proliferation and one for the phenotypic analysis of these 
T cells following activation. For the assessment of T cell proliferation, DCs were 
irradiated at 60 Gray prior to the co-culture experiments. After 48 hours of co-culture, 
T cell proliferation was measured by thymidine incorporation over 18 hours 
(described in Chapter 2, Section 2.7.3, pg100). 
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As shown in Figure 11, DCs matured by different bacteria-derived products were all 
able to stimulate T cell proliferation. In addition, while we noted variation in the 
capacity of these DCs to stimulate T cell proliferation, no statistically significant 
differences in T cell proliferative responses induced by DCs matured by different 
stimuli were observed. 
. 
Figure 11. Monocyte-derived DCs are able to induce naïve T cell proliferation in 
allogeneic MLRs. 
DCs matured with the indicated stimuli were irradiated (60 Gray) and added to naïve T cells 
at a ratio of 1:10 in allogeneic MLRs. T cell proliferation was measured by thymidine 
incorporation after 48 hours of co-culture. As experimental controls, T cells or DCs cultured 
in media alone were used.  
Results are shown as the mean stimulation index +SEM of three independent experiments (SI, 
counts per minute of DC-stimulated T cells divided by counts per minute of T cells alone). The 
mean SI for each experiment was calculated from the triplicate wells of each culture 
condition. Statistical analysis was carried out using two-tailed unpaired student t-test. 
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3.3.3.2 Expression of gut-homing receptors by activated T cells 
To study the gut homing properties of activated T cells following stimulation by 
allogeneic DCs, T cells were harvested and stained for the expression of CD4, CD8, 
integrin α4, β7 and CCR9 and the memory T cell marker CD45RO. As shown in 
Figure 12, two distinct populations of T cells were identified following 7 days of co-
culturing with DCs determined by their size and the expression of the CD45RO. The 
smaller, non-activated T cells (population NA, shown in blue) were CD45RO
-
, and 
the bigger activated T cell blasts were CD45RO
+
 (population A, shown in red).  
 
Figure 12. Activated T cells express CD45RO.  
Monocyte-derived immature DCs and DCs matured by LPS, MDP or LPS and MDP in 
combination were cultured with freshly isolated naive T cells in a ratio of 1:10 for 7 days. 
Cells were then collected and stained for the expression of CD45RO.  
A. For phenotypic analysis, activated and non-activated T cell populations were separately 
gated as illustrated (population A and NA respectively in the dot plot). Histograms show 
CD45RO expression by activated (red) and non-activated T cells (blue). Isotype control 
staining on these cells are shown in orange and green respectively.  
B. The histogram represents the overlay of CD45RO expression on activated and non-
activated T cells.  
The plots shown are representative of six experiments of identical design. 
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Following the identification of CD45RO
+
 activated T cell population in the co-culture 
experiment, the expression of the α4β7 integrin and chemokine receptor CCR9 on 
activated T cells obtained from various cultures were analyzed. The following gating 
strategy was developed and applied for the analysis as illustrated in Figure 13A-D 
and Figure 14A-D.  
α4β7 
Due to the lack of the commercially available monoclonal antibody which 
recognizes the α4β7 heterodimer, the expression of this molecule could only be 
assessed by using two antibodies recognizing the α4 and β7 subunit separately as 
shown in Figure 13A-D. Low levels of α4β7 were expressed by the non-
activated T cells (NA) following 7 days of co-culturing with allogeneic DCs, 
shown in Figure 13A as blue dots (the quadrant gates, represented by the green-
dotted lines, were set based on the isotype controls). To highlight the 
upregulation of both α4 and β7 chains on activated T cells (red dots, Figure 13B-
D) following DC stimulation, the quadrant gates were set based on the 
expression of α4β7 found on the non-activated T cells (shown as black solid 
lines). Activated T cells expressing higher levels of α4β7 were thus termed 
α4β7
high
. This gating strategy was applied consistently throughout the data 
presented.  
CCR9 
The similar gating strategy used for the flow cytometric analysis of integrin α4β7 
was applied for the analysis of CCR9 expression on activated T cells. Non-
activated T cells (blue dots) expressed low levels of CCR9 as shown in Figure 
14A, to highlight the higher expression of CCR9 on activated T cells (Figure 
14B-D), quadrant gates (black lines) were set based on the background 
expression of CCR9 displayed on the non-activated T cells.  
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Results from each of the three independent experiments carried out are shown in 
Figure 13B-E (α4β7) and Figure 14B-E (CCR9). 
In all three experiments, the co-expression of α4 and β7 chains was upregulated on 
both activated CD4
+
 and CD8
+
 T cells (red dots) compared to the non-activated T 
cells (blue dots) independent of the type of stimulator DCs. A proportion of activated 
T cells was also found to express integrin α4 chain but not β7, these α4
+
 β7
-
 T cells 
maybe express integrin β1 chain instead, whose expression can be upregulated 
following T cell activation (Tarkowski et al., 2000). While non-activated T cells were 
α4β7
+
 compared to isotype controls (green dots), activated T cells expressed a much 
higher level of integrin α4β7, and these cells were thus termed α4β7
high
. It was also 
noted from all three experiments that larger proportions of the CD8
+
 T cells became 
α4β7
high
 following activation by allogeneic DCs compared to the CD4
+
 population. 
Meanwhile, we noted a great degree of variability with regards to the capacity of T 
cells to upregulate α4β7 following activation by DCs matured by either TLR4 or 
NOD2 ligand. For example, in one experiment (Figure 13B), DCs matured by 
triggering either TLR4 or NOD2 induced similar level of α4β7 upregulation in both 
activated CD4
+
 and CD8
+
 T cells, and TLR4 and NOD2 appeared to act 
synergistically in the induction of α4β7. However, these results were not reproducible 
as shown in Figure 13C and Figure 13D. 
As shown in the pooled data (from three independent experiments, Figure 13E), 
following stimulation by LPS-matured DC, on average 32.2% (± 13.3%) of activated 
CD8
+
 T cells were α4β7
high
 compared to 6.5% (± 1.2%) of activated CD4
+
 T cells. The 
smallest proportion of T cells expressing a high level of α4β7 was those stimulated by 
immature allogeneic DCs. While DCs matured by LPS and MDP in combination 
appeared to induce the largest proportion of integrin α4β7
high
 T cells – 14.4% (± 5.5%) 
of CD4
+
 and 45.5% (± 16.7%) of CD8
+
 compared to DCs matured by either LPS or 
MDP alone, these observed differences did not reach statistical significance for either 
CD4
+
 or CD8
+
 T cells (p>0.05). Thus, in conclusion, DCs matured by different 
bacterial stimuli have comparable capacity to induce the acquisition of gut-homing 
molecules on activated T cells. These results are summarized in Figure 13E which 
represents the mean percentage of α4β7
high
 CD4
+
 and CD8
+
 T cells (gated on activated 
CD4
+
 and CD8
+
 T cells respectively) calculated from three independent experiments.  
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The expression of CCR9 on non-activated T cells and T cells activated by allogeneic 
DCs are shown in the dot plots in Figure 14A-E (from three independent experiments) 
using the gating strategy described.  
The CD4
+
 and CD8
+
 T cell subsets were gated within the non-activated and activated 
T cell population and analyzed separately for the expression of CCR9. In all 
experiments, in comparison to non-activated T cells (blue dots), CCR9 was 
upregulated by a proportion of activated CD4
+
 and CD8
+
 T cells (red dots). Among 
the three experiments conducted (Figure 14B-D), it was noted that DCs matured 
differently induced variable levels of CCR9 upregulation in activated T cells. These 
observations might be attributed to the sample variation between different donors 
from whom DCs and naïve T cells were derived. As shown in the pooled data, 
(Figure 14E), in conclusion, DCs stimulated by different maturation stimuli did not 
result in significantly different degrees of CCR9 upregulation in activated T cells 
(p>0.05). The cumulative data is presented as the mean percentage of CD4
+
 CCR9
+
 
cells and CD8
+
CCR9
+ 
T cells (gated on activated CD4
+
 or CD8
+
 T cells respectively) 
calculated from multiple experiments. 
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Figure 13. T cells acquire the expression of integrin α4β7  when stimulated by DCs 
matured by bacteria- derived products. 
Following naïve T cells co-culture with allogeneic DCs for 7 days, cells were collected and 
stained for the expression of CD4, CD8, integrin α4, and β7.  
A. The dot plots display the expression of integrin α4β7 detected on the non-activated CD4
+
 
and CD8
+
 T cells (blue dots). Two quadrant gates were drawn on each dot plot to illustrate 
the gating strategy adopted for the phenotypic analysis of integrin α4β7 expression by 
activated T cells following DC stimulation. The green dotted lines represent the quadrant 
gates based on the isotype controls (green dots); while the black solid lines represent the 
background level of integrin α4β7 expressed by non-activated T cells. 
B-D. Results from three independent experiments are displayed in these panels. Activated and 
the non-activated CD4
+
 and CD8
+
 T cell populations were gated separately and analyzed for 
the co-expression of the α4 and β7 integrin chains. The expression of α4β7 on activated T cells 
is shown as the red dots (isotype controls as orange dots) in the dot plots, and shown as the 
blue dots (isotype controls as green dots) on non-activated CD4
+
 and CD8
+
 T cells. The 
percentage of α4β7
high 
cells within the activated CD4
+
 and CD8
+
 T cell population are 
indicated.  
Dot plots shown in A and B are from one experiment illustrating the gating strategy, and plots 
shown in C and D depict results from two other experiments of identical design.        
E. Graphs represent the mean percentage of CD4
+
 α4β7
high
 and CD8
+
 α4β7
high
 within non-
activated T cells and activated T cells calculated from three independent experiments of 
identical design. Results were analyzed using two-tailed unpaired student t-test and are 
presented as mean +SEM.  Error bars indicate the standard error of the mean.  
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Figure 14. The chemokine receptor CCR9 is upregulated on T cells activated by 
allogeneic DCs matured with bacteria- derived products.  
Following naïve T cells co-cultuing with allogeneic DCs for 7 days, cells were collected and 
stained for the expression of CD4, CD8 and CCR9. 
A. The expression of CCR9 on non-activated CD4
+
 and CD8 
+
 T cells is shown in the dot 
plots. Two gates were drawn for the illustration of the gating strategy developed for the 
analysis of CCR9 on activated T cells. The green dotted lines represent quadrant gates based 
on isotype controls, the solid black lines represent the gates based on the background level of 
CCR9 expressed by non-activated T cells. 
B-D. Results each of the three independent experiments are displayed. 
CD4
+
 and CD8
+
 T cells within the activated and non-activated populations were gated and 
analyzed for the expression of CCR9. The expression of CCR9 on activated CD4
+
 and CD8
+
 
T cells is shown as the red dots (orange dots are isotype controls), blue dots represent the 
expression of CCR9 on non-activated CD4
+
 and CD8
+
 T cells with their isotype controls 
shown as the green dots. Quadrant gates on the activated T cells were set based on the 
background level of CCR9 expression by the non-activated T cells, the percentage of 
CD4
+
CCR9
+
 and CD8
+
CCR9
+ 
T cells is indicated on the dot plots. 
Dot plots shown in A and B are from one experiment illustrating the gating strategy using for 
the analysis of CCR9 expression. Panel C and D display results from two other experiments 
of identical design.                                             
E. Graphs indicate the mean percentage of activated and non-activated CD4
+
CCR9
+ 
and 
CD8
+
CCR9
+ 
T cells generated by different DCs. Cumulative data is presented as mean 
+SEM, and analysed using two-tailed unpaired student t-test. Error bars indicate the 
standard error of the mean.  
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3.3.4 Can T cells acquire gut homing specificity following activation 
by mature DCs in the presence of soluble gut-derived factors (other 
than bacteria)?...... 
Having assessed T cell proliferation and phenotype following activation by DCs 
matured with bacteria-derived products, we then sought to investigate the ability of 
other components of the gut microenvironment to instruct the acquisition of gut 
homing properties by T cells following activation.  
Found at a high concentration in the small intestine of both human and mice 
(Bowman et al., 2002, Campbell and Butcher, 2002, Kunkel et al., 2000, Papadakis et 
al., 2000, Hieshima et al., 2004), the gut chemokine CCL25 has been identified as a 
key molecule in attracting lamina propria memory T cells to the small intestine and 
further to the small intestinal epithelium by binding to its receptor CCR9(Stenstad et 
al., 2007, Kunkel et al., 2000, Zabel et al., 1999). We therefore decided to test 
whether the presence of CCL25 during naïve T cell activation by allogeniec DCs in 
vitro would have any effect on the induction of the gut-homing receptor integrin α4β7 
and CCR9 on activated T cells. It has been described that vitamin A metabolism (into 
retinoic acid) by gut-derived DCs is responsible for the induction of gut tropism on T 
cells during activation in the secondary lymphoid tissue (Iwata et al., 2004). We 
therefore included all-trans-RA, which is the metabolized form of vitamin A and the 
major physiologic form of retinoic acid in our experiment as a positive control.  
In our experiments, monocyte-derived DCs were matured using a combination of 
cytokines - TNF-α, IFN-γ and IL1β for 24 hours in the absence of any bacteria-
derived factors. Mature DCs were co-cultured with allogeneic naïve T cells in MLRs 
with the addition of either CCL25 or all-trans-RA in experiments similar to those 
described in Section 3.3.3 of this chapter. Two cultures were prepared in parallel; one 
for the assessment of DC‟s ability to induce T cell proliferation by thymidine 
incorporation following 48 hours of culturing, one for the phenotypic analysis of these 
T cells by flow cytometry. For the phenotypic analysis, cultures were harvested 7 days 
after stimulation. 
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3.3.4.1 T cell proliferative responses induced by cytokine- matured DCs 
As shown in Figure 15, cytokine-matured DCs were powerful stimulators of naïve T 
cells. In addition, the presence of the gut-chemokine CCL25 or all-trans-RA did not 
affect T cell proliferative responses.  
 
Figure 15. Cytokine-matured DCs induce naïve T cell proliferation in allogeneic 
MLRs. 
Following maturation, DCs were irradiated (60 Gray) prior to co-culture experiment. DCs 
and naïve T cells were mixed at a ratio of 1:10 in allogeneic MLR as described in Figure 11. 
Co-cultures were set up in triplicate: naïve T cells and DCs in medium, naïve T cells and DCs 
in the presence of CCL25 (300 ng/ml) or all-trans-RA (2 μM). T cell proliferation was 
measured by thymidine incorporation after 48 hours. Naïve T cells cultured in medium alone 
were prepared as the negative controls for the experiment. Results are shown as the mean SI 
+SEM of three independent experiments. The mean SI for each experiment was calculated 
from the triplicate wells of each culture condition. Statistical analysis was carried out using 
two-tailed unpaired student t-test. 
 
T
 c
el
ls
 a
lo
ne
 
T
 c
el
ls
+T
N
F-
D
C
T
 c
el
ls
+T
N
F-
D
C
+C
C
L
25
T
 c
el
ls
+T
N
F-
D
C
+R
A
0
20
40
60
80
S
ti
m
u
la
ti
o
n
 I
n
d
ex
Chapter 3 Acquisition of gut-homing receptors by T cells activated by dendritic cells 
in the presence of the gut-derived factors
 
124 
3.3.4.2 Expression of gut-homing receptors by T cells stimulated by allogeneic 
cytokine-matured DCs in the presence of the gut chemokine CCL25...... 
To study the gut-homing properties of T cells activated by cytokine-matured DCs in 
the presence of CCL25 or all-trans-RA, T cells were harvested 7 days after 
stimulation and stained for the expression of CD45RO. Figure 16 shows the two 
different populations of T cells generated following T cell activation by cytokine-
matured DCs. Activated T cells (bigger cells, shown in red) were CD45RO
+
, whereas 
non-activated T cells (smaller cells, shown in blue) were CD45RO
-
.  
 
Figure 16. T cells express CD45RO following activation by DCs matured with 
cytokines.  
Monocyte-derived DCs were matured by a combination of cytokines (TNF-α, IFN-γ and IL1β, 
described in Chapter 2, Section 2.5.2, pg 92). DCs and the freshly isolated naive T cells were 
mixed at a ratio of 1:10 in allogeneic MLRs as described previously. Cells were harvested 
and stained for the expression of CD45RO. The same gating strategy described in Figure 12 
was applied. 
A. The activated T cells (labeled A) and non-activated T cells (labeled NA) is shown in the dot 
plot. The histograms respectively show the CD45RO expression on activated T cells (red) 
(isotype control is shown in orange) and non-activated T cells (blue)(the isotype control is 
shown in green).  
B. The histogram shows the overlay of CD45RO expression on population ‘A’ and ‘NA’. 
Results shown are representative of six experiments of identical design.  
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For the phenotypic analysis of α4β7 on T cells activated by cytokine-matured DCs, the 
same gating strategy mentioned previously (in Section 3.3.3.2, pg 118 of this chapter) 
was applied. As shown in Figure 17A, integrin α4 and β7 chain were both upregulated 
on activated CD4
+
 and CD8
+
 T cells (red dots) upon DC stimulation compared to the 
non-activated T cell population (blue dots). As previously mentioned, these activated 
T cells were termed α4β7
high having taken into account the background level of α4β7 
expressed by non-activated T cells. When comparing the levels of α4β7 expressed by 
activated T cells from the three culture conditions (T cells + DCs in media, in the 
presence of CCL25 or all-trans-RA) the fraction of α4β7
high
 activated T cells was 
significantly increased (p<0.05) in the presence of CCL25. This increase was also 
more marked for CD4
+
 T cells (23.6% ±7.5% compared to 12.8% ± 5.1%) than CD8
+
 
T cells (53.3% ± 9.2% compared to 44.2% ± 6.3%). As anticipated, the highest 
frequency of CD4
+
 α4β7
high
 (86.6% ±5.8%) and CD8
+
 α4β7
high
 T cells (83.6% ± 6.8%) 
were obtained from cultures containing all-trans-RA. These results are summarized 
and presented as the mean percentage of CD4
+ α4β7
high
 and CD8
+
 α4β7
high
 T cells 
calculated from multiple experiments of identical design as shown in Figure 17B.  
To assess the expression of CCR9 on DC-activated T cells, the same gating strategy 
(described in Section 3.3.3.2, pg 121 of this chapter) was applied. The dot plots in 
Figure 18A show the expression of CCR9 on non-activated T cells and T cells 
activated by allogeneic DCs in the same culturing conditions described above. Across 
all conditions, CCR9 was upregulated on activated T cells (red dots) compared to the 
non-activated population (blue dots). The largest upregulation of CCR9
 
was observed 
in T cells activated by allogeneic DCs alone (31.3% ± 6.5% of CD4
+
 T cells were 
CCR9
+
, 27.6% ± 7.2% of CD8
+
 T cells were CCR9
+
 as shown in the cumulative plots). 
The presence of either CCL25 or all-trans-RA considerably reduced the upregulation 
of CCR9 by CD4
+
 and CD8
+
 T cells. As shown, on average, 31.3% ± 6.5% of 
activated CD4
+
 T cells expressed CCR9 when T cells were culture with matured DCs 
alone in media. However, in the presence of CCL25, the percentage of CD4
+
CCR9
+ 
T 
cells fell to 19% ± 6.4% (p<0.05). Lower upregulation of CCR9 was also noted in 
activated CD8
+
 T cells (16.8% ± 4.6% in the presence of CCL25 compared to 27.6% 
± 7.2% as shown in the cumulative plots), however these differences were not 
statistically significant. 
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In addition, within the CCR9
+
 activated T cell population, a subset expressing high 
levels of CCR9 - termed CCR9
high
 (shown in the box gate) was also detected among 
the DC-activated CD4
+
 and CD8
+
 T cells.  
We thus calculated the percentage of the CCR9
high
 subset within the total CCR9
+
 T 
cells (CCR9
high
/CCR9
+
), and noted a trend of increase (p>0.05) in the proportion of 
CCR9
high
 T cells when CCL25 or all-trans-RA was present. On average, CD4
+
 
CCR9
high
 T cells observed in cultures containing DCs alone accounted for 6.1% ± 2.4% 
of the total CD4
+
CCR9
+ 
T cells. In the presence of CCL25 or all-trans-RA, this figure 
rose to 10.9% ± 5.5% and 17.9% ± 13.2% respectively. 
These results have been summarized in Figure 18B and presented as the mean 
percentages of CD4
+
CCR9
+
 and CD8
+
 CCR9
+ 
T cells gated on activated CD4
+
 or 
CD8
+
 T cells respectively. The percentage of CCR9
high
 within the total CCR9
+
 
activated T cell populations are summarized and presented in Figure 18C.  
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Figure 17. T cells are induced to upregulate integrin α4β7 following stimulation 
by allogeneic DCs in the presence of the gut chemokine CCL25.  
Cytokine-matured DCs and naïve T cells were set up in allogeneic MLRs (as described 
previously in Section 3.3.3 of this chapter) in media alone, or in the presence of CCL25 (300 
ng/ml) or all-trans-RA (2 μM). After 7 days, cells were collected and stained for the 
expression of CD4, CD8, integrin α4, and β7 subunit. The same gating strategy described in 
Figure 13 (Section 3.3.3.2, pg118) was applied.  
A. The expression of α4β7 on non-activated CD4
+
 and CD8
+
 T cells are shown as the blue dots 
(isotype controls are shown in green) in the dot plots shown. The expression of α4β7 on 
activated CD4
+
 and CD8
+
 T cells T cells are represented by the red dots (isotype controls are 
shown in orange). The percentages of CD4
+α4β7
high
 and CD8
+α4β7
high 
T cells are indicated 
within each quadrant. Results shown are representative of six independent experiments of 
identical design.  
B. Cumulative data showing the mean proportion of CD4
+
 α4β7
high
 and CD8
+
 α4β7
high
 T cells 
among the non-activated and activated T cell populations calculated from six experiments of 
identical design. Data was analyzed using two-tailed Wilcoxon matched pairs test. Error bars 
indicate the standard error of the mean. * p<0.05  
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Figure 18. T cells upregulate CCR9 following activation by allogeneic DCs in the 
presence of the gut chemokine CCL25.  
A. Activated and non-activated CD4
+
 and CD8
+
 T cell populations were gated separately and 
analyzed for the expression of CCR9. In the dot plots displayed, the expression of CCR9 on 
activated CD4
+
 and CD8
+
 T cells is represented by the red dots (isotype controls are shown 
as orange dots), on non-activated CD4
+
 and CD8
+
 T cells is represented by the blue dots 
(isotype controls are represented by the green dots). The same gating strategy described 
previously in Figure 14 (Section 3.3.3.2, pg 121) was applied. The boxed gates represent the 
proportion of T cells expressing the highest level of CCR9 (CCR9
high
) within activated CD4
+
 T 
cells and CD8
+
 T cells. The dot plots shown are representative from a total number of five 
independent experiments of identical design.  
B. The graphs indicate the percentage of CD4
+
CCR9
+
 and CD8
+
CCR9
+
 T cells gated on the 
non-activated and activated T cells under different culture conditions. Results are shown as 
mean+SEM. Statistical significance is indicated with *(* p<0.05) 
C. The proportion of CCR9
high
 T cells within the total CCR9
+ 
activated CD4
+
 and CD8
+
 T 
cells is shown as mean percentage+SEM. Cumulative data was analyzed using two-tailed 
Wilcoxon matched pairs test. Error bars indicate the standard error of the mean.  
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3.4 Discussion  
Memory T cell preferential homing to the gut requires the following interactions: 
integrin α4β7 and its ligand MAdCAM-1, and for the small intestine - the chemokine 
receptor CCR9 binding to the gut–chemokine CCL25. These homing receptors (HRs) 
allow memory T cells to migrate to the effector site of the gut mucosa - lamina 
propria (Berlin et al., 1993, Lefrancois et al., 1999b, Hamann et al., 1994, Svensson et 
al., 2002, Kantele et al., 1999). In vivo, naïve T cells become activated during 
interaction with antigen-presenting DCs in the SLOs, and subsequently differentiate 
into a heterogenous memory T cell population (TEFF, TCM, TEM). It is during activation 
that T cells receive signals from DCs and subsequently express the appropropriate 
HRs which enable their access to the non-lymphoid tissue where initial priming 
occurs (Sallusto et al., 2004; Sallusto et al., 1999)(Masopust et al., 2001, Weninger et 
al., 2002, Kantele et al., 1999, Mora et al., 2006). In this part of our project, we 
investigated previously unidentified mechanisms that contribute to the induction of 
gut HRs (gHRs). 
As the gut hosts a large amount of commensal bacteria, which is constitutively 
sampled by the gut-resident DCs (Rescigno et al., 2001) we hypothesized that 
bacteria-signaling via the pattern recognition receptors (PRRs) might play a role in the 
induction of HRs on T cells following stimulation by gut-derived DCs. Secondly, 
based on the previous observations that soluble factors of low molecular weight 
present in the non-lymphoid tissue can be delivered to the local draining lymph nodes 
(LNs) (Gretz et al., 2000, Roozendaal et al., 2009) and the well-established role of 
tissue microenvironment in driving the acquisition of gHRs by T cells (Mora et al., 
2003, Stagg et al., 2002, Johansson-Lindbom et al., 2003, Elgueta et al., 2008), we 
investigated whether the gut-chemokine CCL25 may participate in this process.  
First, we phenotypically characterized human naïve T cells. In several previous 
studies using human PBMC, it was found that a subset of human CD45RA
+
 naïve T 
cells express low levels of integrin α4β7 (Erle et al., 1994, Rott et al., 1996, 
Schweighoffer et al., 1993). Having characterized multiple donors, our results are 
consistent with these observations. However, it is important to note that this result 
does not imply that naïve T cells migrate to the gut parenchymal tissue, as the ability 
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to efficiently bind to its ligand MadCAM-1 in the intestinal microvessels requires a 
much higher level of α4β7 expression only associated with memory T cells (Nakache 
et al., 1989, Berg et al., 1989, Rott et al., 1996). On the other hand, the expression of 
α4β7 may facilitate naïve T cell entry to the Peyer‟s patches (Kyd and Cripps, 2008), 
as mice with a β7 mutation have been found to display a 90% reduction in lymphocyte 
migration to the PPs (Wagner et al., 1998). 
Furthermore, our study has confirmed that human naïve T cells constitutively express 
low levels of CCR9 as observed by others (Zabel et al., 1999). CCR9 is expressed by 
all thymocytes and it has been proposed that following exit from the thymus, T cell 
downregulate CCR9. Thus, the CCR9
+
 naïve T cell population observed in our study 
might represent those recently generated thymocytes that have not yet downregulated 
CCR9 (Vicari et al., 1997, Zabel et al., 1999, Ebert et al., 2005).  
Next, to test our hypothesis, we cultured monocyte-derived DCs and set up allogeneic 
MLR experiments to study the gHR acquisition by activated T cells. First, 
functionally matured DCs were generated by stimulating monocyte-derived DCs via 
their PRRs such as the TLR4 and NOD2 (alone or in combination), which are chosen 
as their ligands are both present in large quantity in the intestine (Vavricka et al., 2004, 
Marshall, 2005). TLR4 is the major receptor for bacteria cell wall-derived 
lipopolysaccharides (LPS), while NOD2 senses bacterial peptidoglycan (PGN) 
through the recognition of MDP (muramyl dipeptide), which is the minimal bioactive 
peptidoglycan motif common to all bacterial cell walls (Girardin et al., 2003). As 
expected, naïve T cells responded to mature DCs by undergoing proliferation. While 
it has been reported that signalling via TLR4 and NOD2 produces a synergistic effect 
in the cytokine production of peripheral blood mononuclear cell, we did not observe 
any synergy in T cell proliferative responses induced by DCs matured by 
simultaneous triggering of both TLR4 and NOD2 in my experiments (Netea et al., 
2005, van Heel et al., 2005).  
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After measuring naïve T cell proliferation in response to DC stimulation, we assessed 
the phenotype of activated T cells. As anticipated, both gut-homing receptor integrin 
α4β7 and the chemokine receptor CCR9 were upregulated by activated T cells. In 
addition, I did not observe any significant differences in the capacity of T cells to 
upregulate these homing receptors following activation by DCs matured with either 
TLR4 or NOD2 ligand. Similarly to what was observed in T cell proliferative 
responses, TLR4 and NOD2 did not appear to act in synergy in the induction of either 
α4β7 or CCR9 in activated CD4
+ 
or CD8
+
 T cells. These results might be partially due 
to high variability in the data that we collected, and therefore requires further 
investigation. 
Receptors in the TLR and NOD PRR family are both crucial in the recognition of 
bacteria-derived proteins. NOD2, in particular has attracted much attention since it 
was first characterized (Inohara and Nunez, 2001). In humans and mice, NOD2 
expression has been found on antigen-presenting cells (APC) such as the macrophages, 
monocytes, monocyte-derived DCs but not on T or B cells (Gutierrez et al., 2002, 
Inohara and Nunez, 2003). Intestinal epithelial cells can also be induced to express 
NOD2 when stimulated by TNF-α or LPS (Gutierrez et al., 2002). More importantly, 
polymorphism in the NOD2 gene has been strongly linked to an increased 
susceptibility to Crohn‟s disease (Ogura et al., 2001, Hugot et al., 2001, Economou et 
al., 2004); defects in the MDP-sensing pathway in Crohn‟s disease patients who are 
carriers of certain NOD2 mutations have been observed (van Heel et al., 2006). 
Others have reported that NOD2 variants are associated with signaling defects in host 
responses to both LPS and peptidoglycan (PGN) (Bonen et al., 2003). A previous 
study has also shown that in healthy individuals, prolonged stimulation of NOD2 by 
pre-treating monocyte-derived macrophages results in a reduced secretion of pro-
inflammatory cytokines following re-stimulation of NOD2 or TLR agonists, however, 
this effect was not observed in macrophages harboring a known Crohn‟s disease 
susceptibility NOD2 variant (Hedl et al., 2007).Thus, it has been postulated that 
inappropriate bacterial-sensing pathways could be a cause for the uncontrolled gut 
inflammation associated with Crohn‟s disease (Marks and Segal, 2008).  
While it was shown in the current study that NOD2 triggering in DCs subsequently 
induces T cells to express gut-homing receptors, the association between defects in 
Chapter 3 Acquisition of gut-homing receptors by T cells activated by dendritic cells 
in the presence of the gut-derived factors
 
134 
NOD2 signalling and memory T cell homing to the intestine in patients with Crohn‟s 
disease requires further investigation. 
Next, we investigated whether other mechanisms are in place to induce gHR 
acquisition in activated T cells other than via DCs that had been exposed to bacteria-
derived products. In this respect, many studies have acknowledged the vital 
importance of the local microenvironment in „educating‟ T cells to selectively express 
the tissue-specific homing molecules (Campbell and Butcher, 2002, Johansson-
Lindbom et al., 2003, Stagg et al., 2002). However, the essential element present in 
the microenvironment responsible for this process was unknown until a recent study 
published by Iwata and colleagues. This study demonstrated that gut-derived retinoic 
acid, the metabolite of vitamin A, was responsible for gut homing specificity 
imprinted on T cells (Iwata et al., 2004).                   
Recent evidence suggests that other tissue-derived factors present in the non-
lymphoid tissue may also constitute the microenvironment within the tissue-draining 
lymph nodes where T cell priming occurs, therefore such factors are potentially 
important in endowing T cells with a gut-homing phenotype. For instance, it has been 
shown that low molecular weight soluble factors such as tissue-specific chemokines 
can be transported into the tissue draining lymph nodes via a conduit system (Gretz et 
al., 2000, Roozendaal et al., 2009). As the gut chemokine CCL25 is constitutively 
present in the small intestine of both humans and mice and plays a key role in 
attracting memory T cells to the small intestine (Bowman et al., 2002, Campbell and 
Butcher, 2002, Kunkel et al., 2000, Papadakis et al., 2000, Hieshima et al., 2004, 
Stenstad et al., 2007, Zabel et al., 1999), we hypothesized that if present, CCL25 
might enhance the subsequent acquisition of gHRs following T cell activation. 
To test this hypothesis, DCs were cultured and matured using a cocktail of cytokines 
to avoid contamination by any bacteria-derived products such as LPS. These DCs 
were then co-cultured with allogeneic naïve T cells in the presence or absence of 
CCL25, following which T cells were phenotypically characterized. First, in line with 
previous observations (Mora et al., 2003, Mora et al., 2005), following naïve T cell 
activation by DCs, both α4β7 and CCR9 were upregulated in activated T cells 
compared to the non-activated population that did not respond to DC stimulation. 
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These data suggest that T cell activation is a prerequisite signal for the upregulation of 
gHRs T cells irrespective of the DC tissue origin. 
Our results also showed that the proportion of activated T cells expressing high levels 
of α4β7 was significantly raised (p<0.05) when CCL25 was present upon T cell 
activation. At this stage, we cannot conclude whether this effect of CCL25 was due to 
CCL25 direct signalling to T cells (discussed later in Chapter 6) or via DCs. It is 
possible that CCL25 may have a „conditioning‟ effect on DCs which leads to their 
enhanced ability to selectively induce the expression of α4β7 during T cell activation. 
Although not tested in my study, results from a preliminary study in our lab support 
this possibility. These experiments suggest that murine DCs pre-treated with CCL25 
are able to drive T cell acquisition of integrin α4β7 (Georgina Cornish, unpublished 
data) indicating the effect of CCL25 is DC-dependent. However, unlike murine DCs 
(Drakes et al., 2009), human monocyte-derived DCs cultured in vitro do not express 
CCR9 (Cravens and Lipsky, 2002), this conditioning effect therefore is unlikely to be 
mediated by CCR9 binding to DCs. 
While CCL25 appeared to promote T cell acquisition of α4β7, it led to a significantly 
lower level of CCR9 upregulation. Meanwhile, within the CCR9
+ 
T cell population, 
we observed a trend of increase in the proportion of T cells expressing high levels of 
CCR9 (CCR9
high
) when CCL25 was present during T cell activation, suggesting that 
CCL25 might favour the emergence of CCR9
high
 T cells. 
As expected, when active vitamin A metabolite – all-trans-RA was used as a positive 
control in our experimental system, the majority of activated T cells were induced to 
express high levels of α4β7. Similarly to what was observed for CCL25, the presence 
of RA also led to a reduced level of CCR9 upregulation as compared to T cells co-
cultured with DCs alone. In addition, RA also appeared to support the development of 
the T cell subset expressing high levels of CCR9 (CCR9
high
). 
As CCL25 and all-trans-RA appeared to have similar effects on T cell acquisition of a 
gut-homing phenotype, we speculate that these two molecules may share common 
pathways leading to the expression of integrin α4β7 and CCR9 on T cells.
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Chapter 4 Induction of gut-homing receptors on T cells 
stimulated by immature DCs in the presence of CCL25  
4.1 Introduction 
In the previous part of our study, we have shown that T cells upregulate gut-homing 
molecules integrin α4β7 and chemokine receptor CCR9 upon stimulation by allogeneic 
mature DCs in the presence of gut-derived factors such as CCL25 and retinoic acid. In 
this part of our study, we sought to investigate the induction of α4β7 and CCR9 on T 
cells stimulated by allogeneic immature DCs.  
It has been well established that the maturation state of dendritic cells (DCs) directly 
influences their function during interaction with T cells; while mature DCs are 
immunogenic, immature DCs promote tolerogenic immune responses in vivo (Miller 
and Morahan, 1992, Steinman et al., 2003, Hawiger et al., 2001). Compared to mature 
DCs, immature DCs express low levels of surface MHC II molecules and no co-
stimulatory molecules (Lee et al., 1993, Mommaas et al., 1995).  
In the steady state (lack of inflammatory stimuli), DCs residing in the peripheral 
lymphoid tissue remain immature and induce tolerance by deleting autoreactive T 
cells, sub-optimally priming T cells resulting in T cell anergy or by promoting the 
differentiation of naïve T cells into FoxP3
+
 regulatory T cells (Steinman and 
Nussenzweig, 2002, Manicassamy and Pulendran, Ng et al., 2010, Coombes et al., 
2007, Sun et al., 2007, Thomson). In the gut, 50% of DCs in the mesenteric lymph 
nodes (MLNs) at steady state are found to be non-migratory lymphoid-resident DCs 
that are phenotypically and functionally immature, with a principle function to 
maintain gut tolerance (Wilson et al., 2003, Lutz and Schuler, 2002, Henri et al., 
2001).  
In vitro, repetitive simulation of naïve T cells with monocyte-derived allogeneic 
immature DCs leads to the production of IL-10-producting non-proliferating T cells 
(Jonuleit et al., 2000). In addition, bone marrow-derived murine immature DCs have 
been described to promote the expansion of Foxp3
+
 regulatory T cells in vitro (Chai et 
al., 2008).  
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These evidence prompted us to use immature DCs to stimulate allogeneic naïve T 
cells in order to study gut-homing receptor (gHR) acquisition under steady state. In 
the previous chapter, we have shown that exposure to the gut chemokine CCL25 and 
the active vitamin A metabolite retinoic acid (all-trans-RA) during activation by 
allogeneic mature DCs enhances T cell acquisition of gHRs. In this chapter, we 
sought to evaluate the effect of CCL25 and all-trans-RA on the induction of α4β7 
integrin and CCR9 on T cells upon stimulation by immature DCs.  
In addition, we assessed the expansion of FoxP3
+
 T cells following naïve T cell 
stimulation by allogeneic DCs (immature and mature) and whether CCL25 played a 
role in the induction of integrin α4β7 expression in these cells. 
4.2 Aims 
To answer the questions outlined above, the following experiments were carried out in 
this part of our project.  
1. Examination of T cell proliferative responses towards immature DCs in the 
presence or absence of CCL25 or all-trans-RA 
2. Evaluation of the expression of α4β7 and CCR9 induced on T cells following 
stimulation by allogeneic immature DCs, and the effect of CCL25 or all-trans-RA 
on the acquisition of α4β7 and CCR9 by T cells 
3. Assessment of the effect of CCL25 and all-trans-RA on the induction of integrin 
α4β7 on FoxP3
+ 
T cells generated from co-cultures of naïve T cells and allogeneic 
DCs 
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4.3 Results 
4.3.1 Can T cells acquire gut homing selectivity following stimulation 
by immature DCs? 
To study T cell acquisition of gHRs under steady state conditions, allogeneic 
immature DCs were used to stimulate naïve T cells in MLR experiments as described 
before. Immature DCs were generated from the CD14
+
 monocytes purified from the 
peripheral blood in a well-established procedure described before (Chapter 2, 
Section 2.4.2, pg 89). Similar to the experiments described before (Chapter 3, 
Section 3.3.4, pg 122), immature DCs alone, or in combination with CCL25 or all-
trans-RA were co-cultured with freshly isolated naïve T cells in allogeneic MLRs. 
Two cultures were prepared in parallel; one for the assessment of T cell proliferation 
in response to immature DCs by thymidine incorporation and one for the phenotypic 
analysis of T cells upon stimulation by immature DCs.  
4.3.1.1  T cell proliferation generated by allogeneic immature DCs 
T cell proliferation following stimulation by allogeneic immature DCs was 
determined by thymidine (
3
HTdR) incorporation over 48 hours (described in Chapter 
2, Section 2.7.3, pg 100). As shown in Figure 19, compared to mature DC 
stimulation, T cells proliferated to a similar extent in response to allogeneic immature 
DCs (p>0.05). In addition, the presence of either CCL25 or all-trans-RA in culture 
had no significant effect on T cell proliferative responses generated by allogeneic 
immature DCs or mature DCs. 
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Figure 19. T cell proliferation in response to allogeneic immature DC stimulation. 
Irradiated immature DCs or matured DCs were co-cultured with allogeneic naïve T cells in 
media alone or in the presence of CCL25 (300 ng/ml) or all-trans-RA (2 μM) at a ratio of 
1:10. T cell proliferation in triplicate wells was measured by 
3
HTdR after 48 hours. T cells 
cultured in media alone were prepared as negative controls. The results are shown as the 
mean stimulation index (SI) of three independent experiments and presented as mean SI  
SEM. The mean SI for each experiment was calculated from the triplicate wells of each 
culture condition. Statistical analysis was carried out using two-tailed unpaired student t-test. 
  
0
10
20
30
40
50
60
70
S
ti
m
u
la
ti
o
n
 I
n
d
ex
Chapter 4 Induction of gut-homing receptors on T cells stimulated by immature DCs 
in the presence of CCL25
 
141 
4.3.1.2 Expression of gut-homing receptors on T cells following stimulation by 
allogeneic immature DCs in the presence of gut-derived factors 
T cells were phenotypically analyzed by flow cytometry following 7-days of co-
culture with allogeneic immature DCs in the presence of absence of CCL25 or all-
trans-RA. First, as shown in Figure 20, following stimulation, a proportion of T cells 
became activated, increased in size (bigger cells shown in the red gate in the dot plot) 
and expressed memory T cell marker CD45RO. The population that did not respond 
to DC stimulation remained non-activated and was CD45RO
-
 (smaller cells within the 
blue gate in the dot plot). 
           
Figure 20. T cells become activated and express CD45RO following stimulation 
by allogeneic immature DCs. 
Immature DCs and allogeneic naive T cells were co-cultured in a ratio of 1:10 for 7 days, 
cells were then collected and stained for the expression of CD45RO.  
A. Activated T cells (indicated by the red gate) and non-activated T cells (blue gate) were 
separately gated and analyzed. The histograms respectively show the level of CD45RO 
expressed by non-activated T cells (blue) and activated T cells (red).Staining of isotype 
controls are shown in green on non-activated T cells and orange on activated T cells. 
B. The histogram shows the overlay of CD45RO expression on the two T cell populations 
shown in panel A.  
Results shown are representative of six independent experiments of identical design.  
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To assess the gut homing phenotype of T cells following simulation by allogeneic 
immature DCs, T cells were stained for the expression of CD4, CD8, integrin α4, β7 
chains, CCR9 and analyzed by flow cytometry. Within activated and non-activated T 
cell populations (illustrated in Figure 20), CD4
+
 and CD8
+
 T cell subsets were gated 
and analyzed for their expression of α4β7 integrin and CCR9 using the same gating 
strategy previously developed (described in Chapter 3 Section 3.3.3.2, Figure 13, 
Figure 14, pg 118-121). The results are displayed in Figure 21 and Figure 22. 
First, Figure 21A shows that T cells (red dots) stimulated by allogeneic immature 
DCs displayed a higher expression of integrin α4β7 (α4β7
high
) compared to non-
activated T cells (blue dots) in all culture conditions. In the presence of CCL25, a 
larger proportion of activated CD4
+
 and CD8
+
 T cells were α4β7
high
. As shown in the 
cumulative data (Figure 21B), 15.8% ± 7.6% of activated CD4
+
 T cells became 
α4β7
high
 following stimulation by immature DCs alone, and this was increased to 40.9% 
± 1.4% in the presence of CCL25 (p<0.05). An increase was also observed in 
activated CD8
+
 T cells albeit not reaching the level of statistical significance. As 
expected, the presence of all-trans-RA during T cell activation induced α4β7
 
upregulation in the majority of T cells (83.3% ± 5.3% of CD4
+
, 64.9% ± 11.2% of 
CD8
+
). Cumulative analysis of these observed phenotypic changes, indicated as the 
mean percentage of α4β7
high
 cells within activated CD4
+
 or CD8
+
 T cells generated 
under these culture conditions is summarized in Figure 21B. As shown, CCL25 
significantly enhanced α4β7 upregulation in T cells upon stimulation by immature DCs, 
similarly to what was observed previously following T cell activation by allogeneic 
mature DCs (Chapter 3, Section 3.3.3.2, pg 128).  
CCR9 upregulation was also observed in a subset of T cells following simulation by 
allogeneic immature DCs (Figure 22). However, CCL25 did not appear to have any 
significant effect on the level of CCR9 expression in these activated T cells. As shown, 
the percentage of CD4
+
CCR9
+
 (28.7% ± 7.2% compared to 20.1% ± 6.4%) and 
CD8
+
CCR9
+
 T cells (22.4% ± 6.5% compared to 14.8% ± 3.9%) remained unchanged 
in the presence of CCL25. Similarly, all-trans-RA also did not have any significant 
effect in the upregulation of CCR9 in T cells activated by immature DCs. These 
results have been summarized in Figure 22B. 
Chapter 4 Induction of gut-homing receptors on T cells stimulated by immature DCs 
in the presence of CCL25
 
143 
Next, we examined the T cell population expressing high levels of CCR9 following 
stimulation by allogeneic immature DCs. It was noted that neither CCL25 nor all-
trans-RA had any significant effect in the development of the CCR9
high
 population in 
the presence of immature DCs, as shown in the summary graphs displayed in Figure 
22C.   
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Figure 21. CCL25 promotes the upregulation of α4β7 integrin in allo-specific T 
cells stimulated by immature DCs. 
The same gating strategy described in Figure 13 (Chapter 3, pg 118) was applied for the 
analysis of α4β7 integrin expressed by T cells stimulated by allogeneic immature DCs. The 
quadrant gate on each dot plot was set based on the background level of α4β7 expression 
detected on non-activated T cells. 
A. The dot plots show the expression of α4β7 on non-activated and activated CD4
+
 and CD8
+
 
T cell subsets. Blue dots represent non-activated T cells (staining of isotype controls on these 
cells are shown as the green dots),and the red dots represent activated T cells (isotype 
controls are represented by the orange dots). The percentage of α4β7
high
 T cells within the 
gated activated CD4
+
 and CD8
+
 T cell subsets is indicated in the top right corner of the dot 
plots. The results shown are representative of three independent experiments of identical 
design. 
B. The graphs show cumulative data from three independent experiments presented as the 
mean percentage of α4β7
high
 subset with the gated CD4
+
 and CD8
+
 T cells obtained from each 
culture condition indicated. Cumulative data was analyzed using two-tailed unpaired student 
t-test. Error bars represent the standard error of the mean. Statistical significance is 
indicated with * (* p<0.05, ** p<0.01) 
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Figure 22. Expression of CCR9 on T cells stimulated by allogeneic immature 
DCs.  
The same gating strategy described in Figure 14 (Chapter 3, pg121) was applied for the 
results shown.  
 A. The expression of CCR9 on activated (red dots) and non-activated (blue dots) CD4
+
 and 
CD8
+
 T cells are shown in the dot plots. The isotype control staining on the activated T cells 
are represented by the orange dots, and by the green dots on non-activated T cells.  
The percentage of CCR9
+
 T cells within the gated CD4
+
 and CD8
+
 T cell subset in each 
culture condition is shown in the top right corner of the dot plots. Within activated T cells, the 
proportion of those expressing the highest level of CCR9 is indicated in the box gate. The 
results shown are representative of six independent experiments of identical design. 
B. The graphs show cumulative data from six independent experiments and are presented as 
the proportion of CCR9
+
 T cells within the activated CD4
+
 and CD8
+
 T cells subsets 
C. Cumulative data indicate the percentage of CCR9
high
 T cell subset within the activated 
CD4
+
 CCR9
+
and CD8
+
 CCR9
+
 subset (CCR9
high
 / CCR9
+
).  
Cumulative data was analyzed using two-tailed Wilcoxon matched pairs test. Error bars in 
panel B and C indicate the standard error of the mean. Statistical significance is indicated 
with * (* p<0.05). 
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4.3.1.3 Allogeneic DCs are able to endow CD4+CD25highFoxP3+ T cells with gut 
homing property in the presence of CCL25 
In our study, following naïve T cells and allogeneic DC co-culture, we observed a 
minor subset of activated T cells expressing high levels of CD25 and FoxP3 (Figure 
23B and Figure 23C), which are characteristics of regulatory T cells or recently 
activated T cells (Baecher-Allan et al., 2001, Fontenot et al., 2003, Allan et al., 2007, 
Wang et al., 2007, Gavin et al., 2006, Sakaguchi et al., 2008). Due to their low 
frequency, we were unable to isolate these cells and carry out functional tests to 
confirm whether these CD4
+
CD25
high
Foxp3
+
 represented regulatory T cells with 
suppressor functions. Nonetheless, as previous studies have shown that the gut-
homing receptor α4β7 can be induced on human regulatory T cells generated in vitro in 
the presence of retinoic acid (Kang et al., 2007a), we assessed if CCL25 was able to 
promote the gut homing phenotype on these „putative‟ Tregs as well as on 
conventional T cells like we observed before (Chapter 3). 
First, as shown in Figure 23A, prior to DC stimulation less than 2% of freshly 
isolated naive CD4
+ 
T cells were CD25
high
Foxp3
+
 regulatory T cells. A subset of these 
regulatory T cells (37.5%) was found to express low levels of α4β7 integrin. 
Following naïve T cell activation by allogeneic DCs, we noted that on average, 
CD4
+
CD25
high
Foxp3
+
 T cells represented less than 10% of the total activated CD4
+
 T 
cells (Figure 23B-D). We also noted very little difference in the frequency of the 
Foxp3
+ 
T cells generated upon T cell stimulation by either allogeneic immature or 
mature DCs. The presence of neither CCL25 nor all-trans-RA significantly affected 
the proportion of CD4
+
CD25
high
Foxp3
+
 T cells generated.  
Next, we gated on the Foxp3
+ 
T cell population and analyzed the level of α4β7 
expressed by these cells having adopted a similar gating strategy to what was 
described before for the analysis of α4β7 expression on conventional T cells (Figure 
13, Chapter 3, pg118).  
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As shown in Figure 24A, among non-activated T cells that did not respond to 
allogeneic DC stimulation, FoxP3
+ 
T cells accounted for only 0.1% of total CD4
+
 T 
cells, and that these cells were also α4β7
-
. Having subsequently gated on activated 
CD4
+
FoxP3
+
 T cells, cumulative data suggest that on average, a small subset of these 
cells (1-5%) had upregulated the α4β7 integrin (α4β7
high
) following naïve T cell 
activation by immature or mature DCs (Figure 24B and Figure 24C). Interestingly, 
upon stimulation by allogeneic mature DC the presence of CCL25 significantly 
increased the proportion of α4β7
high 
CD4
+
FoxP3
+
 T cells (Figure 24C) (p<0.05). 
Similarly to our previous observations, the active vitamin A metabolite all-trans-RA 
induced the greatest proportion of CD4
+
FoxP3
+
 T cells to express high level of α4β7. 
These observations were also consistent with previous reports in which all-trans-RA 
was shown to mediate the induction of integrin α4β7 on FoxP3
+
 regulatory T cells in 
humans and mice (Menning et al., 2010, Kang et al., 2007a, Moore et al., 2009).  
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Figure 23. The frequency of CD4
+
CD25
high
Foxp3
+
 T cells generated following 
naïve T cell stimulation by allogeneic immature or mature DCs. 
Freshly isolated naïve T cells were co-cultured with either allogeneic immature or mature 
DCs at a ratio of 10:1alone, in the presence of CCL25 (300 ng/ml) or all-trans-RA (2 μM) in 
allogeneic MLRs as described before. 
A. The dot plots illustrate the gating strategy applied for the identification of 
CD4
+
CD25
high
Foxp3
+
 T cells present among the isolated naïve T cells and the expression of 
α4β7 on these cells.  
B-C. Having gated on activated CD4
+
 T cells (shown as the red dots), the dot plots show the 
percentage of CD4
+
FoxP3
+
 T cells obtained from the indicated co-culture conditions. Orange 
dots represent the isotype control stain on these cells. The dot plot in panel C shows that the 
CD4
+
FoxP3
+
 T cells obtained in all culture conditions (shown in panel B) expressed high 
levels of CD25 (red dots). 
Plots in A-C are representative results of three independent experiments of identical design.  
D. Cumulative data indicate the mean percentages of Foxp3
+
 T cells in the gated activated 
CD4
+
 T cell population and was analyzed using two-tailed unpaired student t-test. 
Error bars indicate standard error of the mean.  
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Figure 24. Acquisition of α4β7 integrin by CD4
+
FoxP3
+
 T cells generated in vitro 
by allogeneic DCs in the presence of CCL25. 
A. The dot plot on the left represents CD4
+
FoxP3
+
 T cells in the gated non-activated T cells 
(blue dots). The green dots represent isotype control staining on these cells. The dot plot on 
the right shows that these cells were α4β7
-
. 
B. The dot plots show the expression of α4β7 on CD4
+
Foxp3
+
 T cells gated respectively on 
non-activated T cells (blue dots) or activated T cells (red dots).  
Dot plots in A-B are representative of three independent experiments. 
C. Cumulative data show the mean percentages of CD4
+
Foxp3
+
a4β7
high
 T cells in the gated 
CD4
+
Foxp3
+ 
T cell population obtained from different culture conditions as indicated.  
Error bars indicate the standard error of the mean. Statistical analysis was carried out using 
two-tailed unpaired student t-test, statistical significance is indicated with *, where p<0.05. 
*** indicates p<0.001. 
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4.4 Discussion 
So far, we have demonstrated in vitro that T cells upregulate gut-homing receptors 
(gHRs) upon activation by allogeneic matured DCs, confirming other reports that T 
cell activation is a prerequisite for the induction of homing receptors (Mora et al., 
2003, Mora et al., 2005). In addition, we observed that exposure to gut-derived 
soluble factors such as the gut chemokine CCL25 during T cell activation enhances 
the acquisition of a4β7 integrin and CCR9 by T cells. While the underlying 
mechanisms behind these observations are not immediately clear, these data support 
the notion that soluble factors from the tissue microenvironment make a vital 
contribution to the acquisition of tissue-specific HRs (Campbell and Butcher, 2002, 
Dudda et al., 2005, Mora et al., 2005).  
In this part of our study, we sought to investigate gHR acquisition by T cells 
stimulated under steady state by using phenotypically immature DCs.  
In the current study, the level of T cell proliferation stimulated by allogeneic 
immature DCs was found to be similar to as that generated by mature DCs. However, 
previous study of similar design has shown that T cells display reduced proliferative 
response following allogeneic immature DCs stimulation compared to mature DCs 
(Jonuleit et al., 2000). Thus further studies are required in order to verify this 
observation.  
Next, through flow cytometric analysis it was noted that T cells stimulated by 
allogeneic immature DCs upregulated a4β7 integrin and CCR9 to a similar extent to 
those stimulated by mature DCs. These results thus suggest that T cell acquisition of 
gut-homing receptors might be independent of DC functional status.  
In the presence of CCL25, we noted that the upregulation of a4β7 in T cells stimulated 
by immature DCs was further enhanced; similar to what was observed in T cells 
activated by mature DCs. Thus, the „mode‟ of T cell activation (mature versus 
immature DCs) did not have any bearing on the effect of CCL25 in the acquisition of 
a4β7 integrin by activated T cells. Similarly to our previous observations, all-trans-RA 
induced the highest level of a4β7 integrin upregulation following T cell stimulation by 
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allogeneic immature DCs due to retinoic acid direct signalling to its receptors on 
naïve T cells (Napoli, 1999, Sigmundsdottir and Butcher, 2008).  
Furthermore, while both CCL25 and all-trans-RA were able to drive CCR9 
upregulation in T cell activated by functionally mature DCs, these effects were not 
observed in the presence of immature DCs. It is thus possible that unlike a4β7, the 
regulation of CCR9 expression by CCL25 may depends on the antigen-presenting cell 
functional state. Specifically, this effect might be determined by the level of co-
stimulatory molecules expressed by DCs. As immature DCs lack the expression of co-
stimulatory molecules, we hypothesize that co-stimulatory signals delivered during 
antigen presentation by DCs might modulate CCR9 expression as well as T cell 
activation and differentiation. To our knowledge, the role of co-stimulation in the 
regulation of CCR9 has never been described; however, binding of CD28 has been 
found to affect chemokine receptor expression in CD4
+ 
T cells (Carroll et al., 1998).  
Last, we noted a T cell subset expressing FoxP3 and high levels of CD25 among T 
cells activated by either allogeneic immature or mature DCs, which could represent 
either regulatory T cells with suppressor functions or recently activated T cells 
(Baecher-Allan et al., 2001, Fontenot et al., 2003, Allan et al., 2007, Wang et al., 2007, 
Gavin et al., 2006, Sakaguchi et al., 2008). As our studies suggest that CCL25 
enhances the acquisition of α4β7 integrin on conventional T cells upon activation by 
either mature DCs or immature DCs, we sought to investigate if CCL25 was also able 
to „imprint‟ α4β7 on these „putative‟ Tregs.  
Interestingly, it was noted that CCL25 significantly enhanced α4β7 upregulation in 
FoxP3
+ 
T cells following naïve T cell simulation by allogeneic mature DCs only but 
not immature DCs. This suggests that unlike conventional T cells, CCL25 requires 
fully functional DCs in order to regulate the expression of a4β7 integrin in FoxP3
+
 T 
cells. However, further studies are required to fully understand the underlying 
mechanisms behind these observations, the suppressor function and the migratory 
ability of these α4β7
high
FoxP3
+
 population generated in vitro in the presence of CCL25. 
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Finally, our data confirmed that the active vitamin A metabolite retinoic acid (all-
trans-RA) is capable of inducing α4β7 acquisition in human FoxP3
+
 T cells in vitro 
(Benson et al., 2007, Moore et al., 2009, Kang et al., 2007a). Previous studies in mice 
have also demonstrated that regulatory T cells generated in the presence of retinoic 
acid express gut homing properties and are able to suppress acute intestinal 
inflammation in vivo (Menning et al., 2010).  
 
 157 
 
 
 
 
CHAPTER FIVE 
 
 
THE ROLE OF INTERLEUKIN-2 IN THE 
ACQUISITION OF GUT-HOMING 
RECEPTORS BY T CELLS 
 
Chapter 5 The role of interlukin-2 in the acquisition of gut-homing receptors by T cells
 
158 
Chapter 5 The role of interleukin-2 in the acquisition of gut-
homing receptors by T cells................ 
5.1 Introduction 
Interleukin-2 (IL-2) has been long established as an essential growth factor for T 
lymphocytes (Smith, 1988). In vivo, following antigen recognition, T cells become 
activated and subsequently produce IL-2, which binds to its receptors on activated T 
cells triggering T cell proliferation and differentiation in an autocrine fashion 
(Waldmann, 1991). Other than activated T cells, IL-2 can also be secreted by murine 
DCs following bacteria uptake in vitro (Granucci et al., 2001). DC‟s ability to produce 
IL-2 has been shown in vivo following priming by microbial stimuli but not 
inflammatory cytokines; the same group also reported that this ability is not limited to 
DCs of any particular tissue origin (Granucci et al., 2003). Recently, Fazekasova and 
colleagues have also shown that both human and rat tolerogenic DCs 
(pharmacologically induced) are able to secrete IL-2 as well as induce human T cell 
anergy and expand rat regulatory T cells (Fazekasova et al., 2009). 
During antigen presentation, DCs not only activate T cells but also play an 
instrumental role in endowing T cells with tissue-homing specificity (Horgan et al., 
1992, Mora et al., 2003, Stagg et al., 2002, Johansson-Lindbom et al., 2003, Elgueta 
et al., 2008, Campbell and Butcher, 2002). It is therefore conceivable that the 
production of IL-2 during DC-T cell interaction may influence the acquisition of 
homing specificity by T cells. In line with this hypothesis, previous studies have 
suggested that IL-2 signaling could be associated with T cell migration, as IL-2 
deficient mice when injected with myelin oligodendrocyte glycoprotein failed to 
induce experimental autoimmune encephalomyelitis (Petitto et al., 2000, Schimpl et 
al., 2002). In addition, there is direct evidence associating IL-2 with the induction of 
homing receptors. For example, it was shown that IL-2 could induce 
glycosyltransferase, a molecule required to create the core structure on which P-
selectin ligands are built (Carlow et al., 2001).  
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Based on these findings, we sought to examine whether IL-2 could influence the 
acquisition of gut-homing receptors integrin α4β7 and CCR9 by T cells upon 
activation in our experimental system.  
5.2 Aims  
The aim of this part of our study was to investigate the contribution of IL-2 to the 
induction of α4β7 integrin and gut chemokine receptor CCR9 by T cells following 
stimulation by allogeneic DCs. In order to address this, we set up in vitro MLR co-
cultures similar to those described previously (Chapter 3 and Chapter 4) in the 
presence or absence of exogenous IL-2 and carried out the following experiments.  
1. Analysis of gut-homing receptor (gHR) expression following T cell activation 
under inflammatory conditions (by mature allogeneic DCs) in the presence or 
absence of IL-2 
2. Assessment of the effect of IL-2 on the acquisition of gut homing phenotype 
by T cells upon stimulation by immature DCs (steady state) 
3. Comparison of the effect of IL-2 in gHR acquisition by T cells under 
inflammatory conditions and steady state  
4. Comparison of the effect of CCL25 or active vitamin A metabolite (all-trans-
RA) on the upregulation of gHRs in T cells stimulated by either allogeneic 
mature DC or immature DCs in the presence or absence of IL-2 
5. Evaluation of the role of IL-2 in the acquisition of α4β7 integrin by 
CD4
+
CD25
high
FoxP3
+
 T cells generated upon T cell stimulation by allogeneic 
DCs 
6. Examining the contribution of CCL25 and all-trans-RA in the induction of 
α4β7 integrin on CD4
+
CD25
high
FoxP3
+
 T cells in the presence of IL-2 
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5.3 Results  
5.3.1 Role of IL-2 in T cell acquisition of α4β7 integrin and CCR9 
following activation by mature allogeneic DCs 
In previous chapters, we have shown that the gut-chemokine CCL25 is able to drive 
the acquisition of gHRs integrin α4β7 and chemokine receptor CCR9 on T cells 
following stimulation by allogeneic DCs.  
In this part of our project, we carried out experiments of similar design, and set up 
additional co-cultures in the presence of IL-2 to investigate the effect of IL-2 on the 
upregulation of gHRs by T cells upon stimulation by either allogeneic mature or 
immature DCs. 
5.3.1.1 Effect of IL-2 on naïve T cell proliferation following stimulation by 
mature allogeneic DCs 
We first measured T cell proliferative responses induced by DCs in the presence of 
IL-2 (20 U/ml) by thymidine incorporation over 48 hours. Naïve T cells were co-
cultured with allogeneic mature DCs alone, together with CCL25 or all-trans-RA in 
the presence or absence of IL-2. The addition of IL-2 to all the culture conditions 
mentioned above did not significantly alter the level of T cell proliferation, as shown 
in Figure 25. 
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Figure 25.T cell proliferation stimulated by allogeneic mature DCs is not affected 
by exogenous IL-2. 
Allogeneic mature DCs (matured by cytokines) were co-cultured with naïve T cells (isolated 
from PBMC) at a ratio of 1:10 alone, in the presence of CCL25 (300 ng/ml) or all-trans-RA 
(2 μM) in triplicate wells. Exogenous IL-2 was added at a concentration of 20 U/ml to some 
co-cultures. T cell proliferation was counted by thymindine (
3
HTdR) following co-culture. 
Results are shown as the mean stimulation index+SEM of three independent experiments. The 
mean SI for each experiment was calculated from the triplicate wells of each culture 
condition. Results were analyzed using two-tailed unpaired student t-test. NS = non-
statistically significant   
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5.3.1.2 Induction of α4β7 integrin and CCR9 on T cells activated in the presence 
of IL-2 
To assess the effect of IL-2 in the induction of α4β7 and CCR9 in activated T cells, we 
carried out similar experiments as previously described with the addition of IL-2 (20 
U/ml) at the beginning of the 7-day co-culture experiment. The expression of gHRs 
on T cells following stimulation by DCs was analyzed by flow cytometry using the 
same gating strategy previously described (Chapter 3, Section 3.3.3.2). 
As shown in Figure 26, the presence of additional IL-2 appeared to support the 
upregulation of integrin α4β7 in T cells following activation by allogeneic mature DCs. 
However, the increase in the percentage of CD4
+α4β7
high 
and CD8
+α4β7
high 
T cells (red 
dots) following T cell stimulation (28.9% ± 9.3% of CD4
+
 compared to 9% ± 3% 
were α4β7
high
, 58.9% ± 5% of CD8
+
 compared to 44.4% ± 7.9%  were α4β7
high
) 
observed did not reach statistical significance. Moreover, while CCL25 alone (in the 
absence of exogenous IL-2) significantly enhances the expansion of α4β7
high
 activated 
T cells as we have shown before, we did not observe any additive effect when both 
CCL25 and IL-2 were present. For instance, on average, CCL25 and IL-2 together 
induced high levels α4β7 on 26.8% ± 10.5% of activated CD4
+ 
T cells, compared to 
28.9% ± 9.3% and 22.9% ± 9% generated respectively by IL-2 or CCL25 alone 
(Figure 26B). 
The presence of the active vitamin A metabolite all-trans-RA generated the largest 
proportion of α4β7
high
 activated T cells, in the presence of IL-2 this effect was not 
modified.  
The results described above have been summarized in Figure 26B. 
We next assessed the effect of IL-2 on CCR9 upregulation by T cells activated in the 
presence of allogeneic mature DCs.  
First, we compared the percentage of the CCR9
+
 population within the gated activated 
CD4
+
 or CD8
+ 
population. It was noted that the percentages of CCR9
+ 
activated T 
cells did not change significantly following T cell stimulation in the presence of IL-2 
as shown in the cumulative data in Figure 27B. For example, in the presence of IL-2, 
24% ± 5.7% of activated CD4
+
 T cells were CCR9
+
 compared to 32.9% ± 9.8% in the 
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presence of DCs alone. Similarly, the extent of CCR9 upregulation in CD8
+
 T cells 
activated by DCs remained unaffected in the presence of IL-2. 
Next, we examined the effect of IL-2 on CCR9 upregulation when CCL25 or all-
trans-RA was present. As shown previously (Chapter 3), both CCL25 and all-trans-
RA lowered CCR9 upregulation. Furthermore, the addition of IL-2 in culture did not 
influence the effect elicited by either CCL25 or all-trans-RA.  
As described before, the total CCR9
+
 activated T cell populations contained a subset 
of T cells expressing higher levels of CCR9 (CCR9
high
, shown as the red dots in the 
box gate in Figure 27A) following T cell activation by allogeneic mature DCs. As 
shown in Figure 27C, we noted that IL-2 alone had little effect on the CCR9
high
 
subset. When present in combination with either CCL25 or all-trans-RA, the 
percentage of CCR9
high 
T cells also remained unaltered. In conclusion, IL-2 does not 
appear to have any significant effect on the level of gut-homing receptor acquisition 
on T cells upon activation by allogeneic mature DCs.  
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Figure 26. Induction of integrin α4β7 in activated T cells is not affected by the 
presence of exogenous IL-2 during T cell activation.  
Co-culture experiments were carried out under the same conditions as previously described 
with additional cultures containing IL-2 (20 U/ml). Results were analyzed using the same 
gating strategy described in Figure 13(Chapter 3, pg 118).  
 
A. The dot plots display the expression of α4β7 by activated T cells (red dots) and non-
activated T cells (blue dots) following stimulation by allogeneic mature DCs under the 
conditions indicated.  
The results shown are representative of three independent experiments with identical design.  
B. The graphs represent cumulative data obtained from three independent experiments 
presented as the mean percentages of α4β7
high
 subset in the gated CD4
+
 or CD8
+
 T cells. 
Results were analyzed using two-tailed unpaired student t-test. Error bars indicate the 
standard error of the mean. NS = non-statistically significant 
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Figure 27. IL-2 does not affect CCR9 upregulation by activated T cells. 
A. The expression of CCR9 on activated T cells (red dots) and non-activated T cells (blue 
dots) following DC stimulation under the indicated condition is shown on the dot plots. The 
same gating strategy developed previously (Chapter 3, Figure 14, pg 121) was applied for the 
phenotypic analysis  
The results shown are representative of three independent experiments of identical design.                      
B. Cumulative data (obtained from three independent experiments) indicating the mean 
percentage of CCR9
+
 T cells in the gated CD4
+
 or CD8
+
T cells activated by DCs under each 
indicated culture condition (X-axis). 
C. The graphs display cumulative data representing the mean percentages of CCR9
high
 T cells 
within the overall CD4
+
 CCR9
+
or CD8
+
 CCR9
+
T cell populations (CCR9
high
/ CCR9
+
). 
Cumulative results were analyzed using two-tailed unpaired student t-test. 
In panel B and C, error bars indicate the standard error of the mean. NS = non-statistically 
significant 
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5.3.2 Does IL-2 affect the acquisition of gut-homing receptors by T 
cells under steady state? 
 
5.3.2.1 Effect of exogenous IL-2 on T cell proliferation upon stimulation by 
allogeneic immature DCs  
To assess the role of IL-2 in T cell acquisition of gut-homing receptors in the steady 
state, we cultured naïve T cells with allogeneic immature DCs in the presence of IL-2. 
First, we measured T cell proliferative responses when stimulated under the influence 
of additional IL-2. The results are displayed in Figure 28. The addition of lL-2 during 
T cell stimulation by immature DCs did not lead to a significantly enhanced T cell 
proliferative response as shown below. In the presence of either CCL25 or all-trans-
RA, we also observed little changes in T cell proliferation following the 
administration of additional IL-2.  
 
Figure 28.  Additional IL-2 does not significantly affect T cell proliferative 
responses during immature DC stimulation. 
Allogeneic immature DCs were co-cultured with naïve T cells at a ratio of 1:10 alone or in 
the presence of CCL25 (300 ng/ml) or all-trans-RA (2 μM). IL-2 was added at a 
concentration of 20 U/ml to some co-cultures. Results are shown as the mean stimulation 
index +SEM of two independent experiments. The mean SI for each experiment was 
calculated from the triplicate wells of each culture condition.  
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5.3.2.2 IL-2 enhances the induction of integrin α4β7 on CD4
+
 T cell activated by 
allogeneic immature DCs 
As shown previously, T cells stimulated by either allogeneic immature DCs or mature 
DCs were able to upregulate integrin α4β7. Interestingly, while exogenous IL-2 did not 
have any significant effect on the level of α4β7 upregulation in T cells activated under 
inflammatory conditions (by mature DCs, Section 5.3.1.2 of this chapter), in the 
steady state (when naïve T cells stimulated by immature DCs) IL-2 significantly 
enhanced the upregulation of α4β7 in activated CD4
+
 T cells. As shown in Figure 29, 
the proportion of activated CD4
+ 
T cells expressing high levels of α4β7 (α4β7
high
) 
increased to 27.6% ± 5.7% from 9.7% ± 8% upon stimulation in the presence of 
additional IL-2. 
Secondly, it was previously noted that CCL25 alone significantly promoted the 
development of α4β7
high 
T cells, in the presence of IL-2, this effect was not altered 
(Figure 29). In addition, as expected, all-trans-RA generated the largest proportion of 
α4β7
high 
T cells irrespective of whether IL-2 was present. Cumulative data from three 
independent experiments illustrating these effects are summarized and presented in 
Figure 29B.  
We next assessed the role of IL-2 in the induction of CCR9 upregulation by T cells 
stimulated by allogeneic immature DCs. As previously shown, T cells were able to 
upregulate the expression of CCR9 following stimulation by either allogeneic mature 
or immature DCs compared. Similarly to our early observations (Section 5.3.2.2), in 
the presence of IL-2, the proportion of T cells stimulated by immature DCs that had 
upregulated CCR9 (CCR9
+
) remained unchanged (Figure 30B). In addition, IL-2 did 
not have any significant effect in the development of those T cells expressing higher 
levels of CCR9 (CCR9
high
) (Figure 30C). Furthermore, while CCL25 or all-trans-RA 
alone had little effect on CCR9 upregulation in T cell stimulated by immature DCs, 
(Chapter 4, Section 4.3.1.2, pg 141), when present along with additional IL-2, the 
level of CCR9 upregulation was not modified (Figure 30B and Figure 30C). In 
summary, while IL-2 appeared to have an enhancing effect in the acquisition of 
integrin α4β7 in CD4
+
 T cells stimulated by allogeneic immature DCs, it had no effect 
on CCR9 upregulation in these T cells. The presence of CCL25 or all-trans–RA 
together with IL-2 generated no additive effect on the induction of either molecule. 
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Figure 29. IL-2 boosts the frequency of CD4
+
 α4β7 
high
 T cells stimulated by 
allogeneic immature DCs. 
Results shown are from similar experiments carried out in Chapter 4 with the addition of IL-2 
(20 U/ml) in some co-cultures. The gating strategy previously described (Chapter 3, Section 
3.3.3.2, Figure 13, pg 118) was applied for the data analysis.  
A. The expression of α4β7 on T cells following stimulation by allogeneic immature DCs is 
shown in the dot plots. The red dots indicate activated T cells, and non-activated T cells are 
shown in blue. The results shown are one representative result of three independent 
experiments of identical design. 
B. Graphs display cumulative data from three independent experiments and are presented as 
the mean percentage of α4β7
high
 T cells in the gated activated CD4
+
 or CD8
+
 T cell subset. 
Results were analyzed using two-tailed unpaired student t-test. 
Error bars indicate the standard error of the mean.Statistical significance is indicated with * 
* p<0.05 NS= statistically non-significant.  
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Figure 30. Induction of CCR9 in T cells stimulated by allogeneic immature DCs 
was not affected by IL-2. 
A.The dot plots display the expression of CCR9 by activated T cells (represented by the red 
dots), and non-activated T cells (blue dots) following naïve T cell co-culture with immature 
DCs under the indicated conditions. The results shown are representative of three 
independent experiments and analyzed using the same strategy described in Chapter 3 
(Figure 14, pg 121). 
B. Cumulative data from three independent experiments expressed as the mean percentage of 
CCR9
+
 T cells within the gated activated CD4
+
 or CD8
+
 T cell subset respectively.  
C. The graphs depict cumulative data (from three independent experiments) representing the 
mean percentages of CCR9
high
 T cells gated on the overall CD4
+
 CCR9
+
 and CD8
+
 CCR9
+
 T 
cells(CCR9
high
/CCR9
+
). Results were analyzed using two-tailed unpaired student t-test. 
Error bars in B-C indicate the standard error of the mean. NS = statistically non-significant.  
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5.3.3 IL-2 does not contribute to the acquisition of α4β7 integrin by 
Foxp3
+
 T cells expanded in the presence of DCs 
As previously shown (Chapter 4, Section 4.3.1.3, pg 148), following T cell co-
culture with allogeneic DCs (mature or immature), a small subset of activated T cells 
acquired characteristics of regulatory T cells. These cells were referred as the 
„putative‟ regulatory T cells. We next assessed whether IL-2 would influence the 
upregulation of gut-homing receptor integrin α4β7 in theses „putative‟ regulatory T 
cells. 
First, we examined the frequency of the CD4
+
CD25
high
FoxP3
+
 T cell subset generated 
among T cells activated under different culture conditions. We noted that the 
proportion of FoxP3
+
 T cells generated by allogeneic DCs (either immature or mature) 
did not change significantly following the administration of IL-2. In addition, neither 
CCL25 nor all-trans-RA had any effect in the generation of FoxP3
+
 T cells following 
T cell stimulation by allogeneic DCs. Moreover, when additional IL-2 was present, 
we did not observe any additive effects between CCL25 or RA and IL-2. These 
results are displayed in Figure 31B and Figure 31C. 
Next, we analyzed the expression of α4β7 integrin on these FoxP3
+
 T cells. As shown 
in  
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Figure 32B, cumulative data show that the frequency of α4β7
high
Foxp3
+
 T cells was 
not significantly affected in the presence of additional IL-2 during DC-T cell co-
culture. While CCL25 alone significantly increased α4β7 upregulation in FoxP3
+
 cells 
generated in the presence of mature DCs (Chapter 4), in the presence of additional 
IL-2 we did not observe any additive effect of CCL25 and IL-2.  
While the presence of active vitamin A metabolite all-trans-RA induced the largest 
proportion of α4β7
high
Foxp3
+
 T cells as previously reported (Benson et al., 2007, 
Menning et al., 2010, Moore et al., 2009, Kang et al., 2007a), no synergistic or 
additive effect was detected between IL-2 and all-trans-RA in the proportion of 
α4β7
high
Foxp3
+
 T cells observed. 
In summary, these data suggest that IL-2 might not play a significant role in the 
acquisition of α4β7 integrin by „putative‟ regulatory T cells.  
 CD4
F
o
x
p
3
Immature DCs Mature DCs
-IL2 +IL2 -IL2 +IL2
Media
All-trans-RA
CCL25
Isotype control mAb
Marker specific  mAb…
…
A
CD4
F
o
x
p
3
Immature DCs Mature DCs
-IL2 +IL2 -IL2 +IL2
Media
All-trans-RA
CCL25
Isotype control mAb
Marker specific  mAb…
…
A
Chapter 5 The role of interlukin-2 in the acquisition of gut-homing receptors by T cells
 
175 
  
Figure 31.The effect of IL-2 in the expansion of CD4
+
FoxP3
+
 T cells following 
naïve T cell stimulation by allogeneic DCs.  
Results were obtained from the same experiments described in Figure 29, and analyzed using the 
gating strategy described in Chapter 4 (Figure 23, pg 151). 
A. The dot plots show the proportion of CD4
+
FoxP3
+
 T cells (gated on activated CD4
+
 T cell 
subset, shown as the red dots) expanded following naïve T cell activation by allogeneic DCs under 
the indicated culture conditions. The results shown are representative of three independent 
experiments of identical design. 
B. The graphs display cumulative data from three independent experiments and are presented as 
the mean percentage of CD4
+
FoxP3
+
 T cells (gated on activated CD4
+
T cell subset) expanded 
following T cell co-culture under the conditions indicated on the X-axis. Results were analyzed 
using two-tailed unpaired student t-test. NS= statistically non-significant. 
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Figure 32. Induction of α4β7 by CD4
+
FoxP3
+
 T cells expanded in the presence of 
IL-2. 
A. The dot plots show the expression of α4β7 by CD4
+
 FoxP3
+
 T cells expanded (as shown in 
Figure 31) following naïve T cell stimulation by allogeneic DCs under the indicated culture 
condition. Results were analyzed using the gating strategy described before (Chapter 4, 
Figure 24, pg 153). The dot plots shown are representative results of three independent 
experiments of identical design. 
B. The graphs show cumulative data indicating the mean percentage of CD4
+
Foxp3
+α4β7
high 
T 
cells in the gated CD4
+
FoxP3
+ 
T cell population observed from each culture condition 
(indicated on the X-axis). Results are presented as mean+SEM and analyzed using two-tailed 
unpaired student t-test. NS= statistically non-significant. 
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5.4 Discussion 
In this part of our project, we assessed the role of IL-2 in the induction of gut homing 
specificity in T cells activated by allogeneic DCs.  
DCs have been shown to secrete IL-2 upon antigen uptake in vitro and in vivo 
(Granucci et al., 2001, Granucci et al., 2003) as well as playing a vital role in 
instructing T cell acquisition of tissue-specific homing receptors (Campbell and 
Butcher, 2002, Mora et al., 2003, Mora et al., 2005). We therefore reasoned that the 
production of IL-2 by DCs during antigen presentation may contribute towards the 
acquisition of T cell homing selectivity as well as regulate T cell proliferation and 
differentiation. To this end, we assessed the upregulation of the gut-homing receptors 
(gHRs) a4β7 integrin and CCR9 by T cells in the presence of IL-2 following 
stimulation by functionally matured DCs.  
As discussed already, in the steady state, immature DCs in the peripheral lymphoid 
tissue can induce peripheral tolerance. Interestingly, a recent study has demonstrated 
that both human and rat tolerogenic DCs generated by pharmacological treatment in 
vitro secrete IL-2 (Fazekasova et al., 2009). We thus sought to investigate the effect 
of IL-2 on gut homing phenotype acquisition by T cells stimulated by immature DCs. 
Meanwhile, we compared the role of IL-2 in the induction of gut homing phenotype 
under inflammatory or steady state conditions.  
Our current data suggest that soluble gut-derived factors such as the gut chemokine 
CCL25 and the active vitamin A metabolite retinoic acid (all-trans-RA) are able to 
promote a4β7 and CCR9 upregulation in T cells activated by fully functional mature 
allogeneic DCs, and a4β7 only in T cells stimulated by allogeneic immature DCs. We 
thus also examined whether T cell exposure to IL-2 during stimulation by dendritic 
cells would influence the effect of CCL25 or retinoic acid on gHR upregulation.  
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First, IL-2 did not appear to play a significant role in the upregulation of a4β7 integrin 
in CD4
+
 or CD8
+
 T cells under inflammatory conditions whereby allogeneic mature 
DCs were used to stimulate naïve T cells. Interestingly, following naïve T cell 
stimulation by allogeneic immature DCs (steady state), IL-2 significantly enhanced 
the upregulation of a4β7 integrin in CD4
+
 T cells. IL-2 is essential for T cell survival 
(Smith, 1988), it is thus possible that this was the consequence of improved cell 
survival following direct IL-2 signalling. However, how cell survival selectively 
affects the a4β7
high 
T cell population stimulated in the presence of immature DCs 
remains unaccounted for. Alternatively, IL-2 might be able to selectively modulate 
a4β7 upregulation in T cells stimulated by immature DCs; however further in-depth 
studies are required to address this possibility. Furthermore, it has been reported that 
in vitro generated monocyte-derived DCs express IL-2 receptor CD25 (Velten et al., 
2007). While this was not evaluated in our study, it is possible that immature DCs 
used in our experiments expressed CD25, through which T cells with imprinted with a 
gut-homing phenotype by DCs. In addition, whether the observed effect of IL-2 
requires the presence of DCs will be further assessed in Chapter 6. 
Furthermore, under inflammatory or steady state conditions, we did not observe any 
significant effect of IL-2 on CCR9 upregulation in activated T cells; neither did it 
have any impact on the development of those T cells expressing high levels of CCR9 
(CCR9
high
). To our knowledge, few studies have documented the relationship between 
IL-2 and chemokine receptor expression, among which IL-2 has been shown to 
decrease the level of CXCR3 mRNA and its surface expression in NK cells (Hodge et 
al., 2002). As the underlying mechanisms of these observations are yet to be 
characterized, whether IL-2 plays a role in the modulation of CCR9 in T cells 
following activation requires further investigation. 
So far, we have discussed the effect of IL-2 in the acquisition of gut homing 
properties by T cells activated by fully functional mature DCs as well as those 
stimulated by allogeneic immature DC in the absence of CCL25 or all-trans-RA. We 
next sought to investigate the effect of IL-2 on T cell gHR induction when CCL25 or 
all-trans-RA was present.  
Previously, both CCL25 and all-trans-RA were shown to be able to significantly 
enhance a4β7 integrin upregulation in T cells stimulated by allogeneic mature DCs. In 
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the presence of exogenous IL-2, their enhancing effects remained and we did not 
observe any additive effect. In the presence of CCL25 or all-trans-RA, it was noted 
that CCR9 was upregulated to a lesser degree along with the development of a T cell 
subset with high levels of CCR9 expression (CCR9
high
) following mature DC 
stimulation. The presence of IL-2 did not modify these effects. 
Next, it was noted that CCL25 and all-trans-RA were able to significantly enhance 
a4β7 integrin upregulation but not CCR9 in T cells stimulated by allogeneic immature 
DCs. In the presence of additional IL-2, no additive effects between CCL25 or all-
trans-RA and IL-2 were observed. 
Collectively, these data suggest that contributions of tissue-derived factors in the 
acquisition of gut homing specificity at steady state might be associated with the 
availability of IL-2. Specifically, when IL-2 is limiting, tissue-derived factors may be 
particularly important in driving the acquisition of a4β7 integrin in T cells. Hence, IL-2 
might play a particularly important role in T cell acquisition of gut-homing selectivity 
in the steady state but not under inflammatory conditions. 
Finally, we examined the role of IL-2 in gut-homing receptor acquisition in 
CD4
+
CD25
high 
FoxP3
+ 
T cells following naïve T cell co-culture with allogeneic DCs. 
In addition, as CCL25 and all-trans-RA are both able to mediate a4β7 upregulation in 
these „putative‟ regulatory T cells, we also examined the effects of CCL25 and all-
trans-RA in the gHR upregulation in these FoxP3
+
 T cells in the presence of 
exogenous IL-2. 
A trend of increase in the proportion of a4β7
high
 FoxP3
+
 T cells generated was noted in 
the presence of IL-2, however this effect did not reach the level of statistical 
significance. The importance of IL-2 in the generation of regulatory FoxP3
+
 T cells in 
vivo and in vitro has been well established (Klebb et al., 1996, Zheng et al., 2007, Lu 
et al., 2010). Our studies suggest that IL-2 might also contribute to the acquisition of a 
gut homing phenotype by regulatory T cells, a hypothesis in need of verification by 
future studies. In addition, similarly to conventional T cells, we did not observe any 
additive effect between IL-2 and CCL25 or all-trans-RA on the upregulation of a4β7 
integrin in FoxP3
+ 
T cells. Thus, while IL-2, CCL25 and all-trans-RA might all 
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contribute to the acquisition of gut tropism by FoxP3
+ 
T cells, they may not share 
common pathways in this process. 
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Chapter 6 Expression of gut-homing receptors by activated 
T cells stimulated in the absence of DCs 
6.1 Introduction  
Our previous data suggest that the gut chemokine CCL25 is able to drive the 
upregulation of the gut-homing receptors (gHRs) integrin a4β7 and chemokine 
receptor CCR9 when present during T cell activation by allogeneic DCs. In addition, 
we have shown that T cells acquire gHRs during activation in the presence of all-
trans-RA, the most physiologic form of the vitamin A metabolite retinoic acid (RA). 
While the effect of RA depends on vitamin A metabolism by the gut-derived DCs 
(Iwata et al., 2004, Uematsu et al., 2008), the mechanism by which CCL25 induces 
the acquisition of gut-homing molecules is unknown. We therefore sought to 
investigate whether our observations were the result of CCL25 direct signalling to T 
cells; alternatively, the effect of CCL25 might be dependent on the presence of DCs. 
In the latter context, CCL25 might first „condition‟ DCs and subsequently enhance 
DC‟s ability to drive the induction of gut–homing specificity by the responding T 
cells. In order to address this issue, naïve T cells were activated in vitro using 
immobilized anti-CD3 and anti-CD28 monoclonal antibodies (mAbs) instead of 
allogeneic DCs either in the presence or absence of CCL25. The acquisition of a gut 
homing phenotype by activated T cells was then analyzed. 
As CCL25 was previously found to facilitate the induction of a4β7 by 
CD4
+
CD25
high
FoxP3
+ 
T cells
 
following stimulation by DCs (Chapter 4, Section 
4.3.1.3), in this part of our study we also assessed if this process was DC-dependent. 
In addition, as our previous data have shown that IL-2 contributes to T cell acquisition 
of gHRs, we investigated whether these effects could also be observed in the absence 
of DCs.  
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6.2 Aims 
The following experiments were carried out in order to address the issues highlighted 
above. 
1. Phenotypic characterization of T cells activated by immobilized anti-CD3 and 
anti-CD28 mAbs 
2. Assessment of the effect of CCL25 on gHR acquisition on T cells activated in 
the absence of DCs 
3. Evaluation of the frequency of CD4+CD25highFoxP3+ T cells generated 
following antibody-mediated T cell activation and the effect of CCL25 on the 
induction of α4β7 on these cells 
4. Parallel experiments of similar design were set up to examine the role of IL-2 
in the induction of gHRs on activated T cells and on CD4
+
CD25
high
FoxP3
+
 T cells 
stimulated in the absence of DCs  
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6.3 Results 
6.3.1 DC-independent antibody activation of naïve T cells in the 
presence of CCL25...... 
Prior to assessing the expression of gut-homing receptors on activated T cells, T cell 
proliferative responses to immobilized monoclonal antibodies (mAbs) were first 
measured to set up a reproducible culture system. Freshly isolated naïve T cells 
(described in Chapter 2, Section 2.4.3, pg 90) were incubated in tissue culture plates 
coated with anti-CD3 (1 µg/ml) and anti-CD28 (5 µg/ml) mAb alone or in the 
presence of CCL25 or all-trans-RA. Following 48 hours of incubation, T cell 
proliferation was measured by thymindine incorporation whereby cultures were 
pulsed with tritiated thymidine (
3
HTdR) for a further 18 hours until reaction was 
halted and harvested.  
As shown in Figure 33, anti-CD3 and anti-CD28 treatment stimulated naïve T cell 
proliferation. Consistent with previous observation whereby naïve T cells were 
activated by allogeneic DCs, the presence of either CCL25 or all-trans-RA during 
antibody stimulation of naïve T cells did not appear to have any significant effect in T 
cell proliferative responses. Next, we phenotypically analyzed these T cells 7 days 
after stimulation by immobilized mAbs. Two separate populations of T cells were 
observed, the smaller T cell population that did not proliferate and the more 
differentiated granular T cell population (Figure 34). As expected, the undivided T 
cell population did not express T cell activation marker CD45RO, whereas the more 
granular T cells were activated and CD45RO
+
. 
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Figure 33. T cell expansion induced by plate-bound anti-CD3 and anti-CD28 
mAbs. 
Flat-bottom 96-well tissue culture plates were first coated with anti-CD3 (1 µg/ml) and anti-
CD28(5 µg/ml) mAbs prepared in Tris base – Ph 9.5 buffer solution (50 mM) and incubated 
for 2 hours at 37°C with 5% CO2. Freshly isolated naïve T cells  (1×10
5
) were then added to 
the coated plates alone, or together with CCL25 (300 ng/ml), or all-trans-RA (2 nM) in 
triplicate. Naïve T cells cultured in media alone were prepared as experimental controls. 
Proliferation was measured 48 hours after incubation by 
3
HTdR incorporation. Results are 
shown as the mean stimulation index+SEM of two independent experiments and presented as 
mean stimulation index (SI)+SEM.  
 
 
Figure 34. Small granular T cells stimulated by immobilized mAbs express 
CD45RO.  
Freshly isolated naive T cells were incubated with plate-bound anti-CD3 (1µg/ml) and anti-
CD28(5µg/ml) as described previously (Chapter 2, Section 2.7.2, pg 99). Cells were 
harvested and stained for the expression of CD45RO 7 days following activation.  
A. The dot plot displays the two T cell populations determined by forward and side scatter. 
The activated T cells (labeled A) and the non-activated T cells (labeled NA). The expression 
of CD45RO on these two populations (shown in red and blue respectively) is shown in 
histograms overlaid with their respective isotype controls (represented by the orange and the 
green lines). 
B. The histogram shows that all the small granular activated T cells expressed CD45RO, 
while smaller T cells were CD45RO
-
. Results shown are representative of two independent 
experiments.  
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6.3.2 Are DCs required for CCL25-driven induction of gut-homing 
receptors expressed by activated T cells?  
As our previous data showed that the presence of CCL25 during naïve T cell 
stimulation by allogeneic DCs enhanced the upregulation of gut-homing receptors 
α4β7 and CCR9, we sought to investigate whether this effect was dependent on the 
presence of DCs. T cells were thus activated by immobilized mAbs instead of DCs. 
We then compared the level of gHRs induced on T cells activated in the presence or 
absence of CCL25 having adopted the same analysis strategy described previously 
(Chapter 3, Section 3.3.3.2, pg 112). These results are summarized in Figure 35. As 
show in Figure 35A, both α4β7 and CCR9 were upregulated upon T cell activation by 
antibodies. The presence of CCL25 however, did not further enhance α4β7 
upregulation. 
As we described before, during naïve T cell stimulation by allogeneic DCs, the 
addition of CCL25 to the DC-T cell co-cultures led to a reduced level of CCR9 
upregulation but the emergence of a T cell subset expressing high levels of CCR9 
(CCR9
high
). As it is shown in Figure 35B, the presence of CCL25 during T cell 
activation by immobilized mAbs did not have any significant influences in CCR9 
upregulation. In contrast to what we observed in T cells activated by allogeneic DCs, 
the development of the CCR9
high
 T cell subset was not detected either. 
As the metabolized form of vitamin A, all-trans-retinoic acid (all-trans-RA) was 
included in our previous co-culture experiment (naïve T cells and allogeneic DCs) as 
a positive control due to its known property in imprinting gut homing specificity on 
naïve T cells (Iwata et al., 2004). Following activation (by DCs) in the presence of all-
trans-RA, T cells significantly upregulated the α4β7 integrin but not CCR9. As shown 
in Figure 35A, Figure 35B, all-trans-RA did not have any significant effect on the 
induction of α4β7 or CCR9 on T cells activated by immobilized antibodies.  
Our data therefore suggest that CCL25 requires DCs for the efficient induction of 
gHRs in activated T cells. Although the metabolized form of vitamin A was expected 
to directly signal to naïve T cells and endow them with gut homing specificity as 
previously demonstrated (Iwata et al., 2004), this was not observed in our study. 
However, the reason behind this observation is unclear. 
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Figure 35. CCL25 had no effect on the induction of gHRs in T cells activated in 
the absence of DCs.  
Following naïve T cell stimulation by immobilized anti-CD3(1 µg/ml) and anti-CD28(5 
µg/ml), T cells were harvested and analyzed for the expression of CD4, CD8,integrin α4, 
integrin β7 and CCR9 by flow cytometry using the same strategy developed previously 
(described in Chapter 3,Section 3.3.3.2, pg 112). 
 A. The graphs show the mean percentage of activated CD4
+
 and CD8
+
 T cells expressing 
high levels of α4β7 (α4β7
high
) observed following naïve T cell stimulation under the indicated 
conditions in the X-axis.  
B. The mean percentage of CD4
+
 CCR9
+
 and CD8
+
 CCR9
+
 T cells, respectively, is shown in 
the summary graphs.  
The results shown are summarized from two independent experiments of identical design. 
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6.3.3 The role of IL-2 in the induction of gut-homing receptors 
6.3.3.1 T cell proliferative responses stimulated by mAbs in the presence of IL-2 
Previously, we have shown that IL-2 promotes the induction of integrin α4β7 but not 
CCR9 in T cells activated by allogeneic immature DCs. In this part of the study, we 
sought to investigate whether IL-2 exerted the same effect when DCs were absent 
from our experimental system. To address this issue, we set up parallel cultures to 
those described in Section 6.3.2 and supplemented some T cell cultures with 
exogenous IL-2. First, we measured naïve T cell proliferation following stimulation 
by plate-bound anti-CD3 and anti-CD28 mAbs in the presence of IL-2. As expected, 
T cells proliferated more vigorously when IL-2 was present during activation as 
shown in Figure 36. In addition, our preliminary results suggested that T cell 
proliferation was not influenced by CCL25 or RA during antibody stimulation in the 
presence or absence of exogenous IL-2.  
 
Figure 36. Effect of IL-2 in T cell proliferation upon naïve T cell activation by 
mAbs. 
T cell proliferation assay was set up as previously mentioned in Figure 33 with additional IL-
2 (20 U/ml) in some cultures. Cultures were harvested 48 hours after initial stimulation with 
anti-CD3 and anti-CD28 mAbs. T cell proliferation was counted by 
3
HTdR incorporation. 
Results are shown as the mean stimulation index+SEM of two independent experiments of 
similar design and presented as mean stimulation index (SI) +SEM.  
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6.3.3.2 The effect of IL-2 on the levels of α4β7 and CCR9 expressed by T cells 
activated in the absence of DCs 
Previously, we noted that while IL-2 did not significantly affect T cell acquisition of 
gut-homing receptors following mature DC stimulation, it promoted the upregulation 
of α4β7 integrin in T cells stimulated by allogeneic immature DCs. To assess whether 
this effect persisted when DCs were absent, naïve T cells were activated by plate-
bound anti-CD3 and anti-CD28 mAbs in the presence of exogenous IL-2 and 
phenotypically analyzed following activation. We applied the same strategy 
developed previously to gate T cell populations, and measured the frequency of 
α4β7
high
 activated T cells generated in the presence or absence of IL-2. As shown in 
Figure 37A, the proportion of α4β7
high
 cells among gated CD4
+
 and CD8
+ 
T cells 
appeared to have been raised by additional IL-2. Despite not being able to determine 
the statistical significance of these data, this appeared to be a very clear trend. These 
data thus suggest that the enhancing effect of IL-2 in T cell acquisition of α4β7 
previously observed might be independent of DCs and that IL-2 might selectively 
favour the expansion of α4β7
high 
T cells through mechanism that are not yet clear.  
As shown in Chapter 5, upon naïve T cell stimulation by DCs (either by allogeneic 
mature or immature DCs), exogenous IL-2 did not appear to have any significant 
effect in the modulation of CCR9 in activated T cells. We next measured the effect of 
IL-2 on the expression of CCR9 by T cell activated in the absence of DCs. As shown 
in Figure 37B, in the presence of IL-2, we observed a trend towards a decrease in the 
frequency of CCR9
+
 cells among total activated T cells. In addition, the percentage of 
CD4
+
CCR9
+
 T cells also fell in the presence of either CCL25 or all-trans-RA with 
additional IL-2.  
In summary, further experiments are required in order to verify these preliminary 
observations, at present it was not possible to conclude the effect of IL-2 on gHR 
induction in T cells activated independently of DCs.  
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Figure 37. The effect of IL-2 on the induction of α4β7 and CCR9 in T cells 
activated by immobilized mAbs.  
Naive T cells were cultured in flat bottom 96-well tissue culture plates coated with anti-CD3 
(1 μg/ml) and anti-CD28(5 μg/ml) with additional IL-2(20 U/ml), CCL25(300 ng/ml), or all-
trans-RA(2 μM) alone or in combination to some wells. Cells were harvested from each 
culture condition and phenotypically analyzed. The expression of α4β7 (panel A) and 
CCR9(panel B) by the activated CD4
+
 and CD8
+ 
T cell subset was analyzed using our 
previously developed strategy (Chapter 3, Figure 13 and Figure 14, pg118-121). The graphs 
display cumulative data obtained from two independent experiments and presented as 
mean+SEM. 
A.The graphs show the mean percentage of α4β7
high 
T cells within activated CD4
+
 or CD8
+ 
T 
cell subset obtained from each of the culture conditions indicated on the X-axis. 
B. The summary graphs show the mean percentage of the activated CD4
+
CCR9
+
 and 
CD8
+
CCR9
+
 T cell populations generated following T cell stimulation under the indicated 
conditions.  
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6.3.3.3 Contribution of CCL25 and IL-2 to the expression of integrin α4β7 on 
CD4
+
CD25
high
FoxP3
+
 T cells generated in the absence of DCs 
We previously investigated the role of IL-2 in the expansion of CD4
+
CD25
high
FoxP3
+
 
T cells following naïve T cell activation by allogeneic DCs. In this part of our study, 
we sought to test the effect of IL-2 in the CD4
+
CD25
high
FoxP3
+
 „putative‟ Tregs 
generated in the absence of DCs. To do this, naïve T cells were stimulated with 
immobilized mAbs in the presence of IL-2, the frequency of CD4
+
CD25
high
FoxP3
+
 T 
cells generated as well as the level of α4β7 expressed by these cells were subsequently 
analyzed.   
As shown in Figure 38A, in one experiment, less than 1% of the total activated CD4
+
 
T cells were CD4
+
CD25
high
FoxP3
+
 T cells following antibody stimulation of naïve T 
cells. In contrast, approximately 6-10% of activated CD4
+
 T cells became 
CD25
high
FoxP3
+
 following DC stimulation (Chapter 4, Section 4.3.1.3, pg 148). 
Previously, in the presence of allogeneic mature or immature DCs, IL-2 did not have 
any significant effect in the frequency of CD4
+
CD25
high
FoxP3
+
 T cells generated. 
Based on the preliminary observation from one experiment, we were unable to 
conclude the effect of exogenous IL-2 in the expansion of CD4
+
CD25
high
FoxP3
+
 T 
cells. 
Despite the poor expansion of CD4
+
CD25
high
FoxP3
+ 
T cells, following antibody 
stimulation of naive T cells in the presence of either IL-2 or CCL25, α4β7
 
integrin 
appeared to be upregulated by a greater proportion of CD4
+
CD25
high
FoxP3
+
 T cells 
(Figure 38B) compared to T cells activated by the mAbs alone. However, further 
studies are required to confirm these observations and to conclude on the effect of 
CCL25 and IL-2 in the development of α4β7
high
CD4
+
CD25
high
FoxP3
+ 
T cells.  
Finally, as expected, the combined effect of IL-2 and all-trans-RA resulted in the 
highest frequency of α4β7
high
 CD4
+
CD25
high
FoxP3
+ 
T cells. As this experiment was 
only carried out once, these results require verification by further studies.  
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Figure 38. The effect of IL-2 on the acquisition of α4β7 by CD4
+
CD25
high
FoxP3
+
 T 
cells. 
Following naïve T cell stimulation by anti-CD3 and anti-CD28 mAbs, T cells were harvested 
and stained for the expression of CD4, CD25, FoxP3, and integrin a4 and β7 chain. The same 
gating strategy described previously (Chapter 4, Section 4.3.1.3, pg 148) was adopted for the 
phenotypic analysis. 
A. The dot plots depict the proportion of CD4
+
FoxP3
+
 T cells present among the activated 
CD4
+
T cells (represented by the red dots) harvested from each of the culture conditions 
indicated. The black dots represent the isotype controls of the markers examined. 
B. The dot plots show the expression of α4β7 (the red dots) gated on the CD4
+
FoxP3
+ 
T cells 
shown in panel A. Results presented in A-B are obtained from one experiment.  
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6.4 Discussion 
In this part of our project, we intended to gain a better understanding of the signals 
required for the acquisition of gut tropism by T cells during activation, i.e. the 
upregulation of the gut-homing molecule integrin α4β7 and chemokine receptor CCR9. 
Previous studies have established that optimal induction of tissue-specific HRs 
requires T cell activation and local tissue-derived signals (Campbell and Butcher, 
2002, Mora et al., 2005). In the context of gut homing, the signals are provided either 
in the form of intestinal DCs or soluble gut-derived factors (Stagg et al., 2002, Mora 
et al., 2003, Iwata et al., 2004, Johansson-Lindbom et al., 2003, Dudda et al., 2005). 
While many studies have demonstrated the importance of microenvironmental soluble 
factors in imprinting T cells with tissue-homing specificity, the only soluble factor 
responsible for the acquisition of gut HRs (gHRs) identified so far is the vitamin A 
metabolite retinoic acid (RA) (Iwata et al., 2004, Dudda et al., 2005). Previously, 
Iwata and colleagues have demonstrated that retinoic acid is able to directly signal to 
naïve T cells by binding to its receptor RAR in vitro in the absence of DCs, thus 
leading to highly efficient upregulation of α4β7 and CCR9 by T cells activated by anti-
CD3 and anti-CD28 (Napoli, 1999, Sigmundsdottir and Butcher, 2008, Iwata et al., 
2004). In the current study, preliminary findings suggest that while activated T cells 
upregulated α4β7 and CCR9 in the presence of retinoic acid (all-trans-RA), the level of 
upregulation was not significantly raised compared to T cells activated by anti-CD3 
and anti-CD28. The reason for this discrepancy is not yet clear. It is possible that 
differences in the T cell culturing protocols used might underlie the different results 
obtained.  
As the gut microenvironment consists of many different types of cells (such as 
epithelial cells, stromal cells), cellular matrix components, and other soluble 
molecules such as cytokines and chemokines (Dudda et al., 2005, Dudda and Martin, 
2004), it is possible that tissue-derived factors other than vitamin A metabolites may 
also play a pivotal role in the imprinting of gut-specific HRs. In our earlier studies we 
observed an enhanced level of α4β7 and CCR9 upregulation in T cells activated by 
allogneneic mature DCs in the presence of CCL25, suggesting that CCL25 might play 
a role in T cell acquisition of gut tropism.  
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In this section, we carried out further studies in order to investigate the mechanisms 
by which CCL25 induces the gut-homing phenotype in T cells, particularly the role of 
DCs. To this end, T cells were activated by plate-bound anti-CD3 and anti-CD28 
monoclonal antibodies (mAbs) in the presence or absence of CCL25.  
Consistent with previous reports (Iwata et al., 2004, Mora et al., 2003), strong T cell 
activation signals (by anti-CD3 and anti-CD28 mAbs) induced the upregulation of 
α4β7 and CCR9 in activated T cells. However, our pilot study also showed that CCL25 
had no significant effect on T cell upregulation of α4β7 or CCR9 following antibody 
stimulation of T cells. These preliminary findings suggest that the effects of CCL25 
observed previously might be dependent on the presence of DCs. A few possible 
mechanisms may help explain our observations.  
As discussed earlier, CCL25 may „condition‟ DCs, thus endowing DCs with the 
capability of driving T cell gHR acquisition; however the nature of this conditioning 
effect remains uncharacterized. Secondly, as the only identified receptor for CCL25 is 
CCR9 (Zaballos et al., 1999, Zabel et al., 1999), and others have shown that human 
monocyte-derived DCs generated in vitro in the presence of GM-CSF and IL-4 (used 
in our study) do not express CCR9 (Cravens and Lipsky, 2002), CCL25 may instead 
be „lodged‟ onto DCs by binding to the glycoaminoglycans (GAGs). In vivo, most 
chemokines are present in a secreted form rather than membrane-bound (Moser et al., 
2004), in order to direct leukocyte trafficking, chemokines are immobilized by 
binding to the glycoaminoglycans (GAGs) of the extracellular matrix or on the 
surface of endothelial cells (Rot et al., 1993). As GAGs are synthesized by most cells 
(Taylor and Gallo, 2006), it is possible that CCL25 binds to the GAGs on the cell 
surface of DCs in culture. As a result, the „immobilized‟ CCL25 signals to T cells by 
binding to CCR9, and subsequently leads to the emergence of a T cell population 
expressing high levels of α4β7 and CCR9. In contrast, when DCs are absent, soluble 
CCL25 in culture is unable to strongly signal via CCR9; therefore gHRs cannot be 
efficiently upregulated.  
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While our study has shown that other than RA, CCL25 is capable of instructing the 
acquisition of gut-specific homing receptors on T cells. Further investigations are 
required to fully understand the exact mechanism by which CCL25 and DCs 
„cooperate‟ to induce gHR acquisition. 
Other than CCL25 and RA, IL-2 is found to be capable of selectively driving the 
upregulation of α4β7 in T cells activated by allogeneic immature DCs. While α4β7 
facilitates memory T cells to the large intestine, CCR9 is also required for T cell 
homing to the small intestine (Johansson-Lindbom et al., 2003, Kunkel et al., 2000, 
Mora et al., 2003). Thus, our previous findings suggest that IL-2 might play a role in 
the compartmentalization of the mucosal immune responses. While the underlying 
mechanisms are not clear at this stage, preliminary observations from this part of our 
study suggest that this effect might be independent of DCs, which requires 
verification from further studies. 
Moreover, as shown in Chapter 4, CCL25 might also play a role in the generation of 
α4β7
high
FoxP3
+
 T cells. In this part of our pilot study, a small percentage of activated 
CD4
+ 
T cells were found to be CD4
+
CD25
high
FoxP3
+
 following antibody stimulation 
of naïve T cells. In addition, CCL25 in culture resulted in an increased proportion of 
α4β7
high
FoxP3
+
 T cells. While these preliminary observations require validation by 
future studies, they suggest that CCL25 might be able to promote the acquisition of 
gut homing properties by FoxP3
+
 T cells independently of DCs, similar to that of all-
trans-RA. Although its effect on conventional T cells likely requires the presence of 
DCs, it is possible that CCL25 induces the acquisition of α4β7 integrin in FoxP3
+
 T 
cells follows mechanisms other than that underlying the effect of RA.  
While all-trans-RA has been shown to drive the acquisition of α4β7 on FoxP3
+
 T cells 
(Benson et al., 2007, Menning et al., 2010, Moore et al., 2009, Kang et al., 2007a), the 
role of CCL25 in the generation of gut-homing FoxP3
+
 T cells has not been 
documented and therefore requires further investigation. Furthermore, results from 
our preliminary study also suggest that aside from its well-established role in the 
generation of FoxP3
+
 regulatory T cells (Klebb et al., 1996, Zheng et al., 2007, Lu et 
al., 2010), the effect of IL-2 in the induction of gut-tropism in these cells could also 
be further evaluated. 
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Chapter 7 Characterization of T cell trafficking in 
gastrointestinal immunopathology  
7.1 Introduction 
The expression of key molecules such as the α4β7 integrin and the chemokine receptor 
CCR9 allows memory T cell entry to the site of mucosal injury in order to execute 
their effector functions. Excessive lymphocyte infiltration to the gut along with a 
production of inflammatory cytokines contributes to the initiation and perpetuation of 
intestinal pathology (Xavier and Podolsky, 2007, Koenecke and Forster, 2009). For 
instance, Crohn‟s disease (CD) is associated with T cell infiltration and mainly driven 
by Th1 responses accompanied by the abundant production of pro-nflammatory 
cytokines, including IFN-γ and TNF-α (Parronchi et al., 1997, Danese and Fiocchi, 
2006, Zenewicz et al., 2009). The other subtype of IBD - ulcerative colitis (UC) is 
predominantly associated with Th2 responses (Inoue et al., 1999, Heller et al., 2005). 
Despite their different cytokine signatures, both diseases share similar mechanisms 
for the recruitment of effector T cells to the gut (Sartor, 2006).  
While much is known about the significance of cytokines in IBD, less is known about 
the potential role of dysregulated lymphocyte trafficking in its development. This thus 
led to the current study, in which we analyzed and compared the lymphocyte 
composition in patients with IBD and healthy controls. We also analyzed the 
expression of homing markers expressed by circulating T lymphocytes in patients and 
healthy controls. By doing so, we hoped to determine to what extent dysregulated 
lymphocyte migration was involved in the pathogenesis of IBD and to identify any 
potential T cell trafficking markers which might be associated with IBD. Moreover, 
we investigated the possibility of other IBD-associated biomarkers, such as the TcR-
zeta chain (TcRδ) whose downregulation has been linked to rheumatoid arthritis and 
systemic lupus erythematosus (SLE)(Cope et al., 1994, Gorman et al., 2008). 
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Previous studies have provided evidence that the uncontrolled inflammation observed 
in IBD patients may partly be explained by inadequate regulatory T cell function 
(Maul et al., 2005, Takahashi et al., 2006). In an attempt to test this hypothesis, we 
quantitatively analyzed peripheral blood Tregs in IBD patients and compared it to that 
of healthy volunteers.  
Finally, we conducted a pilot study looking into the mucosal lymphocytes recovered 
from the intestinal biopsies extracted from patients with IBD. In these patients, 
lymphocytes were extracted from biopsies taken from the inflamed intestinal segment 
and the uninflamed segment and phenotypically characterized. Results from this study 
may provide valuable information on the state of immunity in situ. 
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7.2 Aims  
In this part of the study, our main aims were to identify any alterations in the 
trafficking of lymphocytes in patients with IBD, and to identify potential markers that 
might be exclusively associated with IBD. To achieve this, we carried out the 
following analysis. 
1. Quantification of peripheral blood B lymphocytes, T lymphocytes; 
subpopulations of T cells including the CD4
+
 and CD8
+
 T cell subsets, 
memory and naïve subsets in patients with IBD and healthy volunteers  
2. Examination of the frequency of the gut-homing T cells (α4
+β1
lowβ7
+
) and those 
T cells that were targeted to other peripheral non-lymphoid tissues (α4
+β1
highβ7
-
) 
in IBD patients and healthy controls   
3. Investigation of the correlation between circulating small intestine-seeking T 
cells (CCR9
+
) and the disease activity of those patients with CD involving the 
ileum  
4. Quantitative assessment of the percentage of circulating activated gut-homing 
T cells (β7
+
) and those gut-homing T cells with inflammatory properties 
(CXCR3
+
) in IBD patients and controls 
5. Characterization of the expression of TcRδ chains by circulating T cells in 
IBD patients and comparison to healthy controls; additionally, the evaluation 
of TcRδ chain expression on peripheral blood gut-homing T-cells 
6. Assessment of the differences in the proportion of circulating 
CD4
+
CD25
high
FoxP3
+
 regulatory T cells present in IBD patients and healthy 
volunteers, and quantitative examination of Tregs displaying gut-homing 
properties (α4
+β7
+
, CCR9
+
) in these experimental groups 
7. Phenotypic characterization of the lymphocytes isolated from the intestinal 
biopsies of a patient with active ileal CD and a UC patient in remission; 
comparisons of the phenotype of lymphocytes originated from the inflamed 
area of the intestine and the inflamed area in each patient  
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7.3 Study populations 
The phenotypic analysis described in this chapter was carried out in the following 
experimental groups. 1: Patients with Crohn‟s disease (CD). 2: Patients with 
ulcerative colitis (UC). 3: Healthy volunteers were used as controls, which were 
defined as having no IBD or any other known chronic or inflammatory disorders. 
Within each disease group, patients were further grouped by disease activity into 
those with active disease and those in clinical remission (inactive disease). The 
information of patients studied in each group is summarized in Table 12 below. For 
the pilot study investigating the phenotype of intestinal lymphocytes extracted from 
the mucosal biopsies of IBD patients, patients‟ information is listed in Table 13 in 
Section 7.4.6. 
For the analysis of each of the parameters examined in our study, multiple 
comparisons of the results between the experimental groups were made. First, results 
from each disease group were compared to healthy controls separately. Second, 
within each disease group, comparisons were made between those with active disease 
and those who had entered clinical remission. Taking these multiple comparisons into 
account, we used the Kruskal Wallis test with Dunn‟s post test for the statistical 
analysis of our results (described in Chapter 2, Section 2.8, pg 100). Where results 
were statistically significant, p value was calculated using two-tailed Mann-Whitney 
test with Bonferroni corrections. The corrected p value was indicated as pc, the 
uncorrected p value was represented by p.  
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Table 12: Information of subjects in each experimental group  
 Study Groups 
Category Crohn’s disease 
 (n=17) 
Ulcerative colitis 
(n=17) 
Controls  
(n=10) 
Therapy Active  
(n=8) 
Inactive 
(n=9) 
Active 
(n=8) 
Inactive 
(n=9) 
N/A 
NO Medication 3 2 2 1 
Monotherapy 
(non-immunosupressant) 
NONE 5 6 7 
Monotherapy 
(immunosupressant) 
NONE 2 NONE 1 
Combinational Therapy 
   Steroid                           
Non-steroid 
5                
1           
4 
NONE NONE NONE 
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7.4 Results  
7.4.1 Frequency of circulatory lymphocyte subsets in IBD patients 
and healthy controls 
In this part of our study, we first quantitatively analyzed various lymphocyte subsets 
in the peripheral blood of IBD patients. Peripheral blood mononuclear cells (PBMCs) 
were isolated from the blood, stained and analyzed by flow cytometry (methodology 
described in Chapter 2, Section 2.4.1, pg 88). Using one healthy volunteer as an 
example, the gating strategy used to analyze different cell types of interest is 
illustrated in Figure 39. 
Within the total live lymphocytes in the PBMCs, we did not observe any significant 
differences in the overall percentage of the CD3
+
 T lymphocytes when comparing 
either UC (range: 52%-89%) or CD patients (range: 17%-72%) to that in healthy 
controls (16%-74%) (Figure 39B). In addition, IBD disease activity was not found to 
correlate with any significant quantitative changes in the peripheral blood CD3
+
 T 
lymphocytes (pc>0.05). Similarly, we did not identify any significant differences in 
the proportion of circulating CD19
+
 B cells between any of the experimental groups, 
as shown in the scatter plot in Figure 39C.  
Next, we examined the frequency of CD4
+
 and CD8
+
 T cell subsets among the total 
circulatory CD3
+
 T cells (Figure 39D, E), the naïve (CD45RO
-
) and memory 
(CD45RO
+
) T cell subsets (Figure 39F, G) among the gated CD4
+
 or CD8
+
 T cells. 
While a rise in the peripheral blood CD4
+
 memory T cells was previously reported in 
IBD patients (Meenan et al., 1997), we found the frequency of each T cell subset 
analyzed (including the memory subset) comparable between patients and healthy 
controls. 
 
Chapter 7 Characterization of T cell trafficking in gastrointestinal immunopathology
 
204 
Figure 39. Characterization of perhiperal blood lymphocytes in patients and 
controls. 
A. The dot plots illustrate the gating hierarchy applied for the phenotypic analysis of the 
PBMCs extracted from one healthy volunteer. Freshly isolated PBMCs were stained with 
mAbs recognizing the T cell markers indicated (represented by the red dots) or isotype 
controls (shown as the blue dots).The same gating strategy was applied to all experimental 
groups.The result from each patient and the healthy volunteers is indicated in the scatter plots 
in B-G. B-C: The scatter plots show the percentage of circulating T cells and B cells (gated 
on the total lymphocytes). D-E. The scatter plots show the percentage of the CD4
+
 and CD8
+
 
T cell subset present within the peripheral CD3
+
T cells.  
Panel F and G respectively shows the proportion of naïve (CD45RO
-
) and memory 
(CD45RO
+
) T cells gated on the CD4
+
 and the CD8
+
 T cell subset in all the study groups. For 
statistical analysis, Kruskal-Wallis with Dunn’s post test was performed having taken into 
account of multiple comparisons. 
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7.4.2 Expression of tissue-specific homing receptors on circulatory T 
cells in IBD patients and healthy controls 
7.4.2.1 Quantitative analysis of the circulating gut-homing and non-gut-homing 
T lymphocytes  
As the immunopathology seen in IBD (both UC and CD) is strongly associated with 
lymphocyte infiltration into the site of inflammation (Koenecke and Forster, 2009), 
we were interested to find out if there was any aberration in the distribution of gut-
homing T cells in patients with IBD. The expression of tissue-specific homing 
receptors on T cells is mutually exclusive, while integrin α4β7 enables T cell entry to 
the effector site of the gut; the integrin α4β1 targets T cells to the non-mucosal tissues 
(Berlin et al., 1993, Lefrancois et al., 1999b, Rott et al., 1996). Following isolation 
from peripheral blood, PBMCs were stained and analyzed for the expression of CD4, 
CD8, integrin α4, β7 and β1 chain. Meanwhile, as T cells infiltrating the inflamed 
mucosal tissue are predominantly of memory phenotype (Harvey et al., 1989), we also 
quantified the gut-homing memory T cell (CD45RO
+α4β7
+
) subset.  
First, we gated on the total peripheral blood CD4
+
 and CD8
+
 T cells and examined the 
percentage of mucosal-homing T cells (α4β7
+
) within each T cell subset. In parallel, 
we assessed the frequency of those T cells that were targeted to the non-mucosal sites, 
characterized by the co-expression of integrin α4 and a high level of integrin β1 (Batra 
et al., 2007, Rott et al., 1996). The gating strategy for the identification of gut-homing 
or non-gut-homing T cells is illustrated in Figure 40A. As the integrin β7 subunit 
pairs with either α4 forming α4β7 or with the αE chain forming integrin αEβ7 (implicated 
in memory T cell retention in the intestine), to accurately identify those T cells with 
gut-homing properties, we stained T cells for the dual expression of integrin α4 and β7 
chains due to the lack of commercially available mAb recognizing both chains. To 
identify those α4
+β1
high
 T cells that homed to non-mucosal tissues, single staining of 
integrin β1 was sufficient as these cells have been shown to be α4
+ and β7
-
 (Batra et al., 
2007, Rott et al., 1996). 
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α4β7 integrin expression on circulating T cells 
First, we observed numerical differences in the proportion of gut-homing CD4
+
 and 
CD8
+ 
T cells between CD patients (in both active and inactive disease groups) and 
healthy controls. Compared to healthy controls, both groups of CD patients had 
significantly lower percentages of α4β7
+
 T cells in their circulation as shown in Figure 
40B. For example, the median percentage of circulating CD4
+α4β7
+ 
T cells among CD 
patients with active disease was 20.6%, and 17% in patients with inactive CD 
(p=0.02), while in healthy controls the percentage of gut-homing T cells reached 37% 
(p=0.02). A similar degree of reduction in the proportion of CD8
+
 α4β7
+
 T cells in the 
patient groups was also observed compared to healthy controls (p=0.01). In addition, 
changes in the frequency of the overall circulating gut-homing T cells were also 
reflected in the memory T cell subset, as shown in Figure 40C. By contrast, the 
percentages of α4β7
+ 
circulating T cells and α4β7
+ 
memory T cell subsets in UC 
patients (both the active and inactive disease groups) were comparable to those found 
in the control group (Figure 40B, Figure 40C). 
Finally, we compared the frequency of circulating α4β7
+
 T cells and α4β7
+
 memory T 
cells in patients with active disease to those who had entered remission in both UC 
and CD. We noted that changes in disease activity in IBD patients were not 
accompanied by any significant alterations in the circulating gut-homing T cells or 
memory T cells, as shown in the scatter plots in Figure 40B, and Figure 40C. These 
data thus suggest that proportional changes in the frequency of circulating gut-homing 
T cells may be associated with CD but not UC. As some of differences we observed 
did not withhold multiple comparisons, they require verification from further 
hypothesis-proving studies.  
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α4β1 integrin expression on circulating T cells 
To be able to migrate to the non-mucosal tissues, instead of expressing the β7 subunit, 
T cells must have a high level of integrin β1 paring with the α4 subunit. In consistence 
with previous reports, integrin β1 expression on peripheral blood T cells was found to 
be bi-modal. As shown in the histograms in Figure 40A (the right panel), T cells 
express heterogeneous levels of the integrin β1 chain – the β1
high 
population and the 
β1
low
 population.  As the β1
high 
subsets have been shown to express α4 but not β7 (Batra 
et al., 2007, Rott et al., 1996), this population was defined as the non-mucosal homing 
T cells.  
As non-mucosal inflammation was not present in the IBD patients recruited into our 
study, alterations in the frequency of circulating T cells with non-mucosal homing 
specificity were not expected. However, as circulating T cells are either gut-
committed or homed to the non-mucosal sites, fluctuations in the fraction of the gut-
homing subset (as observed earlier in CD patients) would inevitably lead to 
proportional changes in the circulatory non-gut-homing T cell subset. In line with this 
reasoning, we observed that the frequency of the non-mucosal (α4
+β1
high
) T cell subset 
in the circulation of patients with active CD (p<0.05) and inactive CD (p<0.01) both 
significantly rose (Figure 40D) compared to the controls, reflecting the decrease in 
the proportion of the gut-homing subsets (Figure 40B). For example, 50.7% (median) 
of the circulating CD4
+
 T cells in patients with active CD and 56.2% of that in 
patients in remission were respectively found to be α4
+β1
high
 compared to 36.05% in 
healthy controls. As expected, comparable proportions of peripheral blood non-
mucosal homing T cell sub-populations were found in UC patients and the control 
group, as shown in Figure 40D. In addition, the frequency of the β1
high
 memory CD4
+
 
T cell subset also appeared to be comparable across all experimental groups as shown 
in Figure 40E. 
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Figure 40. Altered frequency of gut-homing T cells in IBD patients. 
A. The dot plots (left) and the histograms (right) respectively depict the gating strategy used 
for the identification of the gut-homing (α4β7
+
) and the non-gut-homing CD4
+
 and CD8
+
 T 
cell subsets (β1
high
) in the peripheral blood. The red dots/line represent staining of mAbs 
recognizing the markers indicated, and the blue dots/line represent staining of the isotype 
controls. In the histograms, the T cell population expressing low levels of β1 is indicated in the 
red gate, while the population expressing high levels of β1 is shown in the black gate. The 
results shown are from one healthy volunteer; and are representative of the gating strategy 
consistently applied to all the experimental groups analyzed.  
In panel B-E. The scatter plots display results of each parameter analyzed in each patient 
and healthy control, horizontal bars represent the median. 
B. The percentage of circulating α4β7 
+ 
T cells (gated on CD4
+
 and CD8
+
 T subset 
respectively) in each patient and control is individually plotted in the scatter plots displayed.  
C. The scatter plot shows the percentage of circulating α4β7 
+ 
T cells in the gated memory T 
cell subsets (CD4
+
 CD45RO
+
 or CD8
+
 CD45RO
+
) in patients and the controls.  
D. The proportion of non-mucosal homing (β1
high
) T cell subset (CD4
+
 or CD8
+
) in the 
peripheral blood of each patient and healthy volunteer is individually shown as a scatter in 
the plot. 
E. The percentage of non-mucosal homing memory T cell subsets in patients and controls.  
Kruskal-Wallis with Dunn’s post was performed having taken into account of multiple 
comparisons. P value was calculated manually using two-tailed Mann-Whitney test with 
Bonferroi corrections. Statistical significance is indicated with *, * p<0.05, ** p<0.01, p and 
pc respectively represents the uncorrected and the corrected p value.  
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7.4.2.2 Does T cell expression of CCR9 or α4β7 respectively reflect activity of ileal 
or colonic disease? 
Based on current understanding, while the expression of integrin α4β7 is essential for T 
cell homing to the intestine, in order to access the small intestine, T cells must also 
express the chemokine receptor CCR9 (Berlin et al., 1993, Lefrancois et al., 1999b, 
Johansson-Lindbom et al., 2003, Kunkel et al., 2000, Papadakis et al., 2000, Stenstad 
et al., 2006). Given this topographic specificity, it would be plausible to predict 
differences in T cell expression of CCR9 between CD patients with ileal involvement 
and those with pure colonic disease. 
We first compared the circulatory proportion of CCR9
 
expressing CD4
+
 and CD8
+ 
T 
cells and memory T cell subsets in patients with active or inactive Crohn‟s disease. As 
shown in Figure 41B-C, we did not observe any significant differences in the 
percentages of CCR9
+ 
T cells associated with CD disease activity.  
Next, we further categorized CD patients based on their disease activity as well as 
disease location. Patients with active disease or in remission were thus sub-divided 
into a group with CD involving the colon only and another with CD where the ileum 
was affected either in isolation or together with colonic disease. PBMC isolated from 
each patient and the healthy controls was then stained for the expression of CD4, CD8 
and CCR9; and the frequency of CCR9
+
 cells within each T cell subset in patients and 
controls was then determined by flow cytometry as shown in Figure 41A. The gating 
strategy applied was based on previous reports and our own data (Chapter 3). 
As shown in Figure 41D, it was observed that patients with active CD affecting the 
ileum had comparable proportions of circulating CCR9
+
 T cells compared to healthy 
controls. Interestingly, the group of patients with inactive disease had a significant 
higher proportion of circulating CD4
+
CCR9
+
 T cells compared to healthy controls 
(p=0.02). In addition, we noted that in these patients with ileal involvement in 
remission, there was a trend towards an increase in the proportion of circulating 
CD4
+
CCR9
+
 T cells compared to the group with active disease (p=0.08). These 
differences observed were also reflected in the memory T cell subsets, as shown in 
Figure 41E. In contrast, no significant differences were observed in the frequency of 
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circulating small intestine-seeking CD8
+
 T cells or memory T cells between any of 
the experimental groups (the right panels in Figure 41D and E). 
Meanwhile, we also examined of the frequency of T cells targeted to the small-
intestine in patients with colonic disease only; unfortunately, as only a small number 
of patients were available (n=2 in the group with active colonic disease, n=4 in the 
group of patients with inactive colonic disease), it was not possible to draw any 
conclusions from these data. Nonetheless, as we identified that patients with ileal 
disease had significant different proportions of circulating CCR9
+ 
T cells compared to 
healthy volunteers, and that changes in disease activity appeared to be accompanied 
by proportional changes in the circulating CCR9
+ 
T cells, it it is likely that CCR9 may 
be an important marker for ileal disease.  
Despite not being able to reach a conclusion about the relevance of CCR9 in colonic 
CD patients, we analyzed the expression of CCR9 by the circulating T cells in UC 
patients, whose inflammation was limited to the colon. As shown in Figure 41F and 
Figure 41G, the frequency of circulating CCR9
+
 T cells and memory T cells in each 
patient group (with active or inactive disease) was comparable to that in the healthy 
volunteers. Additionally, as expected, we did not observe any correlations between 
the presence of circulating CCR9
+
 T cells or CCR9
+ 
memory T cell subsets in UC 
patients and their disease activity. Collectively, these data support the hypothesis that 
CCR9 may be a marker particularly associated with Crohn‟s disease involving the 
ileum.  
Finally, we also sought to examine the proportions of α4β7
+ 
T cells and α4β7
+ 
memory 
T cell subsets in patients with or without ileal CD (Figure 41H). As expected, while 
significant differences in CD4
+
 α4β7
+
 and CD8
+
 α4β7
+
 T cells
 
were observed when 
comparing
   
patients with active or inactive CD involving the ileum to the control 
population, changes in the proportions of circulatory α4β7
+ 
T cells were not associated 
with disease activity in these patients. Similar results were also observed in the 
memory T cell subset as shown in Figure 41I. These data suggest that T cell 
expression of α4β7 and CCR9 must be evaluated in the context of disease extent in 
order to accurately establish their correlations with IBD disease activity. 
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Figure 41.The extent of small intestinal inflammation in CD patients is reflected 
by changes in the frequency of circulatory CCR9
+ 
T cells but not α4β7
+
 T cells. 
A. The dot plots depict the gating strategy applied for the identification of CCR9
+ 
small 
intestine-homing T cells. The expression of CCR9 on the peripheral blood CD4
+
 and CD8
+
 T 
cell subset is respectively shown in the dot plots. The green dotted line represents the gates 
illustrated low expression of CCR9. The results shown are obtained from one healthy donor, 
and are representative of the gating strategy applied to all the experimental groups analyzed. 
B-C. The percentage of peripheral blood CCR9
+ 
T cells (panel B, gated on CD4
+
 and CD8
+
 T 
subset respectively) and memory T cells (panel C, gated on CD4
+
CD45RO
+
 and 
CD8
+
CD45RO
+
 T cells) in CD patients (with active or inactive disease) and healthy controls 
is individually plotted in the scatter plots displayed.  
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D. The scatter plots display the frequency of CCR9
+ 
T cells in the circulating CD4
+
 or CD8
+
 
T cells in each of the controls and CD patients (sub-grouped based on disease activity and 
extent as indicated on the X-axis). 
E. The frequency of circulating CCR9
+
 T cells gated on the memory (CD45RO
+
) CD4
+
 or 
CD8
+
 T cell subset in each CD patient and control is presented as a scatter in the plots 
shown. 
F-G: The scatter plots in panel F show the frequency of peripheral blood CD4
+
CCR9
+
 or 
CD8
+
CCR9
+
 T cells in each UC patient and healthy control, in panel G, the scatter plots 
represent the proportion of circulating CCR9
+
 memory CD4
+
 and CD8
+
 T cells in UC and 
healthy controls. 
H. The frequency of α4β7
+ 
T cells among circulating CD4
+
 or CD8
+
 T cells in each of the 
healthy controls and CD patients (sub-grouped based on disease activity and extent as shown 
in panel D and E) is shown in the scatter plots. 
I. The percentage of circulating α4β7
+ 
memory T cells (CD4
+
 and CD8
+
 T cells) in CD 
patients (categorized based on disease extent and activity as shown in panel H)and controls 
are depicted in the scatter plots. 
In panel B-I: The horizontal bar in each graph indicates the median value for each parameter 
analyzed.  
Data displayed was analyzed using two-tailed Mann-Whitney test, the uncorrected p value is 
indicated on the plot. Statistical significance is indicated with *, * p<0.05, ** p<0.01, *** 
p<0.001. 
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7.4.3 Expression of activation and inflammatory markers on 
peripheral blood T cells in IBD patients 
Following the quantitative analysis of circulating T cell subsets in IBD patients and 
characterization of the homing receptors expressed by these T cells, we next analyzed 
the frequency of activated T cells in the peripheral blood of IBD patients and healthy 
volunteers. As IBD is a chronic inflammatory disorder, we hypothesized that repeated 
stimulation of the intestinal immune system could lead to an imbalance in the 
distribution of activated T cells between the circulation and the intestine in patients 
with active disease. First, in order to establish any correlations between IBD disease 
activity and T cell activation, we quantitatively examined the frequency of peripheral 
blood activated T cells (CD25
+
, including a minor subset of FoxP3
+
 cells) in IBD 
patients, in addition, we assessed the expression of gut-homing receptor -integrin β7 
on these activated T cells.  
Among the healthy individuals that were examined in this study, the median 
percentage of the circulating CD4
+
 CD25
+ 
T cells was 25%, in contrast, only 2% 
(median) of CD8
+
 T cells were CD25
+
 (Figure 42A). As shown in the top panel of  
Figure 42B, similar frequencies were also detected in patients with IBD regardless of 
disease activity. Next, we gated on the activated (CD25
+
)
 
T cells, and assessed the 
fraction of the gut-homing T cell subset. We found that the frequency of activated 
gut-homing CD4
+ 
T cells in IBD patients (with active or inactive disease) was 
comparable to that present in the healthy populations (bottom panels in Figure 42B). 
Moreover, no significant differences were observed when comparing the percentages 
of circulatory CD4
+
CD25
+ β7
+
 T cells in patients with active disease to those who had 
improved clinically in both CD and UC. However, as shown in the bottom panel of 
Figure 42B, in patients with active CD, the frequency of activated gut-homing CD8
+
 
T cells we noted was significantly lower compared to healthy controls, suggesting 
possible accumulation of these T cells in the inflamed gut mucosa of these patients 
(pc=0.0007). Unexpectedly, even in CD patients in clinical remission, their circulatory 
activated gut-homing CD8
+
 T cells accounted for similar percentage compared to 
those with active disease, which again was significantly different than that found in 
the healthy controls (Pc=0.008). These data thus suggest that CD8
+
 T cells may play a 
significant role in the pathogenesis of CD, which requires further investigation. 
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While the expression of CD25 indicates T cell activation, the chemokine receptor 
CXCR3 specifically marks those T cells targeted to the inflammatory sites. Previous 
reports have shown that CXCR3 is restrictively found on activated T cells and natural 
killers cells, and it acts as a chemoattractant for Th1 effector T cells to the site of 
inflammation (Loetscher et al., 1996). As mentioned earlier, Th1 responses are 
primarily associated with CD, whereas UC on the other hand, is mainly driven by Th2 
responses (Parronchi et al., 1997, Inoue et al., 1999, Heller et al., 2005). As recent 
evidence also suggests that CXCR3 may be important in directing activated 
lymphocyte trafficking to the gut mucosa (Yuan et al., 2001), we investigated the 
potential importance of CXCR3
+
 T cells in both CD and UC.  
First, we analyzed the percentage of peripheral blood CXCR3
+
 T cells in UC or CD 
patients and compared it to that in the healthy controls. To identify those 
„inflammatory‟ T cells that might be directly responsible for the development of 
inflammatory lesions in these patients, we subsequently measured the expression of 
gut-homing receptor integrin β7 on the CXCR3
+
 T cell subsets. The gating strategy for 
these analysis is demonstrated in Figure 43A. As shown in the summary data (Figure 
43B), IBD patients (CD and UC) and healthy volunteers had similar levels of 
CXCR3
+
 T cells in their circulation, accounting for 1-2% of the total CD4
+
 or CD8
+
 T 
cell subset. In addition, changes in disease activity were not accompanied by any 
alterations in the frequency of circulating inflammatory T cells in either UC or CD.  
Among the „inflammatory‟ T cells (CD4+ CXCR3+ or CD8+ CXCR3+ T cell subset) in 
the circulation, the frequency of the gut-homing subset was also found to be 
comparable between IBD patients and healthy volunteers (p>0.05). These 
observations were in line with previous reports, in which no differences in the number 
of CXCR3
+ 
T cells were found when comparing the gut mucosa of IBD patients to 
that of the healthy controls (Agace et al., 2000, Yuan et al., 2001). Thus these data 
suggest that the level of CXCR3 expression on T cells may not be associated with 
either UC or CD.  
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Figure 42. A decline in the frequency of circulating gut-homing activated CD8
+
 T 
cells is associated with Crohn’s disease. 
In all the study populations, PBMCs were isolated and analyzed for the expression of CD4, 
CD8, CD25 and integrin β7 by flow cytometry. The red dots represent staining of marker-
specific mAbs on the PBMC, while the blue dots represent the isotype control staining.  
A. The results displayed in the dot plots are obtained from one healthy volunteer and 
represent the gating strategy applied to all subjects studied. First, gated on CD4
+
 or CD8
+ 
T 
cells respectively, the frequency of CD4
+
CD25
+
 and CD8
+ 
CD25
+
 T cells were established. 
Gated on activated CD4
+
 or CD8
+
 T cell subset, the expression of integrin β7 chain on these 
cells was then analyzed.  
B. The scatter plots on the top panel indicate the percentages of activated CD4
+ 
and CD8
+
 T 
cells found in IBD patients and healthy controls. The percentage of gut-homing activated T 
cells (β7
+
) gated respectively on the CD4
+
CD25
+
 or the CD8
+ 
CD25
+
 T cell subset in all the 
study groups is individually plotted in the bottom panel. The horizontal bar indicates the 
median value. 
Kruskal-Wallis with Dunn’s post was performed on these data having taken into account of 
multiple comparisons. P value was calculated manually using two-tailed Mann-Whitney test 
with Bonferroni corrections. Statistical significance is indicated with *, * p<0.05, ** p<0.01, 
p and pc respectively represents the uncorrected and the corrected p value.  
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Figure 43. Quantitative analysis of CXCR3
+
 T cells in the peripheral blood of 
IBD patients and healthy controls.  
A. Following isolation, the PMBCs from IBD patients and healthy controls were individually 
stained with mAbs specific for CD4, CD8, CXCR3 and integrin β7 (represented by the red 
dots) or with isotype controls (shown as the blue dots). The dot plots display the frequency of 
peripheral blood CXCR3
+
 T cells (gated on CD4
+ 
or CD8
+
 T cell subset), and the proportion 
of gut-homing ‘inflammatory’ T cells (CXCR3+ β7
+
)gated on the CXCR3
+ 
T cell subset. The 
plots shown represent the gating strategy used in a healthy control sample which was 
consistently applied to all the samples in the study.  
B. In the PBMCs of each patient and healthy volunteer, the percentage of CXCR3
+
 T cells 
within the CD4
+
 or CD8
+
T cell subset and the percentage of gut-homing CXCR3
+
 T cells 
(gated on the CD4
+
 CXCR3
+
 or CD8
+
 CXCR3
+
T cell subset) was individually plotted as a 
scatter in the summary graphs. The horizontal bar represents the median.  
Statistical analysis was carried out using Kruskal-Wallis with Dunn’s post test. 
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7.4.4 Evaluation of TcR-ζ chain expression by T cells from IBD 
patients 
So far, our study led to the conclusion that a number of markers might be associated 
with IBD, such as the integrin α4β7 and the chemokine receptor CCR9. However, 
these markers are not indicative of disease activity, which would be useful in 
evaluating the efficacy of therapeutic regiments. TcRδ chain expression on the other 
hand, has been associated with disease activity in other chronic inflammatory diseases 
such as rheumatoid arthritis and SLE (Zhang et al., 2007, Gorman et al., 2008). We 
therefore sought to evaluate the association between TcRδ chain expression and 
disease activity in IBD in this part of our study.  
The invariant δ-δ dimer together with CD3ε-CD3γ heterodimer, CD3ε-CD3δ 
heterodimer and the variant α and β chains forms the T cell receptor complex 
(Germain and Stefanova, 1999, Samelson, 2002). The δ-δ dimer associates with the 
newly synthesized hexameric complexes αβγεδε resulting in the transport and 
expression of the entire TcR-CD3 receptor complex on T cell surface (Sussman et al., 
1988, Manolios et al., 1991). The δ chain is found to be directly responsible for the 
transport, the number of TcR receptors displayed on the surface of mature T cells and 
the functions of these receptors (Bronstein-Sitton et al., 1999, Samelson, 2002, 
Valitutti et al., 1997). As part of the multi-unit T cell receptor complex, the δ-δ 
homodimer also plays a indispensible role in coupling antigen recognition to a series 
of subsequent intracellular signal transduction pathways which eventually lead to T 
cell activation (Germain and Stefanova, 1999, Samelson, 2002, Pitcher et al., 2003). 
Downregulation of the TcRδ chain has been reported in many chronic diseases such as 
rheumatoid arthritis and SLE, as well as many types of tumors (Zhang et al., 2007, 
Gorman et al., 2008, Baniyash, 2004). However, to our knowledge, this phenomenon 
has yet to be investigated in IBD. Thus, we assessed the level of TcRδ expression 
found on peripheral blood T cells in IBD patients and compared it to healthy controls. 
In addition, we measured the TcRδ expression in those T cells that had a gut-homing 
phenotype (β7
+
).  
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PBMCs from patients and controls were isolated and stained for the expression of 
TcRδ as previously described (Chapter 2, Section 2.6.2, pg 94). As the TcRδ chain is 
a transmembrane molecule with a short extracellular domain, a monoclonal antibody 
recognizing the intracellular domain was used to detect its expression based on 
previously published protocols (Whiteside, 2004, Zhang et al., 2007). First, we found 
that the expression of δ chain on T cells varied considerably among healthy donors, an 
example is shown in Figure 44A. In line with previous studies (Zhang et al., 2007), 
high levels of δ chain expression were defined as δbright, and low levels of δ chain 
expression were referred to as δdim (as shown in Figure 44A). Based on this 
distinction, we calculated the frequency of δdim cells within the CD4+ and CD8+ 
subsets in each patient and healthy control. As shown in Figure 44C, we noted that 
patients with active CD had a significantly high frequency of CD4
+δdim T cells in their 
circulation compared to healthy controls. However, changes in CD disease activity 
did not appear to be associated with any significant changes in the proportion of 
peripheral blood δdim T cells. In addition, the proportion of CD4+δdim or CD8+ δdim T 
cell subsets in UC patients (the group with active disease and the group with inactive 
disease) was found to be comparable to that of healthy donors. 
Next, we analyzed the expression of δ chains by gut-homing T cells (β7
+
) in the 
circulation of patients and healthy donors (the gating strategy is shown in Figure 
44B). We observed that active CD patients hosted a significantly larger proportion of 
gut-homing T cells with a low δ expression (δdim β7
+
) in their peripheral blood 
compared to the healthy control group (p=0.03). Moreover, patients who were in 
clinical remission (had inactive disease) also had a significantly larger proportion of 
peripheral blood δdim β7
+
 T cells compared to healthy controls, as summarized in 
Figure 44D (p=0.04 in the CD4
+
 subset, and p=0.06 in the CD8
+
 subset). In contrast, 
these differences were not observed in UC. These data on peripheral blood T cells 
thus suggest that TcRδ downregulation might be specifically associated with CD, but 
not UC.  
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Figure 44. Characterization of T cell receptor ζ chain expression on circulating T 
cells in IBD patients. 
A-B. PBMCs were isolated from patients and healthy donors, and stained for the expression of CD4, 
CD8, TcRδ and the integrin β7 chain. The dot plots in panel A depict T cell expression of TcRδ chains in 
a healthy donor. T cells with high levels of δ chain expression are indicated as δbright, and δdim 
represents the population expressing low levels of the δ chain. The dot plots in panel B show the co-
expression of integrin β7 chain and TcRδ by the CD4
+
 and CD8
+
 T cell subsets in the same donor as 
panel A. The gating strategy used in A and B was consistently applied to the rest of the experimental 
groups. 
C. The scatter plots represent the proportion of circulating CD4
+δdim and CD8+ δdim T cells 
(δdim/δdim+δbright) found in each IBD patient and healthy donor. D. The percentage of circulating gut-
homing CD4
+
 and CD8
+
 T cells with a downregulated δ chain (β7
+δdim) in each IBD patient and healthy 
donor (δdimβ7
+/δdimβ7
++δbrighβ7
+
) is individually presented as a scatter in the summary plots shown. In 
panel C-D, the median value in each experiment group is indicated by the horizontal bar. Kruskal-
Wallis with Dunn’s post tests were performed on the results displayed. P value was calculated using 
two-tailed Mann-Whitney test with Bonferroni corrections. Statistical significance is indicated as *, 
where p<0.05.   
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7.4.5 Do IBD patients have quantitative defects in gut-homing 
regulatory T cells?  
The contribution of regulatory T cells (Tregs, CD4
+
CD25
+
Foxp3
+
) to the maintenance 
of intestinal immune homeostasis has been investigated through genetic studies, 
phenotypic and functional analysis of the FoxP3
+
 T cells in patients with intestinal 
inflammation (Bennett et al., 2001, Boden and Snapper, 2008). For example, 
compared to healthy controls, a reduction in the proportion of circulating regulatory T 
cells in patients with IBD has been reported (Maul et al., 2005, Saruta et al., 2007b, 
Takahashi et al., 2006), and hypothesized to reflect increased localization of FoxP3
+
 T 
cells to the intestinal lamina propria (Makita et al., 2004, Holmen et al., 2006, Maul et 
al., 2005).  However, compared to patients with non-IBD related colonic disease, a 
reduced Treg infiltration to the colon of IBD patients has been reported (Maul et al., 
2005, Uhlig et al., 2006a). Thus, whether IBD is associated with any quantitative 
defects in regulatory T cells remains to be clarified.  
In order to address this issue, we first quantitatively analyzed peripheral blood 
regulatory T cells in IBD patients and compared it to healthy controls. We then 
further expanded this study by examining the homing specificity of circulating Tregs 
in IBD patients and the healthy controls. 
Through quantitative analysis, we found that CD4
+
CD25
+
FoxP3
+
 regulatory T cells 
accounted for less than 5% of the peripheral CD4
+
 T cells in both IBD patients and 
healthy donors, as shown in Figure 45. In both UC and CD patients, there was little 
quantitative difference in the percentages of circulating Tregs between patients with 
active disease and those who were in disease remission (Figure 45C). The expression 
of the gut-homing receptor integrin α4β7 and the chemokine receptor CCR9 on the 
regulatory T cells was also assessed (Figure 45B). As shown in the summary plots in 
Figure 45D and E, we did not identify any significant differences in the proportion of 
the circulating α4β7
+
 Tregs (Figure 45D) or CCR9
+ 
Tregs (Figure 45E) between any 
patient group and healthy controls. Finally, changes in disease activity were not 
accompanied by any significant fluctuations in the frequency of circulating α4β7
+
 
Tregs and the CCR9
+ 
Tregs. These results thus led to the conclusion that IBD may not 
be associated with any quantitative defects in circulating regulatory T cells. 
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Figure 45. Quantitative analysis of FoxP3
+
 regulatory T cells in the peripheral 
blood of IBD patients and healthy donors. 
Following isolation, PBMCs from each patient and healthy donor were stained for the expression 
of the following markers: CD4, CD25, FoxP3, integrin α4, β7 subunit and the chemokine receptor 
CCR9. Results were then analyzed using flow cytometry. 
A-B. The dot plot in panel A shows the frequency of peripheral blood CD25
+
FoxP3
+
 regulatory T 
cells (gated on the total CD4
+
 T cells) in one healthy donor, the contour plots in panel B 
respectively shows the expression of α4β7 and CCR9 gated on the CD4
+
FoxP3
+
T cell subset. These 
representative plots display the gating strategy applied to all the experimental groups analyzed in 
this study. 
C. The proportion of CD25
+
FoxP3
+ 
Tregs present in the PBMC of each individual examined was 
individually plotted and indicated in the scatter plot.  
D. The scatter plot shows the proportion of α4β7
+
 regulatory T cells in each patient and healthy 
volunteer (gated on the CD4
+
FoxP3
+
 T cells)  
E. The summary graph shows the proportion of CCR9
+
 regulatory T cells within the CD4
+
FoxP3
+
 
T cells identified in each patient and healthy controls. In Panel C-E: Median is indicated as the 
horizontal bar in each scatter plot. Results were analyzed using Kruskal-Wallis test with Dunn’s 
post tests. 
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7.4.6 Phenotypic analysis of intestinal biopsies from IBD patients – a 
pilot study...... 
Following phenotypic analysis of peripheral blood lymphocytes in IBD patients, we 
observed differences in the distribution of various T cell subsets in patients compared 
to that of the healthy controls. Next, we sought to phenotypically characterize the T 
cell infiltrates in the inflamed and the non-inflamed areas of the intestine in patients 
with IBD. To do this, gut biopsy samples were collected from different sections of the 
intestine in two IBD patients based on the endoscopic findings listed below (Table 
13). Lymphocytes were then isolated from the biopsies and analyzed by flow 
cytometry.  
Table 13: Information of the patients from whom gut biopsy samples were 
analyzed 
Patients  Disease 
Characteristics 
Therapy Endoscopy Biopsy analyzed 
1 Active Ileal 
Crohn‟s disease 
None Ileal inflammation of 
previous resection 
margin 
1. Inflamed area 
2. Non-inflamed area 
2 Quiescent 
ulcerative colitis 
(pancolitis) 
Immuno-
suppressant 
Quiescent disease to 
the right colon 
1. Affected area 
2. Unaffected area 
  
Chapter 7 Characterization of T cell trafficking in gastrointestinal immunopathology
 
230 
Patient 1   
In this patient with active ileal Crohn‟s disease, biopsies were taken from areas of the 
ileum displaying signs of inflammation (labeled as I) and the unaffected area (labeled 
as NI) at endoscopic examination. As shown in Figure 46A, biopsies taken from the 
inflamed area of the small bowel was enriched with CD3
+
 T cells with a 
downregualted TcRδ chain (δdim), which accounted for 48% of the total CD3+ T cells. 
In contrast, only 28% of the CD3
+
 T cells were δdim in the biopsy collected from the 
area with no signs of inflammation. Within total CD4
+
 T cells, a larger proportion of 
CD4
+
 CD25
high
FoxP3
+
 regulatory cells was observed in the biopsy of the inflamed 
ileum (7% of the total CD4
+
 T cells) compared to that taken from the non-inflamed 
small intestine (2% of total CD4
+
 T cells)(Figure 46B).  
Patient 2 
Next, we examined intestinal lymphocytes from a UC patient in clinical remission. 
For example, as shown in Figure 47, biopsies taken from the colonic region affected 
by the disease (labeled I) contained a higher proportion of CD3
+
 δdim T cells (45%) 
compared to the unaffected colonic biopsy (13%) (labeled UI). Moreover, biopsies 
collected from the affected colon also contained a larger proportion of regulatory T 
cells (14% of the total CD4
+
 T cells) compared to the unaffected area of the colon (4% 
of the total CD4
+
 T cells). 
In summary, these findings suggest that microscopic immunological changes are 
associated with chronic inflammatory disease such as IBD. Even in clinically 
asymptomatic patients, areas of the intestine that are affected with disease display 
different immunological signatures compared to the unaffected area. Moreover, 
changes in disease activity are also reflected by immunological changes. 
These observations are in line with previous reports, in which δ chain downregulation 
was found in the synovial fluid of rheumatoid arthritis patients (Zhang et al., 2007). 
Clinical improvement in IBD was also found to be accompanied by restoration of 
TcRδ expression, in support of the hypothesis generated from previous studies (Cope 
et al., 1994, Zhang et al., 2007). 
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Previous studies have shown that the frequency of regulatory T cells in the gut 
mucosa of IBD patients varies with disease activity (Holmen et al., 2006, Maul et al., 
2005). This is confirmed in our work, whereby proportionally more regulatory T cells 
were observed in the biopsy taken from the inflamed intestine compared to that taken 
from the area displaying no or little signs of inflammation. In addition, it has been 
reported that Tregs isolated from the peripheral blood or the mucosa of IBD patients 
have similar suppressor functions compared to those isolated from healthy controls 
(Makita et al., 2004, Maul et al., 2005). Collectively, this evidence suggests that IBD 
might not be associated with quantitative or qualitative defects in regulatory T cells. 
Previous studies have shown that T cells with downregulated δ chains despite being 
unresponsive to TcR triggering are able to secrete cytokines upon stimulation in vitro 
via TCR δ independent pathways (Zhang et al., 2007). As the inflamed intestine is 
enriched with these cells as shown in our results, we hypothesize that TcRδ 
downregulation in T cells at the site of inflammation may cause cells to become less 
susceptible to suppression by regulatory T cells. As a result, despite the presence of 
regulatory T cells, the inflammatory process cannot be effectively controlled.  
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Figure 46. Characterization of T cells isolated from the mucosal biopsies of a CD 
patient with active ileal disease. 
Lymphocytes were isolated from ileal biopsies, stained and analyzed for the expression of the 
following markers: CD3, CD4, CD25, FoxP3 and the TcRδ chain. The dot plots in the top 
panel display results obtained from T cells isolated from the ileal sections with signs of 
inflammation (I), the bottom panel displays results of T cells isolated from the ileal segment 
with no or little signs of inflammation (NI). 
A. The dot plots show the expression of TcRδ chain on T cells (δbright and δdim) isolated from 
the inflamed (I) and the non-inflamed ileum (NI)  
B. The frequency of CD4
+
CD25
+
FoxP3
+ 
regulatory T cells (gated on total CD4
+
 T cells) 
isolated from the two different ileal biopsy samples are shown. 
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Figure 47. Phenotype of lymphocytes extracted from the colonic biopsies of a UC 
patient in remission. 
Lymphocytes were extracted from biopsies obtained from a UC patient in remission.  
Following isolation, intestinal lymphocytes were stained as described in Figure 37 and 
analyzed by flow cytometry. The dot plots in the top panel are results obtained from T cell 
isolated in the colonic area affected by disease (I), and the bottom panels show results of T 
cells isolated from the unaffected colon segment (NI). 
A. The dot plots show the expression of TcRδ chain on CD3+ T cells (δbright and δdim) isolated 
from different parts of the colon as indicated. 
B. The dot plots show the frequency of CD4
+
CD25
+
FoxP3
+ 
Tregs (gated on total CD4
+
 T 
cells) isolated from the two different colonic biopsies. 
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7.5 Discussion 
In this part of our project, we aimed to address the question of whether intestinal 
immunopathology associated with the development of IBD was accompanied by 
dysregulated lymphocyte trafficking to the inflamed gut mucosa. The demonstration 
of such differences could lead to the identification of biomarkers associated with IBD 
in the future. In order to achieve this, we phenotypically examined peripheral blood 
lymphocyte composition of different groups of IBD patients (both UC and CD) and 
compared it to that in the healthy populations. Finally, we conducted a pilot study to 
phenotypically characterize lymphocytes present in the gut mucosa of IBD patients in 
order to gain an insight into the immune responses occurring in situ.  
In total, we analyzed the peripheral blood mononuclear cells (PBMC) of 34 IBD 
patients and 10 healthy controls. IBD patients were also sub-grouped based on the 
disease phenotype, activity and location. Overall, no significant differences were 
observed in the proportion of total circulating T and B lymphocytes between patients 
with either sub-type of IBD and the healthy controls.  
Previously conflicting results have been reported on the numerical changes in the 
CD4
+ 
and CD8
+
 T cell subset in IBD patients (Selby and Jewell, 1983, Neil et al., 
1994). In this study, these parameters were found to be comparable between UC or 
CD patients to the controls examined. Though a contraction in the peripheral blood 
memory T cell pool was reported to be associated with chronic inflammation such as 
IBD (Meenan et al., 1997), we and others did not observe any differences between 
CD, UC and the control group (Alkim et al., 2007). The initial phenotypic analysis 
therefore suggests that the development of intestinal inflammation was not 
accompanied by changes in the overall proportion of circulating T cell subsets.  
It is well documented that IBD is driven by T cell responses which depend on T cell 
selective homing to the intestine (Fuss et al., 1996, MacDonald and Monteleone, 2001, 
Zenewicz et al., 2009). Given this, the level of circulating T cells that preferentially 
home to the gut (defined by the expression of integrin α4β7) may simply reflect the 
level of mucosal inflammation. Indeed, in line with previous observations (Meenan et 
al., 1997), we found a significant reduction in the proportion of CD4
+α4β7
+ 
and CD8
+
 
α4β7
+
 T cells in CD patients (with active disease or in remission) compared to the 
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control group, suggesting sequestration of α4β7
+
 T cells to the gut mucosa from the 
peripheral blood as part of the intestinal inflammatory responses. Furthermore, we 
analyzed the expression of integrin α4β7 on the memory T cell subset in these patients, 
and noted that they also had a significantly lower frequency of gut-homing memory T 
cells compared to the healthy control group, consistent with previous findings 
(Meenan et al., 1997). As this significance did not withstand multiple comparsions, a 
further hypothesis-proving study is required to establish whether these associations 
are faithful.  
In addition, we did not detect any correlations between the frequency of circulating 
gut-homing T cells and CD disease activity, as measured by clinical indices. This 
suggests that either measuring peripheral responses in isolation is not sufficient to 
uncover subtle changes at the mucosal level or that clinical indices are not able to 
detect early inflammation. It is thus possible that even in patients in clinical 
remission,T cells are continuously recruited to the intestinal mucosa of CD patients. 
This is compatible with the fact that CD patients in clinical remission often have 
endoscopic with or without histological evidence of disease activity (Rutgeerts et al., 
1990). 
Moreover, CD patients were found to have a significantly higher proportion of 
peripheral blood T cells committed to the non-mucosal sites (α4
+β1
high
) compared to 
healthy controls, likely due to the proportional reduction in the α4β7
+
 T cell subset.  
In contrast to what was reported by Meenan and colleagues (Meenan et al., 1997), we 
did not identify any significant differences in the proportion of α4β7
+ 
T cells or α4β7
+ 
memory T cells in the peripheral blood of UC patients compared to the control group. 
Despite sharing clinical characteristics and that both are immune-mediated disorders, 
UC predominantly affects the colonic mucosa, whereas inflammation in CD is 
transmural and often affects the ileum and the colon (Abraham and Cho, 2009). As 
previously mentioned, UC and CD have different cytokine signatures; it is therefore 
possible that CD and UC are driven by different immune mechanisms, and UC 
disease activity may not be reflected in the distribution of mucosal-homing T cells as 
observed in CD.  
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In the pursuit of IBD-associated biomarkers, studies in animal models have generated 
promising results following the blockade of integrin α4β7 by either genetic 
manipulation or the use of monoclonal antibodies (mAbs). In this context, a reduction 
in the number of intestinal T cells and the production of inflammatory cytokines were 
observed (Wang et al., 2010). Previous clinical trials using humanized mAb to block 
integrin α4β7 have also demonstrated efficacy in the treatment of IBD (Tilg and Kaser, 
2010, Feagan et al., 2005).  
The chemokine receptor CCR9 is shown to specifically facilitate memory T cell 
homing to the small intestine and the associated epithelium (Stenstad et al., 2007, 
Kunkel et al., 2000, Zabel et al., 1999). For these reasons, CCR9 may have 
particularly important implications in the pathophysiology of CD affecting the small 
bowel (ileum). In our study, we found comparable frequencies of CCR9
+
 small-bowel 
homing T cells and memory T cells in the peripheral blood of UC patients and the 
healthy donors, these results were anticipated as the ileum of UC patients is 
unaffected. Interestingly, despite the small number of patients analyzed, our data 
established an inverse correlation between the proportion of circulating CD4
+
 CCR9
+
 
T cells and the disease activity in CD patients with ileal involvement. However, other 
groups have reported that active ileal CD is associated with an elevation in the 
peripheral blood CCR9
+
 T cells (Papadakis et al., 2001, Papadakis et al., 2003). 
Discrepancy in these results may be attributed to differences in clinical phenotype in 
the patients recruited in the two studies; as results from our study were obtained from 
CD patients with ileal involvement with or without colonic disease but no pure 
colonic CD. Disease activity score in the different studies may also have affected the 
results. In addition, a previous study has also reported that, compared to healthy 
controls, CCR9
+
 T cells isolated from the mesenteric lymph nodes in patients with 
small bowel CD produce an increased level of pro-inflammatory cytokines (Saruta et 
al., 2007a).  
Despite these observations, clinical studies using CCR9 inhibitors have not targeted 
patients with predominantly ileal disease, thus the specific indications of treatment 
with this inhibitor might need re-evaluation.  
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Aside from examining the level of lymphocyte migration and the expression of 
relevant gut-homing molecules associated with the development of IBD, markers 
associated with T cell activation in IBD have also been previously investigated. For 
instance, an earlier study reported that IBD patients with moderate or severe disease 
activity had a higher fraction of activated T cells (marked by the expression of IL-2 
receptor α chain – CD25) in their circulation compared to the healthy controls 
(Kirman et al., 1995), however this was not observed in the current study. In addition, 
the proportion of activated gut-homing T cells (CD25
+α4β7
+
) in the circulation was 
found to be comparable to the control group in our study, while another study 
reported an increase (Meenan et al., 1997). It is known that CD25 is mainly expressed 
by activated CD4
+
 T cells (Smith, 1988) and that very few peripheral blood CD8
+
 T 
cells express CD25 (Lim et al., 2006). Despite this, we observed a significant 
reduction in the proportion of activated gut-homing CD8
+
 T cell subset in CD patients 
(with active disease or in disease remission) compared to the control group suggesting 
that these cells might be mostly sequestered in the inflamed intestine. In support of 
this hypothesis, Kappeler and Mueller have indeed observed an increased frequency 
of activated cytotoxic CD8
+
 T cells in the inflamed intestine in both UC and CD 
(Kappeler and Mueller, 2000). Moreover, recent studies in animal models have also 
begun to acknowledge the role of CD8
+
 T cells in driving intestinal inflammation and 
tissue destruction (Nancey et al., 2006, Westendorf et al., 2006). Together with the 
strength of the association between the frequency of circulating activated gut-homing 
CD8
+
 T cells and CD observed in our study, this evidence suggests that these cells 
may play an important role in the pathogenesis of IBD and hence further studies are 
required to reveal their specific contributions to the development of IBD.  
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The role of other markers of T cell activation in chronic inflammatory disease has also 
been studied. In this context, it has been observed that the T cell receptor δ chain is 
downregulated in T cell infiltrates in some chronic inflammatory diseases, and in 
many types of cancer as well as infectious diseases (Baniyash, 2004). As the TcRδ 
chain is a key component of TcR signaling, if dysregulated, it may contribute towards 
perpetuation of chronic inflammatory responses in an antigen non-specific manner 
(Cope, 2002). 
TcR δ chain plays a crucial role in the assembly, and transport of complete functional 
TcR subunits onto the cell surface, it also couples antigen recognition to a series of 
subsequent intracellular signal transduction pathways which eventually lead to T cell 
activation (Germain and Stefanova, 1999, Samelson, 2002, Pitcher et al., 2003), thus 
aberration in the expression of the TcR δ chain will inevitably disrupt the otherwise 
balanced immune responses, which indeed was observed (Cope et al., 1994, Isomaki 
et al., 2001, Zhang et al., 2007). For example, T cells isolated from the synovial fluid 
of rheumatoid arthritis patients were enriched with TcRδdim T cells compared to the 
peripheral blood, following effective therapy, these cells were „released‟ from the 
synovium and appeared in the peripheral blood (Zhang et al., 2007). In addition, 
downregulation of TcRδ has also been reported in SLE patients (Gorman et al., 2008).  
In the present study, we analyzed δ chain expression on a protein level, and observed 
that the TcRδdim T cell population was significantly raised proportionally in the 
peripheral blood of active CD patients but not UC patients compared to healthy 
controls. Further analysis revealed that, the proportion of circulating δdim T cells with 
gut homing specificity (β7
+
) also significantly increased in CD patients (group with 
active disease and in remission) compared to healthy controls. These results suggest 
that TcRδ downregulation is associated with CD. In support of these findings, in situ 
analysis of mucosal T lymphocytes in our pilot study revealed that the inflamed area 
of the intestine was particularly enriched with TcRδdim T cells compared to the non-
inflamed area in the same patient. Interestingly, we also observed that as 
inflammation subsided, the proportion of TcRδdim T cells was reduced in gut mucosa. 
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These data provide further support to a previous hypothesis that TcRδ downregulation 
might be a pathogenic mechanism in T cell-mediated chronic inflammatory disease 
(Zhang et al., 2007). 
There are still many unanswered questions regarding the functional properties of T 
cells with downregulated δ chains in chronic diseases, such as the nature of the 
molecular signals responsible for the downregulation (or the loss of TcR-zeta chain). 
Moreover, despite sharing immunological features with other chronic inflammatory 
diseases, the exact etiology of IBD is still unknown. Among IBD, CD and UC 
patients also have different immunological signatures, thus a better understanding of 
this disease will facilitate unraveling of the functional and / or causative nature of the 
TcRδdim population observed in tissue affected by chronic inflammation.  
Finally, we investigated the relevance of regulatory T cells in IBD. Since their 
discovery, a large body of evidence has become available on the indispensable role of 
Tregs in the maintenance of peripheral tolerance (Sakaguchi et al., 2010). The role of 
regulatory T cells has also been intensively studied in the context of inflammatory 
disorders; however, whether defects in Treg function is the direct cause of IBD and 
the nature of the defect is still controversial (Boden and Snapper, 2008).  
In an attempt to uncover any potential correlations between Tregs and IBD, we first 
carried out quantitative analysis of Tregs in the circulation of IBD patients. We did 
not observe any significant differences in the frequency of these cells in patient 
groups compared to the control group; neither did the proportion of peripheral blood 
Tregs correlate to disease activity in either CD or UC. However, other groups have 
reported a reduction in the proportion of circulating Tregs in IBD patients compared 
to the controls (Maul et al., 2005, Saruta et al., 2007b, Takahashi et al., 2006). It is 
possible that individual variability accounts for the different results. Also, bearing in 
mind that FoxP3 is also transiently expressed by recently activated T cells (Wang et 
al., 2007), until a Treg-exclusive marker becomes available, quantitative analysis of 
these cells may not be conclusive.  
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Current evidence suggests that regulatory T cell migration is associated with its 
suppressor functions, much like conventional T cells (Siewert et al., 2007, Siegmund 
et al., 2005). While analysis of peripheral blood regulatory T cells in patients and 
controls did not reveal any significant quantitative differences in the gut-homing 
regulatory T cell subset (α4β7
+
 Tregs and CCR9
+
 Tregs), in situ analysis of 
lymphocytes isolated from the intestinal biopsy in patients with IBD showed that 
Tregs accumulated in the inflamed areas of the intestine compared to the unaffected 
area. Due to the small number of these cells, suppressor functions of the mucosal 
regulatory T cells could not be determined in the current study. However, it has been 
documented that Tregs isolated from the colonic mesenteric lymph nodes and the 
lamina propria of IBD patients are equally suppressive compared to the controls 
(Makita et al., 2004, Saruta et al., 2007b). Together with our data, it is possible that 
IBD patients do not have any defects in the number, migration or the suppressor 
function of regulatory T cells. Given that a larger proportion of T cells in the inflamed 
area of the intestine was found to have downregulated their TcR δ chain, although the 
exact function of these δdim T cells in tissue affected by chronic inflammation is yet to 
be determined, we hypothesize that downregulation in δ chain not only leads to 
dysfunctional T cell responses, but also may cause T cells to become less susceptible 
to suppression induced by regulatory T cells. Consequently, inflammation cannot be 
controlled. However, further studies must be carried out in order to verify this 
hypothesis.
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Chapter 8 Discussion 
8.1 Role of issue-derived factors in the regulation of gut-homing 
receptor acquisition 
The present study was conducted to address several issues regarding the generation of 
T lymphocyte homing specificity in humans, in particular effector / memory T cell 
homing to the gut.  
It is well established that depending on their state of activation, differentiation and 
functions, T cells have distinctive migratory preferences. By expressing a unique set 
of tissue-selective receptors – the homing receptors, T cells are able to interact with 
their ligands expressed on the microvascular endothelium in a specific organ (Mora et 
al., 2006). In order to home to intestinal non-lymphoid tissue, effector/memory T cells 
require the expression of gut-homing receptor integrin α4β7 and the chemokine 
receptor CCR9 which bind to their respective ligands - Mucosal vascular Addressin 
Cell adhesion Molecule 1 (MadCAM-1) and the gut chemokine CCL25(Butcher et al., 
1999, Briskin et al., 1997, Papadakis et al., 2000, Kunkel et al., 2000, Nishimura et al., 
2009).  
The current understanding of homing receptor acquisition is that this process requires 
two signals, T cell activation and the presence of local tissue-derived soluble factors 
(Campbell and Butcher, 2002, Dudda et al., 2005, Mora et al., 2005, Mora et al., 
2003). This „information‟ from the tissue is passed on to T cells via DCs during 
antigen presentation in the draining lymph nodes. As a result, T cells are „educated‟ to 
home to the tissue where priming first occurred. This concept is supported by both in 
vitro and in vivo observations. The only tissue-factor responsible for endowing T cell 
with gut homing specificity identified so far is retinoic acid, a metabolite derived from 
dietary intake vitamin A mainly via intestinal dendritic cells (DCs) (Iwata, 2009, 
Iwata et al., 2004). Binding of retinoic acid to its receptors on naïve T cells induces 
the upregulation of α4β7 integrin and CCR9 during T cell activation (Napoli, 1999, 
Sigmundsdottir and Butcher, 2008, Iwata et al., 2004). 
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The human intestine is in constant contact with a vast quantity of bacteria, which are 
continuously „sampled‟ by DCs. In the steady state (absence of inflammation) this 
leads to the induction of low levels of immune responses as well as homeostatic 
immunoregulatory mechanisms. However, once DCs are activated by products 
derived from pathogenic bacteria via pattern-recognition receptors (PRRs), they 
subsequently present antigens to naïve T cells and activate T cells initiating protective 
immunity. This led to our first hypothesis – that bacterial signalling in DCs might not 
only result in T cell priming by DCs in vivo, but also in the induction of gut-homing 
receptor (gHRs) expression.  
We found that signalling in DCs via PRRs such as TLR4 and NOD2 subsequently 
induces activated T cells to upregulate gut-homing receptor integrin α4β7 and CCR9. 
However, due to the high variability observed in our data, it was not possible to 
conclude on any differences or synergy in their strength to induce T cell gHR 
acquisition. Polymorphism in the NOD2 gene is associated with the development of 
Crohn‟s disease (Ogura et al., 2001, Hugot et al., 2001, Economou et al., 2004). Our 
preliminary results may thus have implications in understanding the generation of T 
cell migratory responses in the context of intestinal diseases, which requires further 
investigation. 
Many soluble tissue factors such as the growth factors, cytokines and chemokines are 
produced in the gut, which are likely to reach the draining lymph nodes in a cell-
independent manner (Gretz et al., 2000, Kaldjian et al., 2001). It has been shown that 
low molecular weight soluble molecules such as chemokines found in the non-
lymphoid tissue can be „transported‟ to the tissue draining lymph nodes through 
specialized conduits structures (Gretz et al., 2000, Roozendaal et al., 2009). Based on 
this information, our next working hypothesis was that gut-derived factors other than 
retinoic acid might also be able to drive the induction of gut tropism in T cells during 
antigen presentation. In particular, we tested the role of the gut chemokine CCL25 in 
the induction of gut-homing receptors under inflammatory conditions or in the steady 
state by using phenotypically mature or immature DCs.  
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While CCL25 was found to have a significant enhancing effect in the upregulation of 
both α4β7 integrin and CCR9 under inflammatory conditions (activated by allogeneic 
mature DCs), it was only able to efficiently drive the upregulation of α4β7 integrin but 
not CCR9 under steady state (when naïve T cells were stimulated by allogeneic 
immature DCs). In addition, in our pilot study, as we did not observe any significant 
differences in the extent of gHR upregulation in T cells activated in the absence of 
DCs (by anti-CD3 and anti-CD28 monoclonal antibodies instead) with or without 
CCL25 it is likely that these CCL25-mediated effects depend on the presence of DCs.  
Next, we explored the role of IL-2 in the induction of gut homing specificity, as both 
immunogenic and tolerogenic DCs are able to produce IL-2 (Granucci et al., 2003, 
Fazekasova et al., 2009). In contrast to CCL25, our data showed that IL-2 is only able 
to upregulate integrin α4β7 in T cells in the steady state but not under inflammatory 
conditions. In addition, as we did not observe any additive or synergistic effect of 
CCL25 and IL-2 in the upregulation of α4β7, it is unlikely that the two molecules 
share pathways in the modulation of this molecule. Furthermore, data from the current 
study also suggest that IL-2 may not be able to modulate CCR9 expression in either 
inflammatory or steady-state condition. 
Based on these data, we proposed a model which summarizes the differential 
contributions of these tissue-derived factors in the acquisition of gut tropism by T 
cells under immunogenic or steady state-conditions (Figure 48). 
Finally, upon stimulation by allogeneic DCs in vitro for 7 days, we observed a subset 
of T cells expressing regulatory T cell marker CD25 and FoxP3. We thus examined 
the effect of CCL25 and IL- 2 on these 
„putative‟ Tregs under both immunogenic and 
steady state conditions. It was noted that CCL25 significantly enhanced the extent of 
α4β7 upregulation in the FoxP3
+
 T cells expanded in the presence of mature DCs. Thus 
these data provided justification for further studies in which the role of CCL25 in the 
generation of inducible Tregs with gut-homing properties. The role of IL-2 in the 
expansion of gut tropic Tregs also awaits further verification. 
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Figure 48. Different T cell gut-homing phenotypes are generated in different 
physiological contexts under the influence of tissue-derived factors.  
Naïve T cells express low levels of gut-homing receptors (α4β7
low
CCR9
low
), following 
activation by DCs (either immature or mature), low levels of gut-homing receptor 
upregulation is induced (α4β7
+
CCR9
+
). CCL25, IL-2 and the metabolized form of vitamin A – 
retinoic acid (RA) are all capable of efficiently endowing T cells with gut tropism. Their 
efficacy, however, depends on the ‘immunological context’ under which T cells were 
stimulated, thus serving different physiological functions. 
In the absence of gut inflammation, i.e. under steady state, T cells stimulation by immature 
DCs leads to the induction of low immune responses accompanied by the acquisition of a 
colon-homing phenotype (α4β7
high
CCR9
+
) driven by CCL25, IL-2 an retinoic acid (RA). Thus, 
when IL-2 is limiting (predominantly produced by tolerogenic DCs), CCL25 and RA are 
particularly important in the induction of colon tropism in T cells. In summary, in the steady 
state, effector/memory T cells primarily home to the colon which is their ‘default’ migration 
pathway. This is the part of the intestine which is colonized by vast commensal bacteria 
compared to the small intestine, and therefore requires regulatory mechanisms. By contrast, 
under inflammatory conditions, a heterogeneous T cell gut-homing phenotype is generated. 
Productive T cell priming induces upregulation of α4β7 and CCR9. CCL25 and RA (but not 
IL-2) further promote a subset of T cells to acquire high levels of α4β7 as well as CCR9. 
Consequently, this leads to the specialization of T cell migratory responses as compared to 
the ‘default’ pathway, generating effector/memory T cells committed to the colon (α4β7
high
 
CCR9
+
 T cells) as well as to the small intestine (α4β7
high
 CCR9
high
 T cells).  
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8.2 Mechanisms by which CCL25, RA and IL-2 instruct T cell 
acquisition of gut tropism 
As mentioned before, the role and the mechanism by which vitamin A instructs T 
cells to acquire gut tropism is well established. Catalyzed by enzymes, vitamin A is 
converted to its active from - retinoic acid (RA), which subsequently induces T cells 
to upregulate α4β7 integrin and CCR9 during T cell activation by binding to tis 
receptors expressed by naïve T cells (Iwata et al., 2004, Sigmundsdottir and Butcher, 
2008, Sigmundsdottir et al., 2007).  Our study has since shown for the first time that 
other than RA, CCL25 is also able to drive the generation of gut tropic T cells under 
both inflammatory and steady-state conditions. This suggests that CCL25 and RA 
may share pathways in the modulation of integrin α4β7 and CCR9. While the 
underlying mechanisms by which CCL25 employs to modulate the expression of gut-
homing receptor α4β7 and CCR9 in T cells are not immediately clear, this effect is 
likely to be dependent on the presence of dendritic cells.  
As CCL25-CCR9 signalling in T cells has been shown to induce the upregulation of 
integrin α4β1 (Parmo-Cabanas et al., 2007) it is possible that chemokine receptor 
signalling mediated by CCL25 is also able to directly modulate the expression of 
integrin α4β7.  As monocyte-drived DCs do not express CCR9 (Cravens and Lipsky, 
2002), we postulate that CCL25 is immobilized on DCs by binding to the 
glycoaminoglycans (GAGs) on the cell surface of DCs and thus drive the acquisition 
of integrin α4β7 by interacting with its receptor CCR9 on T cells. Alternatively, 
signalling via CCR9 may selectively favour the survival of T cells expressing high 
levels of α4β7 integrin via upregulating anti-apoptotic pathways as demonstrated 
before (Sharma et al., 2010). The molecular mechanisms underlying CCL25-induced 
acquisition of gut-homing receptors is still unclear and awaits further investigation. 
While CCL25 and RA are both able to regulate the expression of α4β7 and CCR9, IL-2 
is able to drive α4β7 upregulation only when naïve T cells are stimulated by allogeneic 
immature DCs. It is possible that under inflammatory conditions, IL-2 secreted by 
DCs or CD4
+
 T cells primarily serves the function of promoting T cell expansion and 
survival. By contrast, under steady state, IL-2 is mainly produced by tolerogenic 
immature DCs in the gut, which in turn drives T cells to express α4β7 allowing their 
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migration to the colon, where immuneregulation is required due to the presence of a 
vast quantity of commensal bacteria. Furthermore, while we have shown that CCL25, 
RA and IL-2 are all able to promote the generation of colon-tropic T cells in the 
steady state, no synergistic effect was detected between CCL25 or RA with IL-2. 
Thus, the ability of IL-2 to induce the expression of α4β7 integrin may involve 
pathways different from that utilized by CCL25 or RA, although this would require 
evaluation by further studies.  
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8.3 T cell homing in patients with inflammatory bowel diseases 
Previously, I investigated factors that contribute to the gut-homing receptor 
acquisition in T cells in healthy individuals and made provision for the possible 
underlying mechanisms involved. In the second part of this study, the relationship 
between the extent of T cell homing to the gut and the severity of intestinal 
inflammatory disease such as inflammatory bowel disease (IBD) (including both 
Crohn‟s disease - CD and ulcerative colitis – UC) was examined. Furthermore, the 
expression of several other potential markers indicative of IBD disease activity was 
also assessed. The following observations were made. 
1. Neither CD patients nor UC patients had significantly different proportions of 
peripheral blood T, B lymphocytes or T cell subsets compared to healthy 
controls. 
2. Among all the parameters assessed, the proportion of peripheral blood CD3+ T 
lymphocytes and gut-homing (α4β7
+
) memory T cells were significantly lower 
in the CD group than that of the UC group analyzed.  
3. Compared to healthy controls, alterations in the proportion of peripheral blood 
gut-homing (α4β7
+
) memory T cells were associated with CD but not UC.  
4. Quantitative changes in gut-homing T cells did not correlate with disease 
activity in either CD or UC. 
5.  T cell expression of CCR9 was only associated with Crohn‟s disease affecting 
the ileum.  
6. TcRδ downregulation was associated with both CD and UC, effective therapy 
was accompanied by a proportional decrease of TcRδdim T cells.  
7. Quantitative or migratory defect in regulatory T cells was not associated with 
IBD. IBD might be associated with an enrichment of dysfunctional effector T 
cells with a downregulated TcRδ chain (TcRδdim) in the inflammatory site. 
These cells might be less susceptible to immunesuppression induced by Tregs.  
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8.4 Lessons from animal models and clinical trials of IBD 
While the exact „signals‟ responsible for triggering chronic T cell activation and 
subsequent infiltration to the intestine in IBD remain unknown, my study has shown 
that patients with CD but not UC display a significantly different T cell gut-homing 
„profile‟ to the healthy population. In addition, T cell expression of chemokine 
receptor CCR9 might exclusively correlate with the disease activity of patients with 
CD affecting the ileum.  
Knockout studies in mice have previously established that α4β7 is essential for the 
formation of gut-associate lymphoid tissue (Wagner et al., 1996). In a study whereby 
T cell-mediated colitis was induced by reconstituting SCID mice with CD4
+
 
CD45RB
high
 T cells, when integrin α4β7 activity was blocked via monoclonal antibody, 
colonic inflammation subsided (Picarella et al., 1997).  Another studies in cotton-top 
tamarin (a new world money) which develops chronic spontaneous colitis closely 
resembling human UC showed that blocking the α4 subunit via monoclonal antibodies 
resulted in a reduction of inflammation (Podolsky et al., 1993). Interestingly, while 
α4β7 was not implicated in the disease activity of CD or UC in my study, clinical trials 
have demonstrated the efficacy of anti-α4β7 therapy (MLN02, Vedolizumab) in the 
induction of disease remission in CD (Feagan et al., 2008) and UC patients (Feagan et 
al., 2005, Parikh et al., 2011). These discrepancies maybe directly attribute to the 
differences in disease extent and severity of IBD patients recruited into the two 
studies. Although Vedolizumab is well tolerated in CD and UC patients, worsening of 
CD following administration of Vedolizumab has been reported (Feagan et al., 2008), 
thus the role of α4β7 expression in the pathogenesis of IBD requires further 
investigation. 
Other than anti-α4β7, earlier studies have shown that humanized anti-α4 monoclonal 
antibody natalizumab is also effective in the induction of clinical remission in patients 
with active Crohn‟s disease (Ghosh et al., 2003). However, it does not benefit those 
patients with moderate to severe disease (Reenaers et al., 2010). As integrin α4β1 
mediates T cell migration to non-mucosal tissues, blocking the common α4 chain may 
not selectively influence T cells infiltration to the gut. However whether this is the 
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cause for the side effects associated with natalizumab remains to be established. For 
this reason, natalizumab is not currently used in Europe (Reenaers et al., 2010).  
While T cells require integrin α4β7 to migrate to the intestine, chemokine receptor 
CCR9 specifically allows their access to the small intestine. For instance, early studies 
have shown that blockade of CCR9 or its ligand CCL25 significantly inhibits T cell 
migration to the small intestine but not colon (Hosoe et al., 2004). In addition, CCR9 
plays an important role in T cell development in the thymus as well as T cell 
migration (Uehara et al., 2002, Wurbel et al., 2006, Kunkel et al., 2000, Wurbel et al., 
2000). Wurbel and colleagues generated CCL25 knockout mice to study the role of 
CCL25-CCR9 axis in T cell migration as T cells from CCR9 deficient mice may lack 
normal TCR repertoire (Wurbel et al., 2007).Through adoptive transfer experiments, 
it was subsequently revealed that infiltration of antigen-specific CD8
+ 
T cells to the 
small intestine is significantly impaired in these CCL25 deficient mice (Wurbel et al., 
2007).  
In my study using human samples, proportional changes in the peripheral blood 
CCR9
+
 but not α4β7
+
 T cells were found to be associated with the disease activity of 
ileal CD. Interestingly, in mice that spontaneously develop chronic ileitis resembling 
human CD affecting the terminal ileum, blockade of the CCL25-CCR9 axis is only 
effective in controlling early but not late disease (Rivera-Nieves et al., 2006). The 
same study has also shown that disease progression is coupled with CCR9 
downregulation (Rivera-Nieves et al., 2006), suggesting that the efficacy of CCR9 
blockade might be dependent on disease severity. Furthermore, despite the current 
success in clinical trials of IBD using CCR9 antagonist (Traficent-EN, developed by 
ChemoCentryx)(Proudfoot et al., 2010), whether this was due to the predominant 
participation of patients with ileal or ileocolonic CD was unclear. In addition, while 
my study has shown that CCR9 may not play a role in UC, it is also inconclusive 
regarding the importance of CCR9 in colonic CD.  
Taken together, current evidence suggests that CCR9 might be a potential marker for 
ileal CD. However, in order to take full advantage of its therapeutic potential, further 
evaluation of its involvement in UC and CD with or without ileal involvement must 
be separately and thoroughly conducted. 
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8.5 Conclusion 
In the current study, we have identified the role of previously unknown gut-derived 
soluble factors, such as the gut chemokine CCL25 and the T cell growth factor IL-2 in 
driving the acquisition of gut-homing receptors. While further studies are required to 
fully understand the signalling events leading to the upregulation of gut-homing 
receptors integrin α4β7 and the chemokine receptor CCR9, our studies strongly 
suggest that these two gut-homing molecules are modulated differently and require 
complex signals, particularly CCR9. In the second part of this study, we investigated 
T cell gut homing in the context of disease, during which several immunological 
markers associated with IBD were identified. For instance, α4β7 integrin expression in 
T cells is particularly associated with Crohn‟s disease but not ulcerative colitis and the 
expression of TcRδ chains indicates disease activity and response to therapy in both 
CD and UC.  
8.6 Future work 
In this section, I briefly discuss potential ideas for the continuation of this study. 
First, functional studies are to be carried out on T cells expressing different levels of 
CCR9 (CCR9
+
, CCR9
high
) that we observed in the current experiments. I proposed 
that only the CCR9
high
 population are able to efficiently migrate towards CCL25 and 
home to the small intestine. Verifying this hypothesis will require the use of 
experimental models of T cell trafficking – such as in vitro chemotaxis assay. In vivo 
studies to be carried out include immunization of mice with CCL25, following which 
T cells are to be isolated from the draining lymph nodes and subsequently phenotyped.  
In addition, CCR9
high
 T cells generated in vitro could be injected into mice and their 
migration patterns followed using imaging technologies. 
Second, due to its potential application in vaccination strategies, I intend to repeat the 
current experiment using CCL25 at a range of concentration in order to establish the 
optimal dose of usage for the generation of gut-tropic T cells.  In addition, integrin 
α4β7 and CCR9 induced in activated T cells are to be measured longitudinally in a 
time-course fashion; which will allow us to gain a better understanding of how these 
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gHRs are modulated. Furthermore, molecular studies could be conducted in order to 
dissect the signalling pathways involved in the regulation of these gHRs.  
While it was demonstrated that CCL25 might be able to induce gut tropism in FoxP3
+
 
T cells, future functional studies should be carried out in order to confirm that these 
cells observed were regulatory T cells with suppressor functions.   
As the current study shows that NOD2 signalling could lead to the induction of gut-
homing receptors in T cells, given the association between NOD2 gene and Crohn‟s 
disease, future work of similar design using dendritic cells derived from IBD patients 
with NOD2 polymorphism could provide valuable information on T cell migration in 
the context of intestinal disease.   
Finally, clinical studies of a larger scale are required for a thorough assessment of the 
association between T cell expression of α4β7, CCR9 and IBD as well as their potential 
as disease biomarkers. For example, phenotypic analysis of T cells could be 
conducted simultaneously in pairs using patients‟ blood and intestinal biopsy samples 
for both CD and UC. If possible, the level of gHR expression in T cells from these 
patients should also be monitored longitudinally and correlated with treatment.  
As discussed previously, the role of regulatory T cells in the pathogenesis of IBD is 
still under debate. In addition, we observed that T cell δ chain downregulation is 
associated with patients with active IBD. Following the current study, I also 
hypothesized that the uncontrolled inflammation observed in IBD is the result of 
effector T cell resistance towards immunesuppression by regulatory T cells as a result 
of δ chain downregulation.  To verify this, I plan to measure the proliferative 
responses of effector T cells with a down-regulated δ chains following incubation 
with regulatory T cells derived from the same patient and compare it to that of healthy 
volunteers.  
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